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Chemotherapy is frequently used in the treatment of cancer. However, their therapeutic 
outcome is compromised by the short circulation time and systemic toxicity. Nanomaterials 
have emerged as ideal platforms to circumvent these limitations and improve the therapeutic 
effect of anticancer agents. 
We first developed a dual function carrier that is based on PEG-derivatized S-trans, 
trans-farnesylthiosalicylic acid (FTS) for delivery of curcumin. FTS is a potent nontoxic Ras 
antagonist and curcumin is a chemopreventive agent for cancers. Both curcumin and FTS 
have poor water solubility and limited bioavailability. The PEG5K-FTS2 led to a synergistic 
antitumor activity by co-delivery of curcumin. Next, we demonstrated that introduction of an 
Fmoc motif to PEG5k-FTS2 led to a significant improvement in the drug loading capacity and 
antitumor effect in vitro and in vivo.  
Unfortunately, delivery of cytotoxic agents is often limited by various negative feedback 
mechanisms during cancer treatment. Immunochemotherapy represents a promising strategy 
to improve anti-cancer effect. Here we developed an immunostimulatory PEG-NLG 
nanomicellar carrier for delivery of paclitaxel (PTX). NLG is an indoleamine 
2,3-dioxygenase (IDO) inhibitor, which can block tumor immune escape. In vivo delivery of 
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PTX using the PEG2k-Fmoc-NLG nanocarrier leads to a significantly improved antitumor 
response in multiple mouse tumor models.  
Although the PEG-NLG-based immunochemotherapy system achieved considerable 
antitumor effect, its efficacy was compromised by the accumulation of myeloid-derived 
suppressor cells (MDSCs). In order to solve this problem, an improved polymeric micelle 
system (PEG5k-Fmoc-NLG2) was developed to codeliver a multi-target receptor tyrosine 
kinase inhibitor, sunitinib (SUN) and PTX. SUN+PTX/PEG5k-Fmoc-NLG2 micelles could 
not only enhance in vivo antitumor activity but also decrease the recruitment and maturation 
of MDSCs in the tumor, too.  
Tumoral expression of immune stimulating cytokines has been show to be an effective 
strategy to boost immunotherapy of cancer. This inspired us to develop a carrier system, 
which could codeliver both gene therapy and small molecule drug. We designed two 
polymeric conjugates POEG-st-Pmor and POEG-st-Ppipe for codelivery of IL-36γ plasmid 
DNA and Doxorubicin (Dox). Both carriers could achieve efficient Dox and pDNA 
co-delivery in vitro and in vivo and achieved lung-specific accumulation for treatment of lung 
cancer.  
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1.0 INTRODUCTION 
 
1.1 NANOPARTICLES FOR CANCER THERAPY 	  
Cancer is defined as diseases involving uncontrolled growth of cells with the metastatic 
potential. It accounts for 15.7% of human deaths world-wide1. Conventional anti-cancer 
strategies include surgery, radiation, chemotherapy and targeted therapy agents2, 3, 4. 
Chemotherapy drugs are distributed nonspecifically in the systemic circulation and this lead 
to toxicities to normal cells and limited exposure in the tumor5. Cancer nanotherapeutics has 
emerged as an important approach to solve problems such as nonspecific toxicity in addition 
to low water solubility, low bioavailability, and poor therapeutic effect of certain 
chemotherapeutic agent. Nanoparticles, including polymeric nanoparticles, micelles, 
dendrimers, hydrogel nanoparticles, liposomes, metal and inorganic nanoparticles with the 
size around 3-200 nm are used as drug delivery systems6, 7, 8, 9. The optimal size and 
well-designed surface characteristics of the nanotherapeutic systems allow delivery of 
therapeutic agents to cancer cells by taking advantage of unique pathophysiology of the 
tumor, such as the hypoxia and the enhanced permeability and retention effect (EPR effect)10, 
11. Tumor specific ligands or antibodies are also incorporated on the surface of the therapeutic 
nanoparticles to improve active targeting and overcome drug resistance, mediated by 
P-glycoprotein, via receptor-mediated endocytosis7, 12.  
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1.1.1 POLYMERIC MICELLES DELIVERY SYSTEM IN ONCOLOGY 
Polymeric micelles are colloidal nanoparticles with a size around 5-200 nm. Micelles consist 
of amphiphilic molecules, which have both a hydrophobic head and a hydrophilic tail. The 
well-designed hydrophilic shell of the micelle can stabilize the micelle, achieve prolonged 
circulation upon injection and thus avoid recognition by reticuloendothelial system (RES)13. 
The Poly(ethylene glycol) (PEG) is the most widely used hydrophilic structure due to its 
highly water solubility, low cytotoxicity and biocompatibility14. The hydrophobic structure 
should be able to interact with the loaded hydrophobic drug with a high drug loading capacity. 
Polyesters, polyethers, and polyamino acids are commonly used as hydrophobic core 
materials15. With increasing concentration of these amphiphilic molecules of polymer in an 
aqueous solution, the polymer can self-assemble to form micelles at the critical micelle 
concentration (CMC)16. The formation of micelles above the CMC is relied on the 
hydrophobic-hydrophobic interaction and/or π-π stacking inside the hydrophobic core of 
micelle or the hydrogen bonding between the hydrophilic motifs.  
Micelle has gained increasing attention as carriers for hydrophobic drugs in anticancer 
therapy due to its structural simplicity, nano-scale sizes and targeted accumulation in the 
tumors17, 18. Currently, five anticancer micellar formulations have entered the clinical trials 
and among which, Genexol-PM for delivery of PTX has been approved by FDA for treatment 
of breast cancer19, 20. The Genexol-PM was effective and safe in treating metastatic breast 
cancer and advanced pancreatic cancer in phase II studies. Moreover, micelle formulation 
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allowed delivering higher doses of PTX compared to the Taxol formulation without 
significant toxicity in clinical study21.  
Although inspiring results have been achieved by micelle-based cancer therapy, there are 
still many ways to further improve the antitumor efficacy. Firstly, micelles can be modified 
with actively tumor targeting ligands to increase the tumor specific accumulation with 
reduced systemic toxicity22. Active ligands such as monoclonal antibodies and peptides allow 
the micelles bind to specific receptors on the cancer cell and thus increase the micelle 
endocytosis, achieving higher intracellular drug concentrations22, 23. Many reports have 
demonstrated the ligand modified micelles has shown superior antitumor activity compared 
to non-targeted micelles with higher cellular uptake, stronger cytotoxicity and more effective 
tumor regression24. Secondly, it is possible to improve the drug release profile of micelle by 
designing triggered release micelles based on the mechanisms such as pH-sensitive, 
thermo-sensitive, ultrasound-sensitive and light-sensitive linkers or structures25, 26. The rate of 
drug release from micelles is influenced by the micelle stability, polymer degradation rate 
and drug concentration. Drug release kinetics can be greatly enhanced by applying an internal 
or external trigger to the micelle formulations. For example, pH-sensitive polymer conjugates 
incorporating acid-labile bonds such as hydrazones have been demonstrated tumor specific 
release of loaded drug due to a more acidic condition in tumor (pH~6.8) than normal tissues 
(pH~7.4), which can trigger drug release through the pH-responsive structures in the micelles. 
Third, can incorporate bioactive components in to the carrier system by promoting potential 
synergistic effect or counteracting the side effects of loaded anticancer drugs27, 28. One 
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example of the dual functional micelle system is poly(ethylene glycol)3500 embelin 
conjugation for PTX delivery that was developed in our lab29. Embelin induces antitumor 
activity by increasing cellular apoptosis, inhibiting tumor cell proliferation and suppressing 
cell proliferation pathway such as nuclear factor-kappa B (NF-κB). Data showed that 
PEG-derivatized embelin greatly enhanced the delivery of PTX and achieved better in vivo 
therapeutic effect than Taxol alone. 
1.1.2 COMBINATIONAL CANCER THERAPY USING DUAL-FUNCTIONAL 
NANOCARRIER  
Most of the micelles in drug delivery are using “inert” materials with no therapeutic activity, 
which will cause safety issues due to the large amount of carrier used in the treatment of 
cancer. It is a promising approach to develop biologically active nanocarriers for tumor 
therapy and at the same time, effectively incorporate and deliver hydrophobic drugs. One 
strategy is conjugating selected numbers of hydrophobic anticancer drugs to hydrophilic 
polymers yielding a prodrug, which can self-assemble into micelles in aqueous solution due 
to the interactions between the hydrophobic anticancer drugs30, 31. The hydrophobic core 
formed could be used to interact with incorporated drug to achieve simultaneous delivery of 
both drugs. The drug-formulated bioactive micelles can not only achieve enhanced 
therapeutic effect by targeting different signaling pathways and meanwhile, decrease the 
potential toxicity generated by the co-loaded antitumor drugs. In our lab, several 
dual-functional micelle delivery systems were developed for combinational cancer therapy 
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such as PEG2K-Fmoc-Ibuprofen and PEG5K-Fmoc-(vitamin E)2 micelles for delivery of 
PTX32. 
1.1.3 PEG-FTS BASED DUAL-FUNCTIONAL NANOCARRIER  
In our lab, we developed a dual functional PEG-FTS derivatized nanocarrier for delivery of 
PTX33. FTS is a synthetic nontoxic Ras proteins inhibitor34. Highly mutative Ras was 
constitutively active in promoting tumor cell proliferation by activating downstream 
pathways and was detected in ninety percent of pancreatic and fifty percent of colon cancers. 
FTS is a farnesyl mimetic anticancer drug and takes effect by competing with binding of 
active Ras proteins to cell memberane and further leads to the degradation of Ras protein in 
the cytoplasm35. FTS has been shown to have significant anticancer effect while using in 
combination with other anticancer agents such as gemcitabine or PTX36, 37. Recently, we 
found the FTS could synergize with curcumin in various types of cancers including breast 
and prostate cancer33. Both the FTS and other drugs such as curcumin are poorly water 
soluble with low bioavailability. A PEG-derivatized FTS prodrug based micelle formulation 
was developed and the antitumor activity of FTS was largely maintained upon conjugation. 
The PEG-FTS conjugation greatly enhanced the FTS solubility and could be used to 
formulate hydrophobic drug for targeted delivery. Our group previously demonstrated that 
the PTX formulated PEG5K-FTS2 micelles showed significantly higher antitumor activity 
compared to Taxol at the same dose of 10 mg PTX/kg in a mouse 4T1.2 mouse model. More 
biological active dual-functional nanocarriers were developed to achieve enhanced antitumor 
	  	   6	  
activity such as PEG-derivatized embelin micelle or the camptothecin-tocopherol micelle 
system.  
 
1.2 CANCER IMMUNOTHERAPY  
 
Recently, increasing evicences have shown that cancer treatment with cytotoxic agents was 
often limited by various immunological negative feedback mechanisms38, 39. As a result, 
combing immunotherapy with other thrapeutic stratergy represents a promising approach to 
futher improve anti-cancer effect. Cancer immunotherapy refers to harnessing the power of 
immune system to cure and protect patients from cancer, which is based on the assumption 
that cancer cells are immunogenic and can be recognized and eliminated by the immune 
system40, 41, 42. Under ideal condition, tumor cell growth will disrupt the surrounding 
microenvironment and further induce local inflammation, which will stimulate 
antigen-presenting cells to engulf tumor-derived antigens and trigger activation of 
tumor-specific T cells in an adaptive immune response. However, tumor cells always find 
ways to interfere with the development of antitumor immune response, such as decreased 
expression of major histocompatibility complex or overexpressed immunosuppressive 
costimulatory proteins on the tumor cells, disrupted function of natural killer cells and 
increased expression of proteins that interfere antigen presentation and T cell proliferation42, 
43, 44. As a result, development of strategies that effectively and safely augment antitumor 
responses remains a big challenge.  
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1.2.1 AN OVERVIEW OF CANCER IMMUNOTHERAPY 
 
Over the past decade, immunotherapy in controlling tumor development and progression has 
been investigated intensively. Activation of innate and adaptive immune systems is a critical 
process for generating effective anticancer immune response45. Accumulating evidence 
shows a correlation between tumor-infiltrating lymphocytes in tumor tissue or tumor lymph 
nodes and favorable prognosis in various cancer types46. There are four essential steps to 
achieve effective tumor-specific immune response. Firstly, antigen presenting cells (mostly 
DCs) must engulf tumor specific antigens in order to initiate antitumor immune response, 
which can be achieved during tumor development or by stimulation of antitumor vaccines47. 
Secondly, the DCs would also have to undergo further maturation and differentiation 
processes to present tumor specific antigen-derived peptides. This can be achieved by 
activation of factors released by endogenous necrotic tumor cells or therapeutic approaches 
such as toll-like receptor (TLR) ligands. Third, the tumor antigen/DCs complexes need to 
initiate tumor-killing T cell immune responses such as the proliferation of tumor specific 
cytotoxic CD8+ T cells48. Finally, the produced T cells must enter the tumor 
microenvironment to generate tumor specific cytotoxic effect.  
Tumor cells are smart and may generate immunosuppressive micro-environment to avoid 
recognition of host immune system and inhibit T cell function through diverse mechanisms 
including upregulation of suppressive co-inhibitory receptors or ligands (eg, PD-1 and PD-L1) 
on the cellular surface, recruiting more suppressive regulatory cells (e.g., Treg and MDSCs) or 
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consuming tryptophan to limits T cell proliferation by expressing indoleamine 
2,3-dioxygenase (IDO) enzyme. Drugs or antibody against CTLA4, PD-1/PD-L1 axis or IDO 
may be a good choice to reverse the immunosuppressive status. Reciprocal to the blockade of 
co-inhibitory receptors, diverse strategies are developed to reverse the immunosuppressive 
status and stimulate the antitumor immune response, including immunogenic vaccines, 
immune stimulating antibodies, immunostimulatory cytokines, antitumor viruses, and 
adoptive T cell therapies. 1) vaccines: cancer vaccines are developed to generate and boost 
the body's natural defenses to fight a cancer by increasing the process of tumor antigen 
presentation, such as developing DNAs sequences that encode either tumor-specific or 
tumor-associated antigens that can stimulated T cell immune response49. Sipuleucel-T, is one 
of the therapeutic cancer vaccines approved by FDA for treatment hormone-refractory 
prostate cancer patients.50 However, most of the cancer vaccines have limited efficacy and 
only work in selective patients due to the immune counteracting mechanisms engaged during 
cancer vaccine responses. Also it is very challenging and costly to develop high quality 
vaccine products for clinical use51. 2) cytokines: cytokines are small proteins (~5-20 kDa) 
that play a pivotal role in cell signaling. Nearly all cell types including tumor cells, immune 
cells and nonimmune stromal cells produce cytokines52. Together with cell surface adhesive 
molecules, cytokines mediate the activity of immune cells by altering cell signaling intensity 
and duration between cells and tissues53. Proinflammatory cytokines such as IFNs, IL-2, IL-4 
and IL-15 are currently used to polarize the immune response against cancer through direct 
inhibit tumor cells growth or stimulation T-cell activation54. 3) antitumor virus therapy: 
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oncolytic virus are native or engineered viruses, which can preferentially replicate in cancer 
cells and kill infected cancer via direct oncolysis of tumor cells, targeting tumor vasculature 
and further stimulate immunogenic response towards tumors55. Currently, T-Vec is the only 
oncolytic virus approved by FDA for treatment of metastatic melanoma56. 4). adoptive T-cell 
therapy: adoptive T-cell therapy is a passive immunization strategy which involves the ex 
vivo selection and expansion of antigen-specific T cell clones, transfusion of specific 
T-cells which can recognize tumor associated antigens back to patients and trigger a cascade 
of antigen-specific immunity for treatment of cancer57. However, tumor-infiltrating 
lymphocytes are difficult to harvest and expand from the blood samples and the low 
expression of specific antigen on tumor cells limits the use of adoptive T-cell therapy.  
Recent success of novel anticancer immunotherapies has led to a new era of cancer 
treatment. Immunotherapies have made clinically meaningful progress in multiple tumor 
types. Unfortunately, the patient responses to immunotherapy are still limited and more 
efforts are required to improve therapeutic outcomes with these treatments. Development of 
personalized treatment or combinational immunotherapy with other treatment strategies could 
help overcome some of these limitations. 
 
1.2.2 THE BLOCKADE OF IMMUNE CHECKPOINTS IN CANCER 
IMMUNOTHERAPY  	  
During long term development of cancer immunotherapy, advances have been made in the 
understanding of cancer development and progression, resulting in the availability of 
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promising novel therapeutic options, such as checkpoint inhibitors. Immune checkpoints are 
referred as stimulatory or inhibitory regulators in the immune system, which play important 
roles in modulating body immune tolerance, preventing autoimmunity and protecting tissues 
from damage for abnormal immune response. These checkpoint pathways are used as 
important immune resistance mechanisms for fast-growing tumor cells to protect themselves 
from immune system recognition and elimination. Blockade of immune checkpoints is thus a 
promising strategy for activating and restoring anti-tumor immune responses. 
Many immune-checkpoint pathways were discovered as major mechanisms for tumor 
immune escape, such as CTLA-4, PD-1, TIM-3, IDO1 and LAG-3. Most of the immune 
checkpoint proteins mediate immune response by ligand-receptor interactions, so they can be 
readily blocked by antibodies and modulated by ligands. For example: CTLA-4 is an immune 
checkpoint protein expressed mainly on the surface of T cells and acts as a negative 
regulatory receptor in the antigen presentation process to T cells. Ipilimumab, antibodies 
against CTLA-4 were the first FDA approved immunotherapy for melanoma, worked by 
counteracting immune suppression in tumor microenvironment58. Another immune 
checkpoint pathway, PD-1/PD-L1 axis also plays a critical role in tumor immune escape. 
PD-1 is a co-inhibitory receptor expressed on several immune cells including activated T 
cells, NK) cells and MDSCs and PD-L1 has been found to be overexpressed in myeloid cells 
and various tumors types, including melanoma, non-small cell lung cancer and breast 
cancer59. Interaction between PD-1 and its ligands PD-L1 leads to effecter T-cell apoptosis 
and tumor immune resistance60. Blockade of the PD-1 or PD-L1 by monoclonal antibodies 
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produced both durable anti-tumor response and prolonged survival rate in patients with 
metastatic non-small cell lung cancer and melanoma61. 
Another category of immune-inhibitory molecules includes certain metabolic enzymes, 
such as indoleamine 2,3-dioxygenase (IDO). IDO is an enzyme catalyzes the first and 
rate-limiting step of tryptophan degradation62. IDO overexpression is observed in both tumor 
cells and tumor associated antigen-presenting cells63. Emerging evidence suggests that IDO 
becomes activated during tumor development, helping tumor cells escape the immune system 
through its ability to inhibit effector T cell proliferation and function64. IDO enzymes can be 
inhibited by small molecular analogues of their substrates such as 1-MT or NLG91965. 
 
1.2.3 RATIONALE OF COMBINATION USE OF CHEMOTHERAPY AND 
IMMUNOTHERAPY  
	  
The pre-existing antitumor immune responses are key factors for clinical response using the 
checkpoint inhibitors for IDO, CTLA-4 and PD-1/PD-L166. Only a small potion of patients 
will benefit from immune therapy due to the complexity of immune suppressive mechanisms 
and the varying tumor immunogenicity. Even though the novel checkpoint inhibitors show 
impressive antitumor activity, their efficacy may be further enhanced in combination with 
other agents. In addition, combined treatment may reduce the resistance. Thus, drugs 
combinations therapies, which can target various mechanisms of immune tolerance, are being 
actively investigated67.  
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Combination of chemotherapy and immune therapy has drawn increasing attention in 
treatment of cancer68. Chemotherapy drugs are generally believed to directly kill tumor cells. 
However, increasing evidence shows that chemotherapy also works through immune 
activation by either modifying the tumor microenvironment or directly stimulating anticancer 
immune response69. However, the chemotherapy induced immune response is restricted by 
various counteract mechanisms such as elevation of immune checkpoint proteins70. 
Combination of chemotherapy and checkpoint inhibitor represents one of the most promising 
strategies to treat cancer. For example, co-treatment of PD-1 antibody and chemotherapy 
such as platinum has been reported to have significant antitumor activity in both preclinical 
and clinical condition71.  
1.2.4 MULTIFUNCTIONAL MICELLE DELIVERY SYSTEM FOR 
CHEMOIMMUNOTHERAPY 
	  
Several IDO inhibitors have been reported, among which NLG919 is a highly IDO-selective 
inhibitor with an EC50 of 75 nM72. However, NLG919 has a poor water solubility and 
limited bioavailability, which presents a major challenge in the clinical use73. In addition, 
co-delivery of IDO inhibitors and chemotherapeutic agents faces many problems such as 
hydrophobicity and different pharmacokinetic profiles. To resolve these challenges, we 
synthesized a novel prodrug micellar system based on conjugation of PEG and NLG919. An 
Fmoc group was also introduced into the conjugate to improve drug carrier interactions. 
PEG-Fmoc-NLG could be further used as a carrier for co-delivery of chemotherapeutic drugs, 
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which represented an immunostimulatory dual-functional nanocarrier that improved cancer 
immunochemotherapy.  
 
1.3 TARGETED CODELIVERY OF GRUG/GENE CONBINATION FOR CANCER 
THERAPY  	  
Cancer cells contain various oncogenic and tumor suppressor mutations that enable tumor 
cells to evade programmed cell death and activate invasion and metastasis, thus making 
cancer treatment extremely challenging74, 75. Surgery and chemotherapy remain the 
mainstream of anti-cancer strategies. However, due to the complexity of cancer as a disease, 
it has become increasingly clear that small molecule drugs targeted to specific cellular 
pathways have limitations. Gene therapy involves the delivery of plasmid DNA (pDNA), 
small interfering RNA (siRNA), short hairpin RNA (shRNA) or micro RNA (miRNA) to 
modulate the expression of specific gene or proteins, which has the potential advantages to 
target any disease related gene76. Cancer gene therapy usually works through either 
upregulating apoptotic gene and cytotoxic immune cytokines or downregulating gene 
involved in tumor cell multidrug resistance77, 78. The use of combination therapy involving 
both gene therapy and chemotherapy has resulted in combinational effect and has become an 
increasingly important strategy for the future.  
The usual strategy for co-delivery of drug and gene is using separate carriers, which have 
different pharmacokinetic and pharmacodynamics properties and can hardly achieve 
combinatory effects79. Co-delivery of two therapeutic agents by a single carrier offers several 
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advantages over using separate carriers and ensures the drug and genes are able to work 
synergistically within the same cell to produce an enhanced anti-cancer effect80, 81. However, 
the development of such carrier remains a significant challenge, due to the difference in 
hydrophobicity, molecular weight and release profiles of drug and genes82. Attempts have 
been made to deliver drugs and DNA/RNA simultaneously using nanocarriers such as 
liposomes, polymeric nanoparticles and micelles83, 84. Various functional groups were 
incorporated into the carriers for interaction and binding with drug and gene such as cationic 
quaternary amine groups for the electrostatic binding with DNA or RNA85. Here we report 
cationic micelle nanoparticles POEG-st-Pmor and POEG-st-Ppipe that were self-assembled 
from a biodegradable amphiphilic copolymer. These nanoparticles offered advantages over 
liposomes and other nanoparticles for their simplicity and flexibility in size and charge 
modulation. More importantly, they achieved high gene-transfection efficiency and the 
capability of co-delivering drugs and genes to tumor site. Enhanced gene transfection with 
the co-delivery of DOX had been demonstrated by in vitro and in vivo studies.  
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2.0 TARGETED DELIVERY OF CURCUMIN TO TUMORS VIA 
PEG-DERIVATIZED FTS-BASED MICELLAR SYSTEM 
 
2.1 ABSTRACT 	  
Curcumin and S-trans, trans-farnesylthiosalicylic acid (FTS) are two promising anticancer 
agents. In this study, we demonstrated that the two agents exerted significant synergy in 
antitumor activity in various types of cancer cells with combination indices ranging from 0.46 
to 0.98 (a value of less than unity indicates synergism). We have further shown that 
synergistic-targeted co-delivery of the two agents can be achieved via formulating curcumin 
in polyethylene glycol (PEG)-derivatized FTS-based nanomicellar system. Curcumin 
formulated in PEG-FTS micelles had small size of around 20 nm. The nanomicellar curcumin 
demonstrated enhanced cytotoxicity towards several cancer cell lines in vitro. Intravenous 
application of curcumin-loaded micelle (20 mg/kg curcumin) led to a significantly more 
effective inhibition of tumor growth in a syngeneic mouse breast cancer model (4T1.2) than 
curcumin formulated in Cremophor/EL (P<0.05).  
 
2.2 BACKGROUND 	   	  
Curcumin, a hydrophobic polyphenol compound extracted from Curcuma longa, has a wide 
spectrum of pharmacological activities and holds promise in the management of various 
diseases, such as cancers, cardiovascular diseases, Alzheimer’s disease, and diabetes86, 87, 88. 
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Particularly, curcumin has drawn interests as a therapeutic and chemopreventive agent for 
cancers via suppressing multiple signaling pathways such as MAPKs, PI3K/AKT, and NF-κB 
and inhibiting tumor cell proliferation, invasion, metastasis, and angiogenesis with no 
obvious side effect89, 90, 91. Moreover, curcumin acts as a chemosensitizer that augments the 
cytotoxic effect of other chemotherapeutic drugs such as doxorubicin and cisplatin92, 93, 94.     
S-trans, trans-farnesylthiosalicylic acid (FTS) is a synthetic farnesylcysteine mimetic that 
acts as a potent and especially nontoxic Ras antagonist95, 96. Constitutively active Ras caused 
by mutation in the Ras family of proto-oncogenes is present in one third of human cancers, 
with the highest incidence of mutational activation of Ras being detected in pancreatic and 
colon cancers97. Ras is also activated in cancer cells by other mechanisms98, 99. FTS has been 
shown to cause significant reduction of Ras levels, showing antitumor activity in a wide 
range of human cancers without observable side effects100, 101, 102. FTS also can work in 
combination with other anticancer drugs, such as valproic acid and PKF115-584103, 104. Both 
curcumin and FTS have issues of poor water solubility and limited oral bioavailability despite 
their potentials as anticancer agents105, 106. We have recently shown that PEGylation of FTS 
led to significantly increased solubility of FTS in aqueous solution107. A conjugate of one 
molecule of PEG5000 (PEG5K) with two molecules of FTS via a labile ester linkage 
(PEG5K-FTS2 (L)) well retained the FTS biological activity. Interestingly, polyethylene 
glycol (PEG)-derivatized FTS self-assembled to form small-sized micelles that are effective 
in solubilizing other hydrophobic drugs such as paclitaxel (PTX)107. In addition, 
PEG-FTS-based micelles demonstrated synergistic antitumor activity with co-delivered PTX 
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in vitro and in vivo107. In this study, we examined whether the combination of curcumin and 
FTS exerted a synergy in antitumor activity in various types of tumor cells. The potential of 
PEG-FTS-based micellar system in synergistic-targeted delivery of curcumin was also 
investigated.  
 
2.3 EXPERIMENTAL PROCEDURES 	  
2.3.1 Materials  
Curcumin (synthetic) was purchased from TCI American (OR, USA). Dimethyl sulfoxide 
(DMSO), 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium bromide (MTT), 
trypsin-EDTA solution, Triton X-100, and Dulbecco’s Modified Eagle’s Medium (DMEM) 
were all purchased from Sigma-Aldrich (MO, USA). FTS was synthesized and purified 
following the published literature96. Antibodies against p-Akt (S473) and Akt were purchased 
from Santa Cruz Biotechnology. HRP-labeled goat antirabbit IgG was purchased from 
Amersham Biosciences (Piscataway, NJ, USA). Dulbecco’s phosphate- buffered saline 
(DPBS) was purchased from Lonza (MD, USA). Fetal bovine serum (FBS) and 
penicillin−streptomycin solution were from Invitrogen (NY, USA). 
2.3.2 Cell Culture 
4T1.2 is a mouse breast cancer cell line, and Panc02-H7 (H7) is a mouse metastatic 
pancreatic cancer cell line. DU145 and PC3 are two human androgen-independent prostate 
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cancer cell lines. A549 is a human lung cancer cell line, and MCF7 is a human breast cancer 
cell line. All these cell lines were cultured in DMEM medium containing 10% FBS and 1% 
penicillin–streptomycin at 37°C in a humidified environment with 5% CO2. 
2.3.3 Animals 
Female BALB/c mice (4–6 weeks) were purchased from Charles River Laboratories. All 
animals were housed at controlled temperature and humidity according to AAALAC 
guidelines. All animal-related procedures were performed by fully following the protocol 
guidelines approved by the Animal Use and Care Administrative Advisory Committee of the 
University of Pittsburgh. 
2.3.4 Synthesis of PEG5K-FTS2 Conjugate 
PEG5K-FTS2(L) is a conjugate of one molecule of PEG5000 (PEG5K) with two molecules of 
FTS via a labile ester linkage. PEG5K-FTS2(S) is similar to PEG5K-FTS2(L) in structure but 
has a relatively stable amide linkage between PEG and FTS108. PEG5K-FTS2(L) and 
PEG5K-FTS2(S) conjugates were synthesized and chemically characterized as described 
previously107. Briefly, for the synthesis of PEG5K-FTS2(L), MeO-PEG5k-OH (1 equiv.), 
succinic anhydride (5 equiv.), and 4-(dimethylamino) pyridine (DMAP, 5 equiv.) were mixed 
in DCM to yield carboxyl-terminated PEG monomethyl ether (MeO-PEG5k-COOH). 
Diethanolamine (3 equiv.) was then coupled to the carboxylic group of MeO-PEG5k-COOH 
(1 equiv.) using N-hydroxysuccinimide (NHS 3.6 equiv.) and dicyclohexylcarbodii- mide 
(DCC 3.6 equiv.). PEG monomethyl ether with two hydroxyl groups (MeO-PEG5k-(OH)2) 
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was purified by precipitation with ice-cold diethyl ether and ethanol respectively. 
PEG5K-FTS2(L) conjugate was obtained by coupling MeO-PEG5k-(OH)2 (1 equiv.) to FTS (5 
equiv.) via DCC (3 equiv.) and DMAP (0.3 equiv.) in chloroform. The mixed solution was 
filtered, and the final product was purified by precipitation in cold diethyl ether and ethanol 
respectively. PEG5K-FTS2(S) was similarly synthesized except that MeO-PEG5K-OH was first 
reacted with di-Boc lysine followed by deprotection of Boc using TFA. MeO-PEG5k-(NH2)2 
was then reacted with FTS via DCC and DMAP, and the final product was similarly purified 
as described above. The structures of PEG5K-FTS2(L) and PEG5K-FTS2(S) were confirmed by 
NMR.  
2.3.5 Preparation of Curcumin-Loaded Micelles  
Curcumin (10 mM in chloroform) was mixed with PEG5K-FTS2(L) or PEG5K-FTS2(S) (10 
mM in chloroform) at various carrier/drug molar ratios. The chloroform was removed by a 
stream of nitrogen to generate a thin film at the bottom of the glass tube, and the residual 
organic solvent was further removed under vacuum for 2 h. Subsequently, the thin film was 
hydrated and suspended in DPBS to form the curcumin-loaded micelles. The unincorporated 
curcumin was removed by filtration through a syringe filter (pore size, 0.22 µm). The 
drug-free micelles were similarly prepared as described above.  
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2.3.6 Characterization of Curcumin-Loaded Micelles  
The average size and polydispersity index (PDI) of blank and curcumin-loaded micelles were 
measured by Zetasizer (Zetasizer Nano ZS instrument, Malvern, Worcestershire, UK) under 
room temperature.  
The morphology of micelles was examined through transmission electron microscopy 
(TEM). Briefly, curcumin micelles were diluted with DPBS and placed on a copper grid 
covered with Formvar. Samples were stained with 1% uranyl acetate, and imaging was 
performed at room temperature using TEM (JEM-1011, JEOL, Japan).  
The drug-loading capacity (DLC) and drug-loading efficiency (DLE) of curcumin 
micelles were determined by reverse phase HPLC (Alliance, 2695-2998 system). Briefly, 
curcumin- loaded micelles were prepared as described above and then filtered through a 
syringe filter (0.22 µm). Curcumin in the filtered and nonfiltered micelles was extracted with 
methanol and quantified by HPLC with a mobile phase consisting of methanol/0.3% acetic 
acid (80/20, v/v), a flow rate at 1 mL/min, and a UV detector. The DLC and DLE of 
curcumin micelles were calculated according to the following formula:  
DLC(%)=[weight of drug used/(weight of polymer+drug used)]×100%  
DLE (%)=[weight of loaded drug/weight of input drug]×100 %  
The colloidal stability of curcumin micelles with various carrier/ drug molar ratios was 
evaluated by following the changes in sizes of the particles at different times following 
sample preparation.  
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2.3.7 Cytotoxicity Assay  
Cytotoxicity assay was performed on 4T1.2, MCF7, A549, H7, DU145, and PC3 cell lines. 
All cells were plated at a density of 1,000 cells per well in 96-well plates and incubated for 
24 h in DMEM with 2.5% FBS and 1% streptomycin/penicillin. Then, cells were treated with 
various concentrations of free FTS, free curcumin, and the combination of both respectively 
for 96 h. Viability of cells was evaluated by MTT assay as described30.  
To test the cytotoxicity of curcumin-loaded PEG5K-FTS2(L) or PEG5K-FTS2(S) micelles, 
cells were treated with indicated concentrations of free curcumin, drug-free micelles, and 
curcumin- loaded PEG5K-FTS2(L) or PEG5K-FTS2(S) micelles respectively for 96 h. MTT 
assay was then performed as described above.  
2.3.8 Western Blot Analyses  
Western blotting was performed to evaluate the protein expression levels of phospho-AKT in 
DU145 cells. Cells grown in six-wells plates with 80% confluency were treated with free 
PEG5K-FTS2(L) or PEG5K-FTS2(S) micelles, free curcumin, and curcumin-loaded micelles 
respectively for 12 h. Cells were washed twice with pre-cooled PBS and lysed in a buffer 
containing 0.2% Triton X-100 for 10 min on ice. Protein concentrations were determined, and 
equal amounts of total protein lysate were resolved on a 15% SDS-PAGE and subsequently 
transferred to a nitrocellulose membrane. Membranes were blocked with 5% nonfat milk in 
PBS for 1 h prior to incubation with rabbit p-Akt or Akt primary antibody dissolved in PBST 
(DPBS with 0.1% Tween 20) overnight at 4°C. The blots were washed with PBST and then 
	  	   22	  
probed with goat antirabbit IgG for 1 h at room temperature followed by chemiluminescence 
detection. β-Actin was used as a loading control.  
2.3.9 Transfection Assay  
Transient transfections were performed on DU145 cells using the UF-2 transfection agent as 
described previously109. Briefly, the plasmid-UF2 complexes were formed by incubating 0.01 
mg of NF-κB reporter gene and 0.04 mg of UF-2 transfection agent at room temperature for 
20 min in a total volume of 400 µL of serum-free DMEM medium. The complexes were then 
mixed with freshly trypsinized cells in 5% FBS cell culture medium, and the cells were added 
to a 96-well plate at 50–70% confluency. After 12 h of incubation, the transfection medium 
was replaced with medium that contained 10% fetal bovine serum laced with the designated 
concentrations of free FTS, free curcumin, free PEG5K-FTS2(L) or PEG5K-FTS2(S) micelles, 
and curcumin- loaded PEG5K-FTS2(L) or PEG5K-FTS2(S) micelles respectively. Cells were 
lysed with 0.2% Triton X-100 12 h later and assayed for luciferase activities. Transfection 
experiments were per- formed on at least three occasions, and in each case, experiments were 
done in triplicate. Data were represented as fold induction over reporter gene alone.  
2.3.10 In Vivo Therapeutic Study  
The syngeneic mouse tumor model 4T1 was generated by s.c. injection of 2×105 cells in 100 
µL PBS into the right flank of each female BALB/c mouse. When the tumors reached ~50 
mm3 in size, mice were randomized into four groups (N = 5) for treatment. Mice were 
injected intravenously every other day for six times with 200 µL saline, blank PEG5K-FTS2(L) 
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micelles, curcumin in Cremophor EL (20 mg/kg), and curcumin-loaded PEG5K-FTS2(L) 
micelles (20 mg/kg) respectively. Tumor sizes and body weights were monitored every 2 
days. Tumor volume was calculated according to the formula: volume = (tumor length×tumor 
width2)/2. To compare between groups, relative tumor volume (RTV=V/V0, V0 was the 
tumor volume prior to the first injection) was calculated for each measurement. The mice 
were sacrificed when the tumors became larger than 1.5 cm in diameter or developed 
ulceration.  
2.3.11 Statistical Analysis  
In all statistical analyses, the significance was set at a probability of P<0.05. All results were 
reported as the means ±standard deviation. Statistical analysis was performed by Student’s t 
test for two groups and one-way ANOVA for multiple groups, followed by Newman-Keuls 
test if P<0.05.  
 
2.4 RESULTS  	  
2.4.1 Effect of FTS and Curcumin on Cancer Cell Growth  
The growth inhibitory activity of curcumin and FTS was assessed in a broad range of cancer 
cell lines including DU145 and PC3 (prostate), A549 (lung), H7 (pancreas), and 4T1 and 
MCF7 (breast). Curcumin or FTS caused a concentration-dependent inhibition of 
proliferation in all six cell lines (Figure 1), which was consistent with literature reports 
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(3,20,30–32). When we fixed the concentration of curcumin and gradually increased the 
concen- tration of FTS in co-treatment, the inhibition effect was progres- sively increased 
with increasing FTS concentration, indicating more effective tumor-killing effect in the  
 
 	  	  
Figure 1. Synergistic action between FTS and curcumin in inhibiting the proliferation of 
tumor cells.	   	  
Various types of tumor cells including DU145, PC3, H7, A549, 4T1.2, and MCF7 cells were 
treated with various concentrations of free FTS, free curcumin, and combination of both 
respectively for 96 h, and the cytotoxicity was determined by MTT assay. The experiment 
was performed in triplicate and repeated three times. Data are presented as means ± standard 
deviation.  
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combination treatment (Figure 1). Table I compares the cytotoxicity of single treatment and 
that of combination treatment at a representative FTS concentration of 25 µM in combination 
with curcumin. We calculated the combination index (CI) after co-administration of FTS and 
curcumin to assess whether the combination could confer synergistic, additive, or 
antagonistic effects (Table 1). CI was calculated by the equation CI = (d1/D501)+(d2/D502), 
with D501 being the concentration of FTS producing 50% cell-killing effect in single 
treatment and d1 being the FTS concentration required to achieve the same 50% killing effect 
with d2 in co-treatment. Similarly, D502 is the concentration of curcumin producing 50% 
killing effect in single treatment, and d2 is the curcumin concentration required to obtain the 
same 50% cell-killing effect in combination with d1. A CI of <1, =1, and >1 is suggestive of 
synergism, additive effect, and antagonism, respectively. Data in Table I indicated that the 
combination of FTS and curcumin showed synergism in all of these examined cancer cell 
lines.  
2.4.2 Characterizations of Curcumin-Loaded PEG5K-FTS2 Micelles  
We have previously shown that a micellar system based on PEG5K-FTS2(L) retained the 
biological activity of FTS and was capable of synergistic delivery of paclitaxel. Following 
demonstration of synergy between curcumin and FTS in antitumor activity in various types of 
tumor cells, we then investigated whether curcumin can be formulated in PEG5K-FTS2(L) 
micelles, leading to effective co-delivery of PEG-derivatized FTS and curcumin and the 
subsequent synergistic action between the two at the tumor site.  
	  	   26	  
Table 1. Synergistic Antiproliferative Activity of Curcumin and FTS in Cancer Cells 	  
	  
Combination Index (CI) of simultaneous treatment of curcumin and farnesylthiosalicylic acid 
(FTS) in DU145, PC3, H7, A549, 4T1.2, MCF7 cells. The CI values are interpreted as 
follows: <1.0, synergism; 1.0, additive; and >1.0, antagonism. Each experiment was done in 
triplicate  
	  
 
 
Figure 2. Particle size distribution and morphology of curcumin/PEG5K-FTS2 micelles. 
The average size and size distribution of drug-free micelles (a) and curcumin-loaded 
PEG5K-FTS2 micelles (b) were examined via DLS analysis. The morphology of drug-free 
micelles (c) and curcumin-loaded PEG5K-FTS2 micelles (d) was examined via EM following 
negative staining 
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Figure 2a shows that the particle size of PEG5K-FTS2(L) was around 20 nm, which was 
consistent with our previous report. Incorporation of curcumin into PEG5K-FTS2 (L) micelles 
had minimal impact on the average size and their size distribution (Figure 2b). TEM shows 
that both drug-free and curcumin-loaded PEG5K-FTS2(L) micelles had spherical shape and 
were homogenous in size distribution (Figure 2c, d), which was consistent with the result of 
DLS analysis (Figure 2a, b) 
Table 2 shows the DLC and DLE at various carrier/drug molar ratios. Curcumin could be 
formulated in PEG5K-FTS2(L) micelles at a carrier/drug molar ratio as low as 0.5:1. However, 
the resulting mixed micelles were only stable for 2 h. Increasing the carrier/drug molar ratio 
was associated with an improvement in the colloidal stability of the curcumin-loaded micelles. 
Almost all of the input curcumin was loaded into the PEG5K-FTS2 micelles at a carrier/drug 
ratio of 2.5:1, and the resulting mixed micelles were stable for about 36 h. 
Curcumin/PEG5K-FTS2 mixed micelles prepared under this condition were used for all 
subsequent studies.  
Table 2. Biophysical Characteristics of Curcumin-Loaded PEG5K-FTS2(L) Micelles and 
Free Micelles 
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Curcumin concentration in micelles was 1 mg/ml. Blank micelles concentration was 20 
mg/ml. Values reported at the means±SEM PDI polydispersity index, DLE drug-loading 
efficiency, DLC drug-loading capacity  
2.4.3 In Vitro Cytotoxicity of Curcumin/PEG5K-FTS2 Mixed Micelles  
Curcumin was loaded into PEG5K-FTS2(L) and PEG5K-FTS2(S) micelles. Figure 3a shows the 
cytotoxicity of free curcumin and curcumin-formulated micelles in 4T1.2 cells. It was 
apparent that curcumin formulated in PEG5K-FTS2(L) micelles was more active than free 
curcumin in inhibiting the proliferation of tumor cells. Similar results were observed in 
DU145 (Fig. 3b) and PC3 (Figure 3c) cancer cells. Interestingly, curcumin formulated in 
PEG5K-FTS2(S) micelles was comparable to free curcumin among the three cell lines tested 
(Figure 3a–c).  
	  
Figure 3 ． Cytotoxicity of free curcumin, curcumin/PEG5K-FTS2 (L), and 
curcumin/PEG5K-FTS2 (S) against mouse breast cancer cell line, 4T1.2.  
(a) and human prostate cancer cell lines, DU145 (b), and PC3 (c). Cells were treated for 96 h 
and cytotoxicity was determined by MTT assay. Values are reported as the means ± standard 
deviation for triplicate samples. 
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2.4.4 Effect of Curcumin/FTS Combination on AKT and NF-κB Pathways  
To investigate the mechanism for the improved inhibitory effect of curcumin/ PEG5K-FTS2(L) 
mixed micelles on cancer cells, we examined their effect on AKT and NF-κB pathways in 
DU145 cells as the two signaling pathways are critically involved in the rapid proliferation of 
various types of cancer cells89, 110, 111, and both FTS and curcumin have been shown to 
negatively regulate the two pathways111. As shown in Fig. 4, the level of pAKT was 
significantly downregulated following treatment with curcumin, which was consistent with 
previous reports112. The pAKT level was also decreased following treatment with either 
PEG5K-FTS2(L) or PEG5K-FTS2(S), although PEG5K-FTS2(L) was more effective compared 
to PEG5K-FTS2(S). It was also apparent that curcumin formulated in PEG5K-FTS2(L) micelles 
was more effective in inhibiting the phosphorylation of AKT compared to the treatment of 
either alone (Figure 4).  
	  
 
Figure 4. Inhibitory effect of micellar curcumin on AKT signaling in human prostate 
cancer cells, DU145.  
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Cells grown in medium containing 2.5% FBS were treated with 0.1% DMSO (control), 
PEG5K-FTS2(L), PEG5K-FTS2(S), curcumin/PEG5K-FTS2(L), curcumin/PEG5K-FTS2(S), and 
free curcumin respectively for 12 h. Western blotting was performed with total protein 
extracts using antibody against phospho-AKT. The same blot was reprobed with antibodies 
against total AKT as an internal control and β-Actin as a loading control. 	  
Figure 5 shows the effect of FTS and curcumin on NF-κB signaling as examined in a 
NF-κB reporter assay. NF-κB activity was significantly inhibited by treatment with either 
curcumin or FTS alone. However, the inhibition of NF-κB activity was further enhanced by 
the combination treatment. It is also apparent that curcumin formulated in PEG5K-FTS2(L) 
micelles was more effective in inhibiting NF-κB signaling compared to PEG5K-FTS2(L) 
micelles alone or curcumin formulated in PEG5K-FTS2(S) micelles (Fig. 5).  
2.4.5 In Vivo Therapeutic Study  
A highly metastatic 4T1.2 model (s.c.) was used to evaluate the in vivo antitumor activity of 
curcumin formulated in PEG5K-FTS2(L) micelles. Curcumin formulated in Cremophor EL 
was used as a control. As shown in Figure 6a, treatment with curcumin/Cremophor EL (six 
times, every other day) led to a modest inhibition of tumor growth at the early stage. 
However, there is a rebound in the growth rate of tumor following discontinuation of the 
treatment after d10. At d20, the tumors in curcumin/Cremophor EL-treated group became 
comparable to the tumors in PBS group in size.  
Curcumin formulated in PEG5K-FTS2(L) micelles was significantly more effective than 
curcumin/Cremophor EL in inhibiting the tumor growth. The growth of the tumors remained 
significantly retarded following the discontinuation of the treatment after d10. Figure 6b 
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shows the weights of the tumors collected at the end of the therapeutic study, which were 
consistent with the data of tumor growth curves (Figure 6a). All of the mice showed no signs 
of abnormal appearance, and no loss of body weight was found in these mice (Figure 6c).  
 
Figure 5. Inhibitory effect of micellar curcumin on NF-κB activity as determined in a 
NF-κB reporter assay.  
DU145 cells were transfected with NF-κB reporter gene. At 12 h post-transfection, cells were 
treated with free PEG5K-FTS2, free curcumin, and curcumin-loaded PEG5K-FTS2 respectively 
for 12 h. The firefly luciferase activity was normalized and expressed as fold induction over 
untreated control. Results are presented as means ± standard deviation of the data from three 
independent experiments performed in triplicate. *P<0.05; **P<0.01. 
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Figure 6. Enhanced antitumor activity of curcumin formulated in PEG5K-FTS2 (L) 
micelles.  
BALB/c mice were inoculated s.c. with 4T1.2 cells (2×105 cells/mouse). Mice with palpable 
tumors received various treatments every other day and tumor growth and mouse body 
weight were followed. Tumors were collected at the end of the experiment and weighed. (a) 
Changes of relative tumor volume at different times following the first treatment. Significant 
improvement in antitumor activity was found for the curcumin-loaded PEG5K-FTS2 group 
compared with the control group (*P<0.05; **P<0.01; N=5) and the group of curcumin 
formulated in Cremophor/EL (#P<0.05; N=5). Curcumin formulated in Cremophor/EL had 
moderate tumor inhibitory effect at the early stage when compared to control group 
(&P<0.05; N=5). (b) Weights of tumors collected at the end of the experiment (*P<0.05; 
**P< 0.01; N=5). (c) Change of mouse body weight at different times following the first 
treatment  
 
2.5 DISCUSSION 	  
In this study, we have demonstrated for the first time significant synergistic effect between 
curcumin and FTS in various types of cancers. We have also shown that curcumin can be 
effectively formulated in PEG-FTS micellar system, leading to enhanced antitumor activity in 
vitro and in vivo.  
Various systems have been developed for delivery of curcumin including polymeric 
micelles, liposomes, and hydrogels113, 114, 115, 116, 117, 118, 119. Several polymeric micellar 
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systems have been examined for delivery of curcumin including methoxy poly(- ethylene 
glycol)-zein, monomethyl poly(ethylene glycol)- poly(ε-caprolactone), 
methoxy-poly(ethylene glycol)-poly(- lactic acid)-tris-curcumin, methoxypoly(ethylene 
glycol)-b- poly(ε-caprolactone-co-p-dioxanone), poly(D,L-lac-tide-co- 
glycolide)-b-poly(ethylene glycol)-b-poly(D,L-lactide-co-gly- colide), and stearic 
acid-g-chitosan oligosaccharide micelle119, 120, 121, 122. Incorporation of curcumin into 
polymeric micelles led to enhanced antitumor activity in a number of tumor models including 
lung, breast, and colon cancers116, 117. Curcumin-loaded micelles have also been shown to 
effectively inhibit tumor angiogenesis118. However, most of the carrier materials in polymeric 
drug delivery systems do not have biological activity by themselves. PEG5K-FTS2(L)-based 
micelles are derived from a promising anticancer agent and have been demonstrated to well 
retain FTS-mediated antitumor activity107. FTS-derivatized system shall be particularly 
suitable for delivery of curcumin as curcumin and FTS demonstrated significant synergy in 
various types of cancers (Figure 1, Table 1). Indeed, curcumin formulated in PEG5K-FTS2(L) 
micelles was more active than free curcumin in several cancer cells tested including 4T1.2, 
DU145, and PC3 (Figure 3). The improved cytotoxicity of curcumin formulated in 
PEG5K-FTS2(L) micelles might be attributed to a synergistic action between the released 
curcumin and the free FTS that is cleaved from the PEG5K-FTS2(L) conjugate following 
intracellular delivery of the mixed micelles. Another important mechanism might involve the 
protection of curcumin from decomposition by the PEG5K-FTS2(L) micelles. Curcumin is 
known to undergo rapid degradation in a culture medium or buffer with physiological pH123, 
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124, and incorporation of curcumin into a delivery system has been shown to improve its 
bioavailability via slowing down the process of decomposition125. Interestingly, curcumin 
formulated in PEG5K-FTS2(S)-based micelles was compara- ble to or slightly less active than 
free curcumin in inhibiting the growth of cultured tumor cells (Figure 3). It might be due to 
the fact that PEG-FTS was largely designed for in vivo delivery and that in vitro cellular 
uptake of curcumin delivered via PEG-FTS micelles might be less efficient than that of free 
curcumin due to the steric hindrance imposed by PEG. This was supported by the data that 
the cytotoxicity of curcumin/ PEG5K-FTS2(L) mixed micelles is less active than the 
combination of free curcumin and FTS (Figure 1 and 3). It is possible that the PEG-FTS 
system can be further improved via incorporation of an active targeting ligand to facilitate 
intracellular delivery of curcumin/PEG-FTS mixed micelles.  
The mechanism for the synergy between FTS and curcumin is not clearly understood at 
present. However, FTS and curcumin are known to inhibit both NF-κB and PI3K/AKT 
signaling pathways89, 90. Our preliminary data clearly showed a synergy between curcumin 
and FTS in inhibiting either PI3K/AKT or NF-κB signaling, which likely contributes to the 
synergistic antitumor effect of the combination treatment.  
The in vivo antitumor activity of curcumin/PEG5K-FTS2(L) mixed micelles was 
examined in a syngeneic mouse tumor model, 4T1.2. 4T1.2 is an aggressive, metastatic breast 
cancer model. Although treatment with curcumin formulated in Cremophor/EL led to a 
modest inhibition of tumor growth at the early stage, there was a rapid rebound in the growth 
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rate of the tumor. In contrast, tumor growth was inhibited by curcumin/PEG5K-FTS2(L) 
mixed micelles in a more potent, sustained manner. A number of mechanisms are likely to be 
involved in the improved antitumor activity of curcumin formulated in PEG5K-FTS2(L) 
micelles. First, PEG-FTS formed very small-sized mixed micelles with curcumin. Such small 
sizes (20~30 nm) shall ensure effective penetration into various types of solid tumors 
including poorly vascularized tumors126, 127. In addition, the potential synergistic anti- tumor 
activity between curcumin and the freed FTS will contribute to the overall improved 
antitumor activity. More studies are currently underway in our laboratory to further improve 
the PEG-FTS-based delivery system and to better understand the molecular mechanism for 
the improved antitumor activity of the nanomicellar curcumin.  
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3.0 TARGETED CURCUMIN-LOADED PEGYLATED FTS-BASED 
NANOCARRIER FOR IMPROVED CANCER THERAPY IN VIVO 
 
3.1 ABSTRACT 	  
To improve the anti-tumor activity of curcumin, we have previously developed a 
dual-function carrier based on polyethylene glycol (PEG)-derivatized farnesylthiosalicylate 
(FTS). Despite the improved in vivo delivery, the application of this system is limited by a 
relatively low drug loading capacity (DLC). Here we report that incorporation of a 
drug-interactive motif (Fmoc) into PEG5k-FTS2 that led to further improvement in both drug 
loading capacity and formulation stability through the introduction of an additional 
mechanism of drug/carrier interaction. Curcumin could be effectively loaded into 
PEG5K-Fmoc-FTS2 micelles with a DLC of 37.6%. In addition, curcumin/PEG5K-Fmoc-FTS2 
mixed micelles achieved a more sustained release of curcumin in comparison to the 
counterpart without Fmoc motif. In vitro cytotoxicity study showed that 
curcumin/PEG5K-Fmoc-FTS2 micelles exerted significantly higher levels of cell killing effect 
over free curcumin as well as curcumin/PEG5K-FTS2 in PC-3 and 4T1.2 cells, which might be 
due to improved cellular uptake of curcumin. Curcumin-loaded PEG5K-Fmoc-FTS2 micelles 
were also more effective in inhibiting colony formation by tumor cells. Finally, superior 
antitumor activity was demonstrated by curcumin/PEG5K-Fmoc-FTS2 in 4T1.2 mouse model 
compared to curcumin/Cremophr EL and curcumin/PEG5K-FTS2.  
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3.2 BACKGROUND 
 
Curcumin is a natural polyphenol compound extracted from the plant Curcuma longa. 
Curcumin has various pharmacological activities including anti-inflammatory and 
anti-Alzheimer's. Recently, curcumin has been shown to be highly cytotoxic towards various 
cancer cell lines by blocking AKT and NF-κB pathway and inducing tumor cell apoptosis. In 
addition, curcumin has been under investigation in clinical trials and has shown clinical 
benefits in for patients with various types of cancers including colorectal cancer and 
pancreatic cancer without major side effects; however, its water-insolubility and instability 
make its poorly bioavailable and thus it demonstrates low in vivo anticancer activity in tumor 
bearing mouse model. Therefore, drug delivery systems with high loading capacity and 
tumor-specific distribution represent an attractive strategy for improving cancer treatment 
with curcumin.  
Some attempts have been made to increase curcumin solubility and protect curcumin 
against degradation. Nanotechnology is one of the most promising methods for delivery of 
curcumin, which include liposomes, micelle, dendrimers and polymeric nanoparticles. 
Among these approaches, micelles have attracted increasing attentions as a nanocarrier in 
drug delivery and cancer treatment. Micelles are composed of amphiphilic molecules that can 
self-assemble into particles with a size ranging from 20 to 100 nm in aqueous solution. The 
hydrophobic core of micelle can accommodate hydrophobic drugs due to hydrophobic 
interactions between carrier and the loaded drug, which enable the water insoluble compound 
to stably and homogenously disperse in aqueous solution.  
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Besides, the flexible, hydrophilic PEG coating grafted onto the micelle surface acts as a 
steric barrier and it is effective in preventing rapid uptake of micelles by the RES, lengthens 
micelles circulation time in the blood. This together with small size (~20nm) gives micelles a 
better chance of extravasation through the leaky vasculature and slow accumulation in the 
tumor via the EPR effect. Therefore various polymeric micelles have been developed for 
solubilization and targeted delivery of curcumin. For example，Gou et al. demonstrated the 
encapsulation of curcumin into monomethoxy poly(ethylene glycol)-poly(3-caprolactone) 
(MPEG-PCL) micelles retained the in vitro cytotoxicity of curcumin on C-26 colon cancer 
cells and efficiently inhibited the tumor angiogenesis in vivo. Most recently, Gong et al. 
demonstrated curcumin -loaded mPEG-PCL-Phe(Boc) micelles significantly delayed tumor 
growth in an in vivo multidrug-resistant human erythroleukemia K562/ADR xenograft model. 
With assistance of micelle delivery system, curcumin can be completely dispersible in water 
for intravenous application. However, many polymer micelles can be dissociated by the blood 
components and lose the drug content right after administration. In addition, curcumin is 
quite unstable at physiological conditions. Thus, an efficient curcumin carrier should be able 
to retain it in blood circulation before it can access the tumor site. For most polymeric 
micelles, drug encapsulation is mainly based on carrier-drug hydrophobic interaction, which 
may not provide adequate compatibility for some drug molecules with different 
hydrophobicity. Therefore, it is critical to choose a suitable hydrophobic block to form the 
core. 
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In our previous work, we developed a derivatized FTS nano-carrier for delivery of 
hydrophobic drug including PTX or curcumin. FTS is a nontoxic and potent Ras antagonist 
for treatment of cancer. Ras gene mutations are widely found in different types of human 
cancers, with the highest incidence in pancreatic cancer and colon cancer. Continuously 
activated Ras protein caused by the gene mutations is highly involved in tumor maintenance 
and progression. FTS can effectively inhibit Ras-dependent signaling by causing 
dislodgement of actived Ras protein from the cell membrane and further lead to degradation 
of the protein. By conjugating FTS to PEG5k, the PEG5k-FTS2 itself can maintain the 
antitumor activity of FTS and can be further used to load other anticancer drugs. In addition, 
curcumin and FTS combination has shown synergistic antitumor effect in several cancer cell 
lines and curcumin loaded PEG5k-FTS2 micelles were prepared and investigated for their 
therapeutic effect on mouse breast tumor. In order to further improve antitumor activity of 
our drug delivery system, an Fmoc group was introduced into the improved nanocarrier as we 
recently discovered Fmoc as a drug interactive motif, it can not only improve the DLC but 
also further increase the formulation stability via providing extra carrier-drug interaction. In 
this work, we formulated curcumin into PEG5k-Fmoc-FTS2 copolymer with a solid dispersion 
method to obtain micelles with improved drug loading, prolonged stability and enhanced in 
vivo antitumor activity. Our result indicated that improved curcumin/PEG5K-Fmoc-FTS2 
micelles showed significantly enhanced anti-tumor activity both in vitro and in vivo, and may 
have potential clinical applications in breast cancer therapy.  
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3.3 EXPERIMENTAL PROCEDURES 	  
3.3.1 Materials 
Curcumin (synthetic) was purchased from TCI American (OR, USA). Poly(ethylene glycol) 
methyl ether (MeO-PEG-OH, MW = 5000 kDa), dimethyl sulfoxide (DMSO), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), trypsin-EDTA 
solution, Triton X-100, and Dulbecco’s Modified Eagle’s Medium (DMEM) were all 
purchased from Sigma-Aldrich (MO, USA). Dicyclohexylcarbodiimide (DCC) was 
purchased from Alfa Aesar (MA, USA). FTS was synthesized and purified following the 
published literature. Dulbecco’s phosphate-buffered saline (DPBS) was purchased from 
Lonza (MD, USA). Fetal bovine serum (FBS) and penicillin−streptomycin solution were 
from Invitrogen (NY, USA). All solvents used in this study were HPLC grade.  
3.3.2 Cell Culture  
4T1.2 is a mouse breast cancer cell line, and PC3 is a human androgen-independent prostate 
cancer cell line. Both cell lines were cultured at 37°C cell incubator with 5% CO2 in DMEM 
medium supplemented with 10% FBS and 1% penicillin–streptomycin.   
3.3.3 Animals 
Female BALB/c mice (4−6 weeks) were purchased from Charles River Company (Davis, CA, 
USA). All animals were housed in animal facility under pathogen-free conditions according 
to AAALAC guidelines. All animal-related experiments were performed in full compliance 
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with university guidelines and approved by the Animal Use and Care Administrative 
Advisory Committee at the University of Pittsburgh.  
3.3.4 Synthesis of PEG5k-Fmoc-FTS2 
PEG5k-Fmoc-FTS2 was prepared according to our previously published method. In brief, 1 
equiv. of PEG methyl ether (Mw = 5000 Da, mPEG5k−OH) was first reacted with 3 equiv. of 
a-Fmoc-e-Boc-lysine and DCC in dichloromethane (DCM) in the presence of DMAP for 2 
days at room temperature (RT). The PEG derivative was filtered and precipitated twice with 
cold ether and ethanol. The Boc group was removed by treatment of DCM/TFA (1:1, v/v) for 
2 h at RT and PEG5K-lysine(Fmoc)-NH2 was obtained by cold ether and ethanol precipitation. 
The PEG5K-lysine(Fmoc)-NH2 (1 equiv) was further reacted with succinate anhydride (2 
equiv) in the presence of DMAP (2 equiv) overnight in CH2Cl2. The yielded crude, 
PEG5K-lysine(Fmoc)-COOH was coupled with diethanolamine (3 equiv.) using N- 
hydroxysuccinimide (NHS 3.6 equiv.) and DCC (3.6 equiv.). PEG5K with two hydroxyl 
groups (MeO-PEG5k-Fmoc-(OH)2) was purified by precipitation with ice-cold diethyl ether 
and ethanol respectively. PEG5K-Fmoc-FTS2 conjugate was obtained by coupling 
PEG5k-Fmoc-(OH)2 (1 equiv.) to FTS (6 equiv.) via DCC (6 equiv.) and DMAP (0.6 equiv.) 
in chloroform. The pure PEG5k-Fmoc-FTS2 conjugate was obtained by filtration followed by 
precipitated in cold ether and ethanol twice. The dried powder was further purified by filtered 
the water solution through a 0.22 µm filter and lyophilization. PEG5K-FTS2 was synthesized 
following our reported method. 
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3.3.5 Preparation of Drug-Loaded and Drug-Free Micelles  
Free curcumin (10 mM in chloroform) and PEG5k-Fmoc-FTS2 conjugate (10 mM in 
chloroform) were mixed at various carrier/drug ratios. The organic solvent was dried under 
pure nitrogen flow to obtain a thin film of carrier/drug mixture and the residue of solvent was 
further removed under vacuum for 1 h. curcumin -loaded micelles were obtained by adding 
DPBS to hydrate the thin film followed by filtration (0.22 µm) to remove the undissolved 
curcumin particles. The drug-free PEG5k-Fmoc-FTS2 micelles were similarly prepared as 
described above.  
3.3.6 Characterizations of Curcumin/PEG5k-Fmoc-FTS2 Micelles  
The particle size of drug-free and curcumin-formulated PEG5k-Fmoc-FTS2 micelles were 
measured by dynamic light scattering with a Zetasizer (Zetasizer Nano ZS instrument, 
Malvern, Worcestershire, UK). The micelle morphology was observed by transmission 
electron microscopy (TEM, JEOL JEM-1011, Japan) as described before. In brief, a small 
copper grid was fully immersed in the micelle sample solution and subsequently stained with 
1% uranyl acetate solution. The morphology of micelle was examined by TEM at room 
temperature. 
The curcumin loading efficiency was measured by high performance liquid 
chromatography (HPLC) (Alliance 2695- 2998 system). curcumin-loaded micelles were 
prepared and filtered through a 0.22 µm filter. Methanol was added to the micelles before and 
after filtration and extracted curcumin was quantified by HPLC (mobile phase: methanol/0.3% 
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acetic acid (80/20, v/v), flow rate: 1 mL/min, UV detector). The Drug loading capacity (DLC) 
and drug loading efficiency (DLE) were calculated by the following equation:  
DLC (%) = [weight of drug loaded/(weight of carrier+ drug)] × 100  
DLE (%) = (weight of loaded drug/weight of input drug) × 100  
The micelle stability of curcumin/PEG5k-Fmoc-FTS2 micelles was followed and 
compared with previous curcumin/PEG5k-FTS2 formulation. Either drug precipitation or 
change of size was regarded as unstable.  
3.3.7 In Vitro Curcumin Release Study 
The in vitro curcumin release profile for the curcumin/PEG5k-Fmoc-FTS2 was investigated by 
a dialysis method according to our published paper. Curcumin/Cremophor EL or 
curcumin/PEG5k-FTS2 were added as control groups. Briefly, curcumin formulations at a 
concentration of 1 mg curcumin per mL were placed into a dialysis bag with a molecule 
weight cut off of 3500. The dialysis bag was clamped tightly on both ends and fully 
immersed in 200 mL DPBS containing 0.5% Tween 80 (w/v). The in vitro release studies 
were performed at 37 °C with gentle shaking. The concentration of curcumin remaining in 
the dialysis bag was measured at 0, 1, 2, 4, 8, 20, 40, 80 and 96 hours with HPLC. 
Cumulative percentage of drug released against time was plotted. 
3.3.8 Fluorescence Quenching Studies  
curcumin/PEG5K-FTS2 and curcumin/PEG5K-Fmoc-FTS2 were prepared at various carrier to 
drug molar ratio as described above. The micelles were placed in a 96-well plate and the 
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fluorescence intensity of the carriers or drug was recorded on a plate reader (Synergy H1 
Hybrid reader, BioTek). To examine fluorescence quenching of the carriers, the molar 
concentrations of carrier were kept constant for comparison. The blank micelles and drug 
loaded micelles was excited at an excitation wavelength of 270 nm and emission spectrum 
from 300 to 500 nm was recorded. In another set of experiments, curcumin concentration in 
the micelle was kept constant to examine the fluorescence quenching of curcumin. The 
fluorescence intensity of curcumin was examined using an excitation wavelength of 480 nm 
and emission wavelength from 510 to 650 nm.  
3.3.9 In Vitro Cytotoxicity Study 
The cytotoxicity of curcumin-formulated PEG5K-Fmoc-FTS2 micelles was evaluated in 4T1.2 
and PC3 cancer cell lines and compared to free curcumin in DMSO and curcumin 
/PEG5K-FTS2, respectively. Briefly, 4T1.2 (2000 cells/well) cells or PC3 cells (2000 
cells/well) were placed in 96-well plates for overnight. After cells were attached, various 
concentrations of free curcumin, curcumin/PEG5K-FTS2 or curcumin/PEG5K-Fmoc-FTS2 
were added to cells and incubated for 72h. Cell culture medium was removed and 100 µL of 
3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) solution (0.5 mg/mL 
in DPBS) was added to each well. After 2h of incubation，MTT solution was carefully 
removed and MTT formazan was solubilized by 100 µL of DMSO. The absorbance of each 
well at wavelength of 570 nm was measured by a plate reader. Untreated wells were used as 
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controls. Cell viability was calculated as [(ODtreated − ODblank)/(ODcontrol − ODblank) × 
100%].  
3.3.10 Colony Formation Assay 
In order to determine the antitumor efficacy of the formulation, curcumin/PEG5K-Fmoc-FTS2 
micelles were tested in an in vitro colony formation assay. 4T1.2 tumor cells were counted 
and seeded into a 6-well plate and incubated in 37 °C overnight. Cells were then treated with 
the free curcumin, curcumin/PEG5K-FTS2 or curcumin/PEG5K-Fmoc-FTS2 for 2 weeks, 
colonies consisting of >50 cells were counted. Colonies were washed with PBS and stained 
with 0.4% crystal violet for 1 min, rinsed in water and photographed under a microscope.  
3.3.11 Intracellular Uptake  
3 × 105 4T1.2 cells were seeded into each well of 6-well plates and incubated overnight to 
allow attachment. Then cells were treated with free curcumin, curcumin-loaded PEG5K-FTS2 
and PEG5K-Fmoc-FTS2, respectively at a curcumin concentration of 10 µM for 2h, 4h and 8h 
at 37 °C. Subsequently, cells were washed three times with ice cold DPBS. The intracellular 
uptake of curcumin in various formulations was observed under confocal microscopy (CLSM, 
FluoView 1000, Olympus, Japan).  
Quantitative cellular uptake of various curcumin formulations was evaluated by flow 
cytometry. Briefly, 4T1.2 cells in 6 well plates were prepared as described above. After 
incubation with various curcumin formulations at 37 °C for 4 h, cells were trypsinized, 
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washed thrice with cold DPBS and further resuspended in 0.5 mL of DPBS prior to the flow 
analysis. Curcumin were analyzed using a laser emitting at 488 nm wavelength and 
fluorescence was detected through a 575 nm band pass filter and quantified using flowjo 
Software. Triplicate assays were performed and results were calculated as percentage 
increase of the mean fluorescence intensity of the curcumin/PEG5k-Fmoc-FTS2 group 
compared to curcumin/PEG5k-FTS2 and free curcumin groups.  
3.3.12 In Vivo Therapeutic Study  
A syngeneic murine 4T1.2 breast cancer model was used to examine the therapeutic effect of 
different curcumin formulations. 2 × 105 4T1.2 tumor cells were inoculated subcutaneously at 
the right flank of female Balb/c mice. Treatments were initiated when tumors volume reached 
~50 mm3.  Twenty mice were randomly divided into 4 groups and injected intravenously 
with PBS (control), curcumin/Cremophor EL, curcumin/PEG5K-FTS2 and 
curcumin/PEG5K-Fmoc-FTS2 at a Cur concentration of 25mg/kg, respectively on days 1, 3, 5, 
8 and 11. Tumor sizes were measured with a digital caliper every three days since the start of 
treatment and tumor volume was calculated as V=(L × W2)/2 ( L: longest tumor diameter, W: 
shortest tumor diameter). In order to better compare between groups, relative tumor volume 
(RTV) was calculated (RTV=V/Vday 1). Mice were sacrificed before the tumor reached 2000 
mm3 according to the university animal protocol. Body weighs and mouse survival was 
monitored during the therapeutic study. 
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3.3.13 Statistical Analysis  
All results were reported as the mean ± standard deviation (SD). Statistical analysis was 
performed by Student’s t test for two groups, and one-way ANOVA for multiple groups, 
followed by Newman−Keuls test if P < 0.05. 
 
3.4 RESULTS 	  
3.4.1 Synthesis of PEG5K-Fmoc-FTS2 Conjugates  
PEG5k-Fmoc-FTS2 conjugate was synthesized by solution phase condensation reactions. 
Signals of Fmoc motif was at 7−8 ppm and methylene protons of PEG was located at 3.63 
ppm. Signals of 1.5−2.2 ppm and 7−8 ppm were from carbon chain and benzene ring of FTS, 
respectively. We also synthesized PEG5K-FTS2 conjugates, which were confirmed by 1H 
NMR spectra.  
3.4.2 Biophysical Characteristic of Curcumin Formulated PEG5k-Fmoc-FTS2 Micelles  
PEG2k-Fmoc-FTS2 could readily form micelles in aqueous solution with uniform size 
distribution around 20 nm at the concentration of 20 mg/mL (Figure 7a,c, Table 3).  The 
spherical morphology observed by TEM showed good agreement with the DLS result 
(Figures 7a).  Table 3 showed the sizes and PDIs of curcumin loaded PEG-FTS micelles at 
various carrier to drug ratios and PEG5k-Fmoc-FTS2 micelles were highly effective in 
solubilizing curcumin at a carrier to drug ratio as low as 0.1:1(molar ratio). The particle size 
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and shape were well retained following loading of curcumin into PEG5K-Fmoc-FTS2 micelles 
with a curcumin concentration of 1 mg/mL and a carrier/drug ratio of 2.5/1 (Figure 7b,d). At 
a carrier/drug ratio of 5/1, the curcumin formulated PEG5K-Fmoc-FTS2 micelles were stable 
for more than 1 month at room temperature compared to 4 days of curcumin/PEG5K-FTS2 
micelles at the same carrier/drug ratio. The curcumin loading capacity and efficiency of 
PEG5K-FTS2 and PEG5K-Fmoc-FTS2 micelles with different carrier to drug molar ratios were 
determined by HPLC (Table 3). The curcumin formulated PEG5K-Fmoc-FTS2 micelles could 
achieve a DLC of as high as 37.6%, which was more than 3 fold that of 
curcumin/PEG5K-FTS2 micelles. Overall, the PEG5K-Fmoc-FTS2 conjugates worked better 
than the counterpart without Fmoc motif in both drug loading efficiency and micelle stability.  
 
 
Figure 7. The size distribution of free (a) and curcumin loaded PEG5k-Fmoc-FTS2 
micelles (b).  
TEM morphology of free (c) and curcumin loaded PEG5k-Fmoc-FTS2 micelles (d). 
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3.4.3 In Vitro PTX Release Study 
The profile of curcumin release from the curcumin/PEG5K-Fmoc-FTS2 mixed micelles was 
examined by a dialysis method. As shown in Figure 8, curcumin/Cremophor EL showed a 
relatively fast release of curcumin with greater than 60% of curcumin being released within 4 
h and close to 90% of curcumin was released after 8 h. In contrast, the kinetics of curcumin 
release was significantly slower for either curcumin/PEG5K-FTS2 or 
curcumin/PEG5K-Fmoc-FTS2 formulation. In addition, curcumin/PEG5K-Fmoc-FTS2 mixed 
micelles showed a more sustained release of curcumin compared to curcumin/PEG5K-FTS2 
mixed micelles. Less than 40% of curcumin in PEG5K-Fmoc-FTS2 micelles was released 
within 24 h and more than 45% of the curcumin remained associated with the micelles after 
80 h compared to 65% and 80% released respectively in curcumin/PEG5K-FTS2 mixed 
micelles. 
Table 3. Biophysical Characteristics of Anticancer Drug-loaded PEG2K-Fmoc-NLG(L) 
Micelles and Blank Micelles. 
 
 
	  	   50	  
 
Figure 8. Cumulative release of curcumin from curcumin/Cremophor EL, 
curcumin-loaded PEG5K-FTS2 and PEG5K-Fmoc-FTS2 micelles. 	  
3.4.4 Fluorescence Quenching Studies  
The curcumin formulated PEG5K-Fmoc-FTS2 micelles exhibited a higher loading capacity 
and longer stability suggests that Fmoc groups may play an important role in interaction with 
loaded curcumin. A fluorescence quenching study was conducted to further examine the 
mechanism of drug-carrier interaction. The highest fluorescence intensity of Fmoc group in 
PEG5K-Fmoc-FTS2 alone was recorded at 310 nm at an excitation wavelength of 270 nm 
(Figure 9a). However, after the curcumin was loaded into the micelles, a dramatic 
fluorescence quenching was observed and the extent of fluorescence decrease was positively 
correlated to the amount of curcumin loaded in micelles. This phenomenon was likely due to 
the energy transfer between Fmoc groups and the loaded curcumin through the intermolecular 
π-π stacking interaction between aromatic rings. As a control, PEG5K-FTS2 alone and 
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curcumin/PEG5K-FTS2 showed minimum fluorescence at the wavelength range examined due 
to a lack of Fmoc groups (Figure 9a). 
To further evaluate the mechanism of drug-carrier interaction between curcumin and 
PEG5K-Fmoc-FTS2 carrier, fluorescence quenching of curcumin was examined at an 
excitation wavelength of 460 nm (Figure 9b). Fluorescence emitted at a range of 490-700 nm 
was recorded. Neither PEG5K-FTS2 nor PEG5K-Fmoc-FTS2 carrier showed any fluorescence 
at this wavelength range. Interestingly, curcumin fluorescence intensity was increased with 
increased amount of PEG5K-FTS2 or PEG5K-Fmoc-FTS2 carrier and the 
curcumin/PEG5K-Fmoc-FTS2 showed ~3 folds of increase of curcumin fluorescence intensity 
over that of curcumin/PEG5K-FTS2 at the same concentration of curcumin. This may 
suggested the loaded curcumin had more drug-carrier interaction with PEG5K-Fmoc-FTS2 
compared to PEG5K-FTS2.  
Taking together, these data suggested curcumin/Fmoc interaction played an important 
role in the overall carrier/drug interaction and π-π stacking might be a major mechanism in 
this process besides the hydrophobic interaction and hydrogen bonding. The enhanced 
carrier-drug interaction may contribute to the improved drug loading capacity and micelle 
stability. 
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Figure 9. Fluorescence quenching of curcumin loaded PEG5k-FTS2 and 
PEG5k-Fmoc-FTS2 micelles.  
(a) Curcumin loaded PEG5k-FTS2 and PEG5k-Fmoc-FTS2 micelle fluorescence intensity 
emitted between 310 and 460 was recorded with excitation wavelength at 270 nm. (b) The 
concentration of curcumin loaded in micelles was fixed at 1 mg/mL and intensity of 
fluorescence emitted between 490 and 700 nm was recorded with excitation wavelength at 
460 nm. 
	  
Figure 10. Improved celluar uptake of curcumin with micelle formulation. 
4T1.2 cells were incubated with free curcumin, curcumin/PEG5k-FTS2 micelles or 
curcumin/PEG5k-Fmoc-FTS2 micelles for 2h, 4 h and 8h. Cellular uptake of curcumin was 
examined by confocal laser scanning microscope. 
 
	  	   53	  
	  
Figure 11. Cellular uptake study of curcumin quantified by flow cytometry. 
3.4.5 Improved Intracellular Trafficking of Curcumin/PEG5K-Fmoc-FTS2 Micelles 
Quantitative cellular uptake of various curcumin formulations was evaluated by flow 
cytometry. Cells without curcumin treatment were used as a control. As shown in Figure 10 
and Figure 11, the curcumin formulated in PEG5K-Fmoc-FTS2 micelles showed higher uptake 
compare to curcumin loaed PEG5K-FTS2 and free curcumin after 6h of incubation, which was 
consistent with the imaging study. 
3.4.6 Enhanced In Vitro Cytotoxicity of Curcumin-loaded PEG5K-Fmoc-FTS2 Micelles 
Figure 12 showed the cytotoxicity of curcumin formulated in PEG5K-Fmoc-FTS2 micelles in 
4T1.2 cell line, free curcumin and curcumin loaded PEG5K-FTS2 were used as control. Free 
curcumin inhibited the cell growth in a dose-dependent manner and delivery of curcumin via 
the PEG5K-FTS2 micelles led to a significant improvement of cell killing effect. Incorporation 
of an Fmoc group to the PEG5K-FTS2 resulted in further improvement in the in vitro 
antitumor activity. Table 2 summarizes the IC50s of three treatment groups in both 4T1.2 and 
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PC3 cell lines. The IC50 of curcumin/PEG5K-Fmoc-FTS2 on 4T1.2 cells was significant 
lower (15.8 µM) compared to 24.2 µM of curcumin/PEG5K-FTS2 and 45.3 µM of free 
curcumin. Similar result was obtained from PC3 human prostate cancer cell line. 
 
 
 
 
Figure 12. In vitro cytotoxicity of curcumin formulated PEG5k-Fmoc-FTS2 micelles. 
(a) 4T1.2 mouse breast cancer cell line and (b) PC-3 human prostate cancer cell line were 
treated with free curcumin, curcumin loaded PEG5k-FTS2 micelle or curcumin loaded 
PEG5k-Fmoc-FTS2 micelle for 72 h and cell viability was examined by MTT assay. Results 
are reported as the means ± SD for triplicate samples. 	  
	  	   55	  
 
Figure 13. Improved inhibition of colony formation by cumumin formulated micelles. 
(a) Effects of free curcumin, curcumin loaded PEG5k-FTS2 micelle or curcumin loaded 
PEG5k-Fmoc-FTS2 micelle on the colony formation and cell proliferation of 4T1.2 breast 
cancer cells. (b) Quantitative analysis of colony formation. The numbers of colonies in 
controls were set to 100%. Values are indicated as mean±SD from three experiments. 
*p<0.05. 	  
 
Figure 14. In vivo antitumor activity of curcumin/PEG5K-Fmoc-FTS2 in a 4T1.2 
syngeneic breast cancer mouse model.  
(a) Mice were inoculated with 2×105 cells and treatements were given every 2 days for 5 
times when tumor volume reached ~50mm3 *P < 0.05 (vs control) #P< 0.05 (vs 
curcumin/PEG5k-FTS2). (b) Mice body weight was followed during the therapeutic study. (c) 
Tumors were harvest at day 19 and weighted. 
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3.4.7 Curcumin/PEG5K-Fmoc-FTS2 Suppressed Cell Proliferation and Colony 
Formation 
In vitro colony formation assay was performed to further examine the effects of the 
curcumin/PEG5K-Fmoc-FTS2 compared to free curcumin and curcumin/PEG5K-FTS2. Images 
of the colonies grown following various treatments were shown in Figure 13a. The numbers 
of colonies consisting of >50 cells were counted and normalized to untreated control groups 
(Figure 13b). As shown in figure 13, the curcumin/PEG5K-Fmoc-FTS2 could significantly 
decrease the colony formation compared with free curcumin and curcumin/PEG5K-FTS2, 
which was consistent with the result of MTT assay. 
3.4.8 In Vivo Therapeutic Study  
The in vivo therapeutic effect of curcumin formulated in PEG5K-FTS2 and PEG5K-Fmoc-FTS2 
micelles was evaluated, respectively, in a syngeneic murine breast cancer model (4T1.2), and 
compared to curcumin/Cremophor EL. As shown in Figure 14a, Both curcumin-loaded 
PEG5K-FTS2 micelles and curcumin/PEG5K-Fmoc-FTS2 micelles exhibited a significantly 
enhanced antitumor activity compared to curcumin/Cremophor EL(P < 0.01). Furthermore, 
curcumin formulated in PEG5K-Fmoc-FTS2 was more effective than curcumin formulated in 
PEG5K-FTS2 (P < 0.05). No significant changes in body weight were observed in all 
treatment groups compared to DPBS control group (Figure 14b). Tumors were harvested at 
the completion of the experiment and tumor weights were measured (Figure 14c).  
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3.5 DISCUSSION 	  
Previously, we developed a polymeric micelle system PEG5K-FTS2, curcumin micelles had a 
stronger inhibitory effect on tumor cell proliferation than free curcumin. Furthermore, 
curcumin micelles were more effective in inhibiting in vivo tumor growth in subcutaneous 
metastatic 4T1.2 tumor models. However, the application of curcumin/PEG5k-FTS2 micelle 
was limited by its relatively low drug loading capacity and in vivo stability. In this work, an 
improved PEG5k-Fmoc-FTS2 system was developed for in vivo delivery of curcumin by 
adding an Fmoc drug interactive motif. Amphiphilic PEG5k-Fmoc-FTS2 polymer composed 
of hydrophilic PEG and hydrophobic FTS segments with Fmoc group at the interfacial layer 
and due to the hydrophobicity differences between FTS and PEG segments. The FTS 
segments, tangled with curcumin, serve as hydrophobic core, Fmoc group can provide extra 
interaction to further enhance the drug loading, PEG located at the micelle surface provides 
limited affinity among the particles to prevent the formation of aggregates. Accumulating 
data have demonstrated that the drug loading capacity and stability of micelles can be greatly 
improved by enhancing drug-carrier interaction between inner core segment of micelles and 
drugs. Our previous data showed that the PEG5k-Fmoc-FTS2 could not only greatly improve 
the drug loading capacity of seveal chemotherapy drug such as PTX, but also significantly 
enhanced the tumor inhibitory effect compared to PEG5k-FTS2 delivery system in tumor 
mouse models (4T1.2 and PC3).  
Intracellular distribution of curcumin as free curcumin, curcumin /PEG5K-FTS2 or 
curcumin/PEG5K-Fmoc-FTS2 micelles was followed by confocal microscopy in 4T1.2 cells at 
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2, 4, 8 h after treatment, respectively (Figure 10). Of note, significantly greater amounts of 
curcumin were found inside of cells treated with curcumin/PEG5K-Fmoc-FTS2 after 4 h and 8 
h of incubation compared to free curcumin or curcumin/PEG5K-FTS2, suggesting 
PEG5K-Fmoc-FTS2 help curcumin to stay longer inside cancer cells. This may be attributed to 
the prolonged release of curcumin and better protection of curcumin against inactivation from 
hydrolysis by the PEG5K-Fmoc-FTS2 micelle in the intracellular drug delivery.  
In this study, our data showed that, by adding an extra drug interactive motif, Fmoc, the 
PEG5k-Fmoc-FTS2 is more effective in curcumin drug loading and delivery compared with 
PEG5k-FTS2 (Table 3, Figure 9,10). This may attributed to the improved micelle stability and 
drug carrier interactions. Firstly, Fmoc could enhance the micelle stability by promoting the 
carrier/carrier interaction. Our previous research showed that by incorporation of Fmoc to 
PEG5K-VE2, it could achieve lower CMC compared to the carrier without Fmoc. We noticed 
that the PEG5k-Fmoc-FTS2 had a CMC of 0.2µM, which was 4 times lower than that of 
PEG5k-FTS2. Due to the low CMC, the PEG5k-Fmoc-FTS2 polymeric micelles can remain 
stable in the blood stream at very low concentrations, which makes them relatively 
insensitive to blood dilution after i.v. administration, resulting in an prolonged circulation 
time compared to PEG5k-FTS2 micelles. This is likely due to the Fmoc incorporated may 
increased the balance between the hydrophobic head and hydrophilic tail of the carrier and 
may also contribute to the interaction between PEG5k-Fmoc-FTS2 molecules. The second 
mechanism involved in the carrier/drug interactions of curcumin-loaded PEG5k-Fmoc-FTS2 
micelles. Besides the hydrophobic interaction and hydrogen bonding, the enhanced curcumin 
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loading capacity was most likely due to excellent Fmoc/curcumin interaction. Both Fmoc and 
curcumin had the structure of flat and rigid aromatic rings, which made them easily to 
interact with each other through a π-π stacking effect. This hypothesis was supported by 
Fmoc fluorescence intensity change in PEG5k-Fmoc-FTS2 micellar with loading of curcumin 
in Figure 9A and the decrease of Fmoc fluorescence intensity was likely resulted from the 
fluorescence quenching and energy transfer in the Fmoc/curcumin inter-moleculer interaction. 
This phenomenon was further supported by the increased curcumin fluorescence intensity 
when loaded into the PEG5k-Fmoc-FTS2 drug delivery system in Figure 9B. The application 
of Fmoc in the nanocarrier system may provide new thoughts for the design of novel 
polymeric nanocarriers for delivery of other therapeutic agents with various structures. 
MTT assay and colony formation assay showed that the curcumin formulated in 
PEG5k-Fmoc-FTS2 micelles was more potent than free curcumin solubilized in DMSO in 
several cancer cells tested including 4T1.2 and PC3 (Figure. 12). The improved cytotoxicity 
of curcumin formulated in PEG5k-Fmoc-FTS2 micelles might be attributed to a synergistic 
action between the released curcumin and the free FTS that is cleaved from the 
PEG5k-Fmoc-FTS2 conjugate following intracellular delivery of the mixed micelles. In Figure 
13, curcumin formulated in PEG5k-Fmoc-FTS2 micelles also showed enhanced cytotoxicity 
and more effective inhibition of cell colony formation compared to curcumin/PEG5K-FTS2 
micelles. The fact that the cytotoxicity of curcumin-loaded PEG5k-Fmoc-FTS2 micelles was 
higher than that of curcumin-loaded PEG5k-FTS2 micelles suggests that the 
PEG5k-Fmoc-FTS2 not only retained the function of FTS, but also enhanced the cellular 
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uptake of curcumin into the cells and provided improved protection of curcumin from 
decomposition compared to PEG5k-FTS2 micelles. PEG5k-FTS2 is known to undergo rapid 
degradation in a physiological pH condition, and incorporation of PEG5k-FTS2 into 
PEG5K-Fmoc-FTS2 delivery system has been shown to improve its stability.  
A highly metastatic 4T1.2 murine breast cancer mouse model was used to investigate the 
in vivo therapeutic efficacy of curcumin loaded PEG5K-Fmoc-FTS2 micelles. As shown in 
Figure 14, the PEG5k-FTS2/PEG5K-FTS2 micelles were significantly more effective than 
curcumin/Cremophor EL formulation, which is consistent with our previous report. It is also 
apparent that inclusion of an Fmoc motif into PEG5K-Fmoc-FTS2 micelle led to a further 
improvement in tumor growth inhibition at the same curcumin concentration (Figure 14). The 
overall improvement in antitumor activity is likely due to an improved stability of curcumin 
loaded micelle and an enhanced tumor accumulation of curcumin in the tumor site caused by 
the reduced CMC and improved carrier/drug interaction of the PEG5K-Fmoc-FTS2 delivery 
system. More studies are ongoing in our lab to better understand the underlying mechanisms 
for the improved performance of PEG5K-Fmoc-FTS2 micelles. Biodistribution and blood 
pharmacokinetics will be investigated whether the PEG5K-Fmoc-FTS2 can increase the 
curcumin blood circulation time and achieve tumor specific accumulation. Overall, our 
findings suggested that the prepared curcumin/PEG5K-Fmoc-FTS2 micelles reported in this 
study had excellent potential as an intravenous therapy for breast cancer. 
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3.6 CONCLUSION 	  
In summary, we have extended and improved our previous formulation by introducing a 
drug-interactive motif at the interfacial region of conventional micellar system and 
demonstrated the biodegradable PEG5K-Fmoc-FTS2 polymeric micelles can effectively entrap 
curcumin and their excellent anti-tumor effects against 4T1.2 breast cancer cells in vitro and 
in vivo. In comparison with free curcumin and curcumin/PEG5K-FTS2, the prepared 
curcumin/PEG5K-Fmoc-FTS2 micelles showed enhanced the drug loading capacity of 
curcumin, increased cellular uptake, enhanced in vitro cytotoxicity, more sustained in vitro 
release kinetics, and better colony formation inhibitory effect. Moreover, with this improved 
FTS-based micellar carrier incorporated with Fmoc moiety, the curcumin/PEG5K-Fmoc-FTS2 
micelles suppressed tumor growth in the 4T1.2 tumor model more effectively than free 
curcumin and curcumin formulated PEG5K-FTS2. Our strategy may represent an effective and 
general approach to improve the performance of various delivery systems including micelles. 
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4.0 AN IMMUNOSTIMULATORY DUAL-FUNCTIONAL NANOCARRIER THAT 
IMPROVES CANCER IMMUNOCHEMOTHERAPY 
 
4.1 ABSTRACT 	  
Immunochemotherapy that combines a chemotherapeutic agent with an immune checkpoint 
blocker represents an attractive approach to improve cancer therapy. However, the success of 
immunochemotherapy is hampered by the lack of a strategy to effectively codeliver the two 
therapeutics to the tumors. Here we report the development of the first dual-functional, 
immunostimulatory nanomicellar carrier that was based on a prodrug conjugate of PEG with 
NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor currently used for reversing tumor 
immune suppression. An Fmoc group, an effective drug-interactive motif, was also 
introduced into the carrier to improve the drug loading capacity and formulation stability. We 
showed that PEG2k-Fmoc-NLG alone was effective in enhancing T cell immune responses 
and exhibited significant antitumor activity in vivo. More importantly, systemic delivery of 
paclitaxel using the PEG2k-Fmoc-NLG nanocarrier led to a significantly improved antitumor 
response in both breast cancer and melanoma mouse models. 
 
4.2 INTRODUCTION 	  	  
Chemotherapy remains a mainstay treatment for various types of cancers128, 129. It is generally 
believed that chemotherapeutics work through cytostatic and/or cytotoxic effects130. 
Accumulating evidence suggests that chemotherapy-elicited immune responses also 
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contribute significantly to the overall antitumor activity131, 132, 133, 134. Chemotherapeutic 
agents can modify the propensity of malignant cells to elicit an immune response and/or 
directly exert immunostimulatory effects135. However, the effectiveness of 
chemotherapy-elicited immune response as well as other types of immunotherapies is limited 
by various negative feedback mechanisms that are upregulated during tumor development 
and/or cancer treatment136, 137. Blockade of these immune checkpoints represents one of the 
most promising strategies to reactivate the immune response to cancer. Indeed, exciting 
preclinical and clinical anti-cancer results have been reported with the use of monoclonal 
antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed 
cell death protein 1(PD-1), two important immune checkpoints137, 138, 139, 140, 141, 142, 143. IDO is 
another important immune checkpoint protein involved in generating the immunosuppressive 
microenvironment that supports tumor cell growth144, 145. IDO is overexpressed in some 
cancer cells and functions as an enzyme that catalyzes the degradation of essential amino acid 
tryptophan (Trp) and accumulation of its metabolites145, 146, resulting in cell cycle arrest and 
death of effector T cells, but increases in the number of regulatory T cells147.  
Consistent with previous findings, we have indeed shown that the mRNA expression of 
IFN-γ was significantly increased in 4T1.2 tumor tissues following treatment with Taxol® 
(Figure. 15a). We have also found that Taxol® treatment led to significant upregulation of 
IDO expression in tumor tissues (Figure. 15b), suggesting that IDO was induced, likely by 
IFN-γ, to counterbalance antitumor immune responses. Thus, strategies that are targeted at 
IDO represent an attractive approach for the treatment of cancer, particularly in combination 
	  	   64	  
with chemotherapy133.  
 
 
Figure 15. RT-PCR for (a) IFN-γ and (b) IDO1 RNA transcripts in tumor tissues 
following Taxol treatment. 
 
Several IDO inhibitors have been reported, among which NLG919 is a highly 
IDO-selective inhibitor with an EC50 of 75 nM. However, most IDO inhibitors including 
NLG919 are poorly water soluble, which presents a major challenge in their therapeutic 
delivery and preclinical evaluations73. In addition, co-delivery of IDO inhibitors and 
chemotherapeutic agents to tumors remains a challenge due to their different physical and 
pharmacokinetic profiles. To resolve these challenges, we developed a novel micellar 
nanocarrier that was based on PEG-derivatized NLG919 prodrug. An Fmoc group was also 
introduced into the conjugate based on our recent discovery of Fmoc as a “formulation 
chemophor” or a structural unit capable of interacting with many pharmaceutical agents148. 
We have recently shown that incorporation of an Fmoc motif into a micellar system can not 
only improve the drug loading capacity and formulation stability but also broaden its utility in 
formulating various therapeutic agents of diverse structures149, 150. We hypothesized that 
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PEG-Fmoc-NLG represents an immunostimulatory dual-functional nanocarrier that facilitates 
synergistic delivery of chemotherapeutics and improves cancer immunochemotherapy. 
 
4.3 EXPERIMENTAL PROCEDURES 	  
4.3.1 Reagents  
Paclitaxel (PTX, >99%) was purchased from TSZ Chem (MA, USA). Docetaxel 
(DTX, >99%) was obtained from LC Laboratories (MA, USA). α-Fmoc-ε-Boc-lysine, N, 
N’-dicyclohexylcarbodiimide (DCC), trifluoroacetic acid (TFA), and triethylamine (TEA) 
were purchased from Acros Organic (NJ, USA). Monomethoxy PEG2000, 
4-dimethylaminopyridine (DMAP), ninhydrin, and other unspecified chemicals were all 
purchased from Sigma Aldrich (MO, USA). Dulbecco’s phosphate buffered saline (DPBS), 
Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), 100 
penicillin-streptomycin solution were all purchased from Invitrogen (NY, USA). All solvents 
used in this study were HPLC grade. 
4.3.2 Animals  
Female BALB/c mice (4-6 weeks), female BALB/c nude mice (4-6 weeks) and C57BL/6 
mice (4-6 weeks) were purchased from Charles River (Davis, CA). All animals were housed 
under pathogen-free conditions according to AAALAC (Association for Assessment and 
Accreditation of Laboratory Animal Care) guidelines. All animal-related experiments were 
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performed in full compliance with institutional guidelines and approved by the Animal Use 
and Care Administrative Advisory Committee at the University of Pittsburgh.  
4.3.3 Cell Culture 
4T1.2 murine breast cancer cells, B16 murine melanoma cells, Panc02 murine pancreatic 
ductal adenocarcinoma cells, HeLa human cervical cancer cells, and PC3 human prostate 
cancer cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C in 
a humidified environment with 5% CO2.  
4.3.4 RNA Isolation and qRT-PCR  
RNA extraction from cells and tissues were performed following our published protocols151. 
Briefly, TRIzol was used to extract RNA from cells and tissues, and the cDNA was 
synthesized with a high capacity cDNA reverse transcription kit (Applied Biosystems, CA). 
SYBR Green-based real-time PCR was performed with the ABI Prism 7300 Real-Time PCR 
System (Applied Biosystems, Foster City, CA). Data were normalized against the GAPDH. 
The relative transcript abundance was calculated based on three independent experiments.  
4.3.5 Synthesis of PEG2k-Fmoc-NLG Conjugate  
Both PEG2k-Fmoc-NLG(L) and PEG2k-Fmoc-NLG(S) conjugates were synthesized by 
coupling NLG919 to PEG2k with either ester linkage or ether linkage. PEG2k-Fmoc-NLG(L) 
was synthesized as follow: 1 equiv. of monomethoxy PEG2000 was mixed with 3 equiv. of 
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α-Fmoc-ε-Boc-lysine and DCC in dichloromethane (DCM) in the presence of DMAP for 2 
days at  room temperature (RT). Purified PEG2K-Fmoc-lysine-Boc was obtained by filtering 
the mixture and then ice-cold ether/ethanol precipitation twice. The Boc group was removed 
by treatment with DCM/TFA (1:1, v/v) for 2 h at RT and the deprotected 
PEG2K-lysine(Fmoc)-NH2 was obtained by ice-cold ether/ethanol precipitation. Finally, 
PEG2k-Fmoc-NLG(L) was synthesized by mixing PEG2k-lysine(Fmoc)-NH2 with excess 
amount of NLG919, DCC, and small amount of DMAP in DCM at RT for 2 days. The 
mixture was filtered and the filtrate was precipitated by ice-cold ether/ethanol twice. The 
crude product was dissolved in water and filtered through a 450 nm filter, followed by 
lyophilization to yield the powder of purified PEG2k-Fmoc-NLG(L). To synthesize 
PEG2k-Fmoc-NLG(S), NLG919 was reacted with methyl 4-bromobutanoate to form ether 
bond under NaH condition. After column purification, the methyl ester was hydrolyzed by 
NaOH and the obtained compound (3 equiv.) was conjugated with PEG2k-lys(Fmoc)-NH2 (1 
equiv.) using DCC (3 equiv.) and DMAP (0.3 equiv.). The mixture was filtered and the clear 
filtrate was precipitated by ice-cold ether/ethanol twice. The crude product was dissolved in 
water, filtered followed by lyophilization to obtain the purified PEG2k-Fmoc-NLG(S). 
4.3.6 Cell-based IDO Assays  
The IDO inhibitory effect of PEG2k-Fmoc-NLG was tested by an in vitro IDO assay73. 
Briefly, HeLa cells were seeded in a 96-well plate at a cell density of 5×103 cells per well and 
allowed to grow overnight. Recombinant human IFN-γ was then added to each well with a 
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final concentration of 50 ng/mL. At the same time, various concentrations of 
PEG2k-Fmoc-NLG(L), PEG2k-Fmoc-NLG(S) or free NLG919 (NLG919 concentrations: 50 
nM-20µM) were added to the cells. After 48 h of incubation, 150µL of the supernatants per 
well was transferred to a new 96-well plate. Seventy-five µl of 30% trichloroacetic acid was 
added into each well and the mixture was incubated at 50 °C for 30 min to hydrolyze 
N-formylkynurenine to kynurenine. For colorimetric assay, supernatants were transferred to a 
new 96-well plate, mixed with equal volume of Ehrlich reagent (2% 
p-dimethylamino-benzaldehyde w/v in glacial acetic acid), and incubated 10 min at RT. 
Reaction product was measured at 490 nm by a plate reader. For HPLC-MS/MS detection 
(Wastes Alliance 2695 Separation Module combined with Waters Micromass Quattro Micro 
TM API MS detector), the plate was centrifuged for 10 min at 2500 rpm and 100 µl of the 
supernatants per well was collected for tryptophan and kynurenine assay.  
4.3.7 T Cell Proliferation Study  
A lymphocyte-Panc02 cell co-culture study was conducted to examine whether 
PEG2k-Fmoc-NLG can reverse IDO1-mediated inhibition of T cell proliferation73, 152. Murine 
Panc02 cells were stimulated by IFN-γ (50ng/ml) to induce IDO expression and then 
irradiated (6000 rad) before coculture. Splenocyte suspensions were generated from BALB/c 
mice by passage through the nylon wool columns after lysing of red blood cells. 
IFN-γ-stimulated Panc02 cells (1×105 cell/well) were mixed with splenocytes (5×105 cells 
per well，pre-stained with CSFE) in a 96 well plate. Various concentrations of NLG919, 
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PEG2k-Fmoc-NLG(L) or PEG2k-Fmoc-NLG(S) were added to the cells. To measure the T cell 
proliferation, 100 ng/mL anti-CD3 and 10 ng/mL mouse recombinant IL-2 were added to the 
cocultures. The proliferation of CD8+ and CD4+T cells was measured by FACS after 3 days 
of coculture. 
4.3.8 Measurements of Trp and Kyn in Plasma and Tumor Tissues  
The kynurenine to tryptophan ratios in plasma or tumors in 4T1.2 tumor-bearing mice 
following different treatments were examined by LC-MS/MS as an indication of IDO enzyme 
activity153. BALB/c mice bearing 4T1.2 tumors of ~50mm3 were treated with DPBS, TAXOL 
(10 mg PTX/kg), PEG2k-Fmoc-NLG(L), or PTX/PEG2k-Fmoc-NLG(L) (10 mg PTX/kg) via 
tail vein once every 3 days for 5 times. One day after the last treatment, the plasma and tumor 
samples were harvested. Plasma samples were mixed with methanol (plasma: methanol, 1:2.5, 
v/v) and centrifuged at 14,500 rpm for 15 min. Supernatants were collected for LC-MS 
quantification of kynurenine and tryptophan.  
Tumor samples were homogenized in water and the homogenates were mixed with 
acetonitrile (1:1, v/v), centrifuged and supernatants were transferred to clean tubes. Equal 
volumes of methanol were added to precipitate proteins and supernatants were collected 
following centrifugation for HPLC-MS/MS measurement. 
4.3.9 Quantification of Tumor-infiltrating Lymphocytes  
BALB/c mice bearing 4T1.2 tumors of ~50mm3 received various treatments via tail vein 
injection once every 2 days for 3 times. Tumors and spleen were harvested one day following 
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the last treatment. Single cell suspensions were prepared and costained for CD4, CD8 and 
Foxp3 for FACS analysis. 
4.3.10 In Vivo Therapeutic Study of PEG2k-Fmoc-NLG Micelles Alone in a Murine 
Breast Cancer Model (4T1.2)  
To investigate whether IDO1 inhibition by PEG2k-Fmoc-NLG micelles can suppress tumor 
growth, female BALB/c mice of 4-6 weeks old were s.c. inoculated with 4T1.2 tumor cells 
(2×105 cells/mouse)147, 154. Mice were randomly grouped (N = 5) when the tumor volume 
reached ~50 mm3 and treated with PEG2k-Fmoc-NLG(L) or PEG2k-Fmoc-NLG919(S) once 
every 3 days for 5 times via tail vein injection. Tumor sizes were measured twice weekly in 
two dimensions using a caliper, and the tumor volumes were calculated with the formula: V = 
(A x B2)/2 (A and B are the long and short diameters of the tumor). Relative tumor volume 
was calculated to compare different treatment groups (relative tumor volume= tumor 
volume/tumor volume prior to first treatment). Mice were sacrificed when tumor volume 
reached ~2000 mm3. The difference between different treatment groups was analyzed by 
ANOVA with significance defined as P < 0.05. 
The above study was similarly performed in BALB/c nude mice to elucidate a role of T 
cell response in PEG2k-Fmoc-NLG-mediated antitumor activity73, 152. 
4.3.11 Preparation and Characterizations of Drug-free or Drug-loaded 
PEG2k-Fmoc-NLG Micelles 
The drug-loaded micelles were prepared by mixing PTX (10 mM in chloroform) or DOX (10 
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mM in chloroform) with PEG2k-Fmoc-NLG(L) or PEG2k-Fmoc-NLG(S) (10 mM in 
chloroform) at various carrier/drug ratios. The solvent was removed by N2 flow to form a thin 
film of drug/carrier mixture. The film was dried under vacuum for 1h and DPBS was added 
to form the drug-loaded micelles. The particle size and zeta potential of micelles were 
measured by a Zetasizer. The morphologies of both drug-free micelles and drug-loaded 
micelles were recorded under transmission electron microscopy (TEM). The critical micelle 
concentration (CMC) was determined by using nile red as a fluorescence probe following our 
published protocol155. 
4.3.12 In Vitro Cytotoxicity of PTX- and DOX-loaded PEG2k-Fmoc-NLG(L) Micelles   
4T1.2, PC3, Panc02, and B16 cells at 2000 cells/well were seeded in 96-well plates, 
respectively. After 12h incubation, the cell culture medium was removed and various 
concentrations of free PTX, free PEG2k-Fmoc-NLG(L) micelles or PTX/PEG2k-Fmoc-NLG(L) 
mixed micelles were added to the cells. After 3 days of incubation, 20µL of 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) in DPBS (5 mg/mL) was 
added to each well and cells were further incubated for 2 h. Medium was removed and MTT 
formazan crystals were solubilized by 100µL of DMSO per well. Absorbance of each well 
was measured with a microplate reader at wavelength of 550 nm. Untreated wells were used 
as controls. Cell viability was calculated as [(ODtreated-ODblank)/(ODcontrol-ODblank) × 100%]. 
Cytotoxicity of DOX-loaded PEG2k-Fmoc-NLG(L) micelles was similarly examined. 
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4.3.13 Intercellular Trafficking of DOX-loaded PEG2k-Fmoc-NLG(L) Micelles 
The intercellular trafficking of DOX-loaded PEG2k-Fmoc-NLG(L) micelles was examined on 
4T1.2 cells. DOX-loaded PEG2k-Fmoc-NLG(L) micelles (carrier:drug, 5:1, m/m) were 
prepared as described above. PEG2k-Fmoc-CBZ with a similar structure as 
PEG2k-Fmoc-NLG(L) was used as control156. 4T1.2 cells were seeded in 29 mm glass bottom 
dishes (In Vitro Scientific, Sunnyvale, CA) at 5 ×104 cells per well in 2 mL optimal DMEM 
and cultured overnight. Cells were then treated for 4 h with free DOX, 
DOX/PEG2k-Fmoc-CBZ or DOX/PEG2k-Fmoc-NLG(L) mixed micelles at a DOX 
concentration of 10 nM. The nuclei of cells were stained with Hoechst and cells were 
observed under a confocal fluorescence microscope. 
4.3.14 Plasma Pharmacokinetics and Tissue Distribution 
Groups of 5 female CD-1 mice were i.v. administered with TAXOL or 
PTX/PEG2k-Fmoc-NLG(L) mixed  micelles at a dose of 10 mg PTX/kg. Blood samples of 
50µL were withdrawn from the retro-orbital plexus/sinus of the mice from 3 min to 12 h (3 
min, 10 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 12 h). The blood collected in heparinized tubes 
was centrifuged at 2,500 rpm for 15 min. To 20µL of plasma, 350 µL of acetonitrile was 
added for protein precipitation and the resulting mixture was centrifuged at 12, 000rpm for 5 
min. Three-hundred microliters of the supernatants were collected from each sample and 
dried under airflow. The residues were dissolved in 50 µL of methanol and analyzed by 
HPLC for PTX. The pharmacokinetic parameters were calculated based on a 
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noncompartment model by Phoenix WinNonlin. 
For tissue distribution study, groups of 5 BALB/c mice bearing 4T1.2 tumors of 400–600 
mm3 were i.v. administered with PTX-loaded PEG2k-Fmoc-NLG (L) micelles or TAXOL at a 
PTX dose of 10 mg/kg. Mice were sacrificed 24 h after injection. Major organs and tumor 
tissues were collected, weighed, and homogenized with 2 mL solvent (acetonitrile to 
H2O=1:1, v/v). The samples were centrifuged at 4°C, 3,500 rpm for 15 min, and the 
supernatants were collected and dried under airflow. The residues were then dissolved in 200 
µL solvent (Methanol to H2O=1:1, v/v) and centrifuged at 4°C, 14,500 rpm for 10 min. The 
supernatants were mixed with equal volume of methanol and centrifuged again at 4°C, 
14,500 rpm for 10 min. Twenty microliters of the clear supernatants were injected into HPLC 
system for detection of PTX.  
4.3.15 In Vivo Antitumor Activity of PTX/ PEG2k-Fmoc-NLG(L)  
In vivo antitumor activity of PTX formulated in PEG2k-Fmoc-NLG(L) micelles was similarly 
examined in 4T1.2 tumor model as described above. Controls included PEG2k-Fmoc-NLG(L), 
TAXOL, and PTX/PEG2k-Fmoc-NLG(S). The PTX dose was 10mg/kg and mice received the 
treatment once every 3 days for 5 times. The growth of tumors was followed every three days 
after initiation of treatment for 19 days and relative tumor volume was calculated. The 
difference between different treatment groups was analyzed by ANOVA with significance 
defined as P < 0.05. The tumors were harvested and weighted at the end of experiment. The 
relative expression of CD8a, CD4, Foxp3 and IFN-γ in tumor tissues was examined by 
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qRT-PCR157.  
Similarly, a dose escalation study (5, 10, and 20 mg PTX/kg) was conducted for 
PTX/PEG2k-Fmoc-NLG(L) in 4T1.2 tumor model. The antitumor activity of 
PTX/PEG2k-Fmoc-NLG(L) was further examined in a murine melanoma model, B16,  as 
described above.  
 
Figure 16. In vitro biological activities of PEG2k-Fmoc-NLG. 
(a) Schematic representation of self-assembled PTX/PEG2k-Fmoc-NLG mixed micelles. (b) 
PEG2k-Fmoc-NLG inhibited IDO enzyme activity in vitro. HeLa cells were treated with 
IFN-g together with free NLG919 or PEG-NLG conjugate. Kynurenine in supernatants was 
measured 2 days later. Data represent means±s.e.m. *P<0.05 (versus PEG2k-Fmoc-NLG(L), 
N=3), #P<0.05 (versus PEG2k-Fmoc-NLG(S), N=3). (c,d) IDO1 inhibition reversed T-cell 
suppression mediated by IDO-expressing mouse pancreatic cancer cells (Panc02). Panc02 
cells and splenocytes were mixed and treated with IL-2, anti-CD3 antibody, IFN-g together 
with NLG919 or PEG-NLG conjugate for 3 days. (c) CD4+ and (d) CD8+ T-cell proliferation 
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was examined by FACS analysis. Representative data of three independent experiments are 
presented as means±s.e.m. *P<0.05. 
4.3.16 Statistics  
All data are presented as mean ± s.e.m. Differences between groups were assessed using 
ANOVA and P < 0.05 was considered statistically significant.  
	  
 
Figure 17. Synthesis schemes of PEG2K-Fmoc-NLG(L) (4) and PEG2K-Fmoc-NLG(S) (5) 
conjugates. 
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Figure 18. In vivo biological activities of PEG2k-Fmoc-NLG. 
(a) PEG2k-Fmoc-NLG(L) treatment decreased kynurenine concentrations in plasma and 
tumours. BALB/c mice bearing s.c. 4T1.2 tumours of ~50 mm3 received PBS or 
PEG2k-Fmoc-NLG(L) i.v. once every 3 days for 5 times at a dose of 25 mg NLG919 per kg. 
Kynurenine/tryptophan ratios in plasma and tumours were determined by HPLC–MS one day 
following the last injection. Data are means±s.e.m. of 3 experiments. *P<0.05, **P<0.01. (b–
g) IDO1 inhibition by PEG2k-Fmoc-NLG(L) increased CD4+ and CD8+ T cells, and 
decreased Treg cells in tumours. Tumour-bearing mice were treated as described above. (b) 
Gating of CD8 þ and CD4+ T cells (marked with black boxes) as a percentage of CD45+ 
lymphocytes. (c) Gating of Treg (CD4+FoxP3+) cells (marked with black boxes) as a 
percentage of CD4+ lymphocytes. (d,e) Relative number of intratumoural CD8+ (d) and CD4+ 
(e) T cells following different treatments. (f,g) Relative number of Treg cells (f) and CD8+ T 
cells/Treg (g) in tumour tissues. Data represent means±s.e.m. (**P<0.01, N=5). (h) 
PEG2k-Fmoc-NLG maintained the tumour inhibitory effect. Mice bearing tumours of ~50 
mm3 received different treatments as indicated (black arrows). *P<0.05; **P<0.01 (versus 
control, N=5), #P<0.05 (versus PEG2k-Fmoc-NLG(S), N=5). (i) Lymphocyte activities were 
required for the in vivo activity of PEG2k-Fmoc-NLG(L) micelles. Female BALB/c-nu/nu 
mice bearing 4T1.2 tumour of B50 mm3 were similarly treated as described above. (j) 
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Enhanced in vivo antitumour activity of PEG2k-Fmoc-NLG(L) compared with oral delivery of 
NLG (#P<0.05, N=5) or NLG formulated in PEG5k-(Fmoc-Boc)2 micelles (&P<0.05, N=5). 
*P<0.05 (versus control, N=5). Data represent means±s.e.m.  
 
 
Table 4. Biophysical Characteristics of Anticancer Drug-loaded PEG2K-Fmoc-NLG(L) 
Micelles and Blank Micelles. 
	  
 
DLC, drug loading capacity. Drug concentrations in micelle were 1 mg/mL and blank micelle 
concentration was 20mg/mL. wMeasured by dynamic light scattering sizer.  
 
4.4 RESULT 	  
4.4.1 Characterization of PEG2k-Fmoc-NLG 
PEG2k-Fmoc-NLG is an amphiphilic molecule that self-assembles into micelles in aqueous 
solutions. The self-assembly of PEG2k-Fmoc-NLG and the loading of hydrophobic drugs into 
the PEG2k-Fmoc-NLG micelles are illustrated in Fig. 16a. Fig. 17 shows the synthesis scheme 
of two PEG2k-Fmoc-NLG conjugates, one with a relatively labile ester linkage 
(PEG2k-Fmoc-NLG(L)) and the other one with a relatively stable amide linkage 
(PEG2k-Fmoc-NLG(S)). The chemical structures of the two conjugates were confirmed by 
NMR and mass spectrometry (MS). 
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The inhibitory activity of PEG2k-Fmoc-NLG(L) and PEG2k-Fmoc-NLG(S) on IDO was 
evaluated by examining their potency in inhibiting the conversion of Trp to kynurenine (Kyn) 
in HeLa cells73, 152.  HeLa cells were treated with IFN-γ to induce IDO expression and the 
amounts of Trp and Kyn in culture medium were determined by a colorimetric assay. As 
shown in Fig. 16b, free NLG919 inhibited the IDO activity in a concentration-dependent 
manner. PEG2k-Fmoc-NLG(L) was only slightly less active in inhibiting IDO compared to 
free NLG919 while PEG2k-Fmoc-NLG(S) was least active. Similar results were obtained 
when the Trp and Kyn concentrations were measured by LC/MS. We then examined if 
inhibition of IDO by PEG2k-Fmoc-NLG(L) led to enhanced T cell proliferation in an in vitro 
lymphocyte and Panc02 (a murine pancreatic cancer cell line) coculture experiment. As 
shown in Fig. 16c, coculture of IDO+ tumor cells with splenocytes isolated from BALB/c 
mice led to significant inhibition of T cell proliferation. This inhibition was significantly 
attenuated when the mixed cells were treated with NLG919. PEG2k-Fmoc-NLG(L) was also 
active in reversing the inhibitory effect of tumor cells although slightly less potent than 
NLG919. PEG2k-Fmoc-NLG(S) is less active compared to PEG2k-Fmoc-NLG(L) (Fig. 16c).  
The in vivo biological activity of PEG2k-Fmoc-NLG(L) was evaluated in an aggressive 
murine breast cancer model, 4T1.2. As detailed later, PEG2k-Fmoc-NLG(L) self-assembled to 
form nano-sized micelles (~90 nm) in aqueous solutions, which shall enable effective and 
selective delivery to tumors via enhanced permeation and retention (EPR) effect158. As shown 
in Fig. 18a, the ratios of Kyn (nM)/Trp (µM) in both blood and tumors were significantly 
reduced following the treatment of PEG2k-Fmoc-NLG(L) while a more dramatic reduction 
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was observed in the tumor tissues, consistent with the intended specific targeting of IDO 
inhibitors to the tumor tissues. Fig. 18b-g shows multi-color flow cytometric analysis of 
tumor-infiltrating lymphocytes in 4T1.2 tumor-bearing mice with or without treatment of 
PEG2k-Fmoc-NLG(L). It is clear that more CD4+ and CD8+ T cells were found in the tumors 
that received the treatment of PEG2k-Fmoc-NLG(L). In addition, the number of regulatory T 
cells (Tregs) was significantly reduced in the tumors treated with PEG2k-Fmoc-NLG(L).  
Fig. 18h shows the in vivo antitumor activity of PEG2k-Fmoc-NLG(L) and 
PEG2k-Fmoc-NLG(S) in 4T1.2 tumor model. Significant antitumor responses were observed 
for both prodrugs. It is also apparent that PEG2k-Fmoc-NLG(L) was more effective than 
PEG2k-Fmoc-NLG(S) in inhibiting the tumor growth. We also showed that 
PEG2k-Fmoc-NLG(L) was essentially not active in inhibiting the growth of 4T1.2 tumor in 
the immunocompromised nude mice that lack T and B cells (Fig. 18i), suggesting that the 
antitumor response was mediated via an enhanced T cell response. The above data clearly 
demonstrated that PEG-derivatized NLG919 prodrug well retained the pharmacological 
activity of NLG919 and that the cleavability of NLG919 from the conjugate affected its 
activity. We have further shown that i.v. PEG2k-Fmoc-NLG(L) was more effective than 
NLG919 delivered orally or NLG919 formulated PEG5k-(Fmoc-Boc)2 micelles (Fig. 2j) 
4.4.2 In Vitro Characterization of Drug-loaded PEG2k-Fmoc-NLG Micelles 
PEG2k-Fmoc-NLG(L) readily formed small-sized (~90 nm) micelles in aqueous solutions 
as confirmed by DLS and TEM imaging (Fig. 19a). Loading of PTX into 
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PEG2k-Fmoc-NLG(L) micelles resulted in minimal changes in the sizes of the particles and  
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Figure 19. In vitro biophysical and biological characterizations of micelles.  
(a) Size distribution and morphology of drug-free and PTX-loaded PEG2k-Fmoc-NLG(L) 
micelles (carrier: drug, 2.5:1, m/m) were examined by dynamic light scattering and TEM, 
respectively. Drug concentration in micelles was kept at 1 mg ml-1. Blank micelle 
concentration was 20 mg ml-1. Scale bar, 100 nm. (b) Measurement of CMC of 
PEG2k-Fmoc-NLG(L) micelles. (c) PTX release kinetics of PTX/PEG2k-Fmoc-NLG(L) 
examined via a dialysis method. PTX concentrations were kept at 1 mg ml1 in 
PTX/PEG2k-Fmoc-NLG(S), PTX/PEG2k-Fmoc-NLG(L) and Taxol. PTX concentrations were 
analysed at 0, 1, 2, 4, 8, 24 and 48 h by HPLC. (d) Cytotoxicity of PEG2k-Fmoc-NLG(L) 
alone, free PTX, and micellar PTX against a mouse breast cancer cell line (4T1.2) and a 
human prostate cancer cell line (PC3). Cells were treated for 72 h and cytotoxicity was 
determined by MTT assay. *P<0.05 (PTX/PEG2k-Fmoc-NLG(L) versus PTX), N=3. (e) 
Cytotoxicity of PEG2k-Fmoc-NLG(L) alone, free DOX, and micellar DOX against a mouse 
breast cancer cell line (4T1.2) and a human prostate cancer cell line (PC3). Data represent 
means±s.e.m.  
 	  
Table 5. IC50 of PTX or DOX in Different Formulation 
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Table 6．Pharmacokinetic Parameters of PTX in Different Formulations. 	  
 
The experiment was performed as described for Fig. 4e. The pharmacokinetic parameters 
were analysed by Phoenix WinNonlin.  
their morphology (Fig. 19a). Similar results were obtained for PEG2k-Fmoc-NLG(S) micelles 
(data not shown). Fig. 19b shows that the critical micelle concentration (CMC) of 
PEG2k-Fmoc-NLG(L) was 0.737 µM. The relatively low CMC may render the micelles stable 
upon dilution in the blood, which is important for systemic delivery to tumors. Table. 4 
shows the drug loading capacity (DLC) of PEG2k-Fmoc-NLG(L) for several commonly used 
chemotherapeutic agents including paclitaxel (PTX), docetaxel, doxorubicin (DOX), gefitinib, 
imatinib, and curcumin.  
Figure 19c shows the kinetics of PTX release from PTX/PEG2k-Fmoc-NLG in 
comparison with Taxol. The kinetics of PTX release was significantly slower for either 
PTX/PEG2k-Fmoc-NLG(L) or PTX/PEG2k-Fmoc-NLG(S) formulation than Taxol. Fig. 19d 
shows the cytotoxicity of PTX-loaded PEG2k-Fmoc-NLG(L) in 4T1.2 cells. 
PEG2k-Fmoc-NLG(L) alone was not effective in inhibiting the tumor cell growth at the test 
concentrations. Free PTX inhibited the tumor cell growth in a concentration-dependent 
manner. PTX-loaded PEG2k-Fmoc-NLG(L) micelles were more effective than free PTX in 
inhibiting the tumor cell growth (Fig. 19d). Similar results were found in the PC3 human 
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prostate cancer cell line (Fig. 19d). We also observed enhanced cytotoxicity for DOX 
following incorporation into PEG2k-Fmoc-NLG(L) micelles (Fig. 19e). The IC50s of free 
drugs (PTX or DOX) and drug-loaded micelles are shown in Table 5. 
4.4.3 Pharmacokinetics and Biodistribution of PTX-loaded Micelles 
Figure 20a shows the kinetics of PEG-Fmoc-NLG in the blood in comparison to NLG loaded 
into PEG5k-(Fmoc-Boc)2 micelles. The concentrations of total NLG (intact 
PEG2k-Fmoc-NLG plus released free NLG) in the blood were significantly higher than the 
blood concentrations of NLG delivered by PEG5k-(Fmoc-Boc)2 micelles at most time points 
examined. It is also apparent that very little free NLG was detected in the blood in the group 
treated with PEG2k-Fmoc-NLG, suggesting the excellent stability of the conjugate in the 
blood. 
Figure 20b shows the amounts of total NLG in the tumours at different time points 
following i.v. administration of either PEG2k-Fmoc-NLG or NLG-loaded PEG5k-(Fmoc-Boc)2 
micelles. The NLG concentrations in the tumours in NLG/PEG5k-(Fmoc-Boc)2 group reached 
the peak levels at 2 h and then quickly declined over time. In contrast, high concentrations of 
NLG (largely intact conjugate) were found in the tumours over the entire 48h in the mice 
treated with PEG2k-Fmoc-NLG. It is also apparent that a relatively constant concentration of 
free NLG was detected in the tumours in this group, albeit at a low level, suggesting that 
NLG was slowly but continuously released from the conjugate over a prolonged period of 
time. Figure 20c,d shows the total amounts of NLG in tumours and other major organs/ 
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tissues at various times following i.v. administration of either PEG2k-Fmoc-NLG or 
NLG/PEG5k-(Fmoc-Boc)2 mixed micelles. 
Figure 20e shows the blood PTX kinetics in BALB/c mice as a function of time 
following i.v. bolus administration of PTX-loaded PEG2k-Fmoc-NLG(L) and Taxol. It is 
apparent that PTX/PEG2k-Fmoc-NLG(L) remained in the circulation for a significantly longer 
time compared with Taxol. The pharmacokinetic parameters are outlined in Table 3. 
Incorporation of PTX into PEG2k-Fmoc-NLG(L) micelles resulted in significantly greater 
t1/2, area under curve (AUC), and Cmax over Taxol. Meanwhile, volume of distribution (Vd) 
and clearance (CL) for PTX/PEG2k-Fmoc-NLG(L) were significantly lower than those for 
Taxol. 
Figure 20f shows the biodistribution of PTX in 4T1.2 tumour-bearing mice 24h 
following i.v. administration of PTX-loaded PEG2k-Fmoc-NLG(L) micelles or Taxol. 
Significantly greater amounts of PTX were found in tumour tissues for PTX-loaded 
PEG2k-Fmoc-NLG(L) micelles in comparison with Taxol. In contrast, PTX-loaded 
PEG2k-Fmoc-NLG(L) micelles showed significantly reduced accumulation than Taxol in 
liver, spleen and other organs/tissues. These data strongly suggest that PTX-loaded 
PEG2k-Fmoc-NLG(L) micelles are stable in the blood and are highly effective in selective 
delivery to the tumour tissues. Figure 20g,h shows the amounts of PTX in tumours and other 
major organs/tissues at various times following i.v. administration of either PTX-loaded 
PEG2k-Fmoc-NLG(L) micelles or Taxol. 
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Figure 20. Pharmacokinetics and biodistribution of drug-free and PTX-loaded micelles.  
(a,b) The kinetics of NLG in blood (a) and tumour (b) in 4T1.2 tumour-bearing mice 
following i.v. administration of PEG2k-Fmoc-NLG(L) in comparison to NLG-loaded 
PEG5K-(Fmoc-Boc)2 micelles (25 mg NLG per kg). (c,d) Tissue distribution of NLG in 4T1.2 
tumour-bearing BALB/c mice following i.v. administration of PEG2k-Fmoc-NLG(L) (c) or 
NLG-loaded PEG5K-(Fmoc-Boc)2 micelles (d) at a NLG dose of 25 mg kg-1. (e) Blood 
kinetics of PTX in BALB/c mice following i.v. administration of Taxol or 
PTX/PEG2K-Fmoc-NLG(L) mixed micelles at a dose of 10 mg PTX per kg. (f) Tissue 
distribution of PTX in 4T1.2 tumour-bearing BALB/c mice 24 h following i.v. administration 
of Taxol or PTX/PEG2K-Fmoc-NLG(L) mixed micelles at a PTX dose of 10 mg/kg. *P<0.05 
(N=5). (g,h) Tissue distributions of PTX at various time points following i.v. administration 
of Taxol (g) or PTX/PEG2K-Fmoc-NLG(L) mixed micelles (h) (10 mg PTX per kg). All data 
represent means±s.e.m. 
	  	   88	  
	  
Figure 21. In vivo antitumour activity of PTX-loaded PEG2k-Fmoc-NLG micelles.  
(a) In vivo antitumour activity of various PTX formulations in 4T1.2 tumour model. PTX 
dose was 10 mg/kg. Tumour sizes were plotted as relative tumour volumes. **P<0.01 (all 
treatment groups versus control group), #P<0.05 (PTX/PEG2k-Fmoc-NLG(L) versus Taxol ), 
&P<0.05 (PTX/PEG2k-Fmoc-NLG(L) versus PTX/PEG2k-Fmoc-NLG(S)). N=5. (b) 
Dose-escalation study on the antitumour activity of PTX-loaded PEG2k-Fmoc-NLG(L) 
micelles. PTX dose was 5, 10 and 20 mg/kg, respectively. **P<0.01 (all treatment groups 
versus control), #P<0.05 (10 mg, 20 mg PTX per kg versus 5 mg PTX per kg). N=5. (c) 
Antitumour activity of PTX/PEG2k-Fmoc-NLG(L) in a 4T1.2 tumour model in comparison to 
a combination of oral NLG with i.v. Abraxane, PEG2k-Fmoc-NLG(L) plus Abraxane or 
PEG5k-(Fmoc-Boc)2 micelles co-loaded with PTX and NLG. *P<0.01 (all treatment groups 
versus control), #P<0.05 (PTX/PEG2k-Fmoc-NLG(L) or PEG2k-Fmoc-NLG(L)+Abraxane 
versus oral NLG+Abraxane), &P<0.05 (PTX/PEG2k-Fmoc-NLG(L) or 
PEG2k-Fmoc-NLG(L)+Abraxane versus (PTX+NLG)/PEG5k-(Fmoc-Boc)2), 
(PTX/PEG2k-Fmoc-NLG(L) versus PEG2k-Fmoc-NLG(L)+ Abraxane), N=5. (d) Antitumour 
activity of PTX/PEG2k-Fmoc-NLG(L) in a murine melanoma (B16) model. PTX dose was 10 
mg/kg. **P<0.01 (all treatment groups versus control), #P<0.05 (PTX/PEG2k-Fmoc-NLG(L) 
versus Taxol), N=5. All data represent means±s.e.m.	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Figure 22. Flow cytometry analysis of immune cell subsets in tumour tissues.  
(a–d) T-cell infiltration in mouse tumours treated with Taxol, PEG2k-Fmoc-NLG(L) or 
PTX/PEG2k-Fmoc-NLG(L) at a PTX dosage of 10mg/kg. The relative abundance of 
CD4,CD8 (a),IFN-g positive intratumoural CD4 T cells (b), IFN-g positive intratumoural 
CD8+ T cells (c), and granzyme B-positive CD8+ T cells (d) in tumour tissues were detected 
by flow cytometry. (e) Flow cytometry gating and histogram analysis of FoxP3+T regulatory 
cells in mouse tumours. (f) Tumour-associated macrophages (TAMs) in mouse tumours. The 
percentages of TAM populations with specific macrophage markers (M1-type 
(CD11b+/F4/80+ /CD206-) and M2-type (CD11b+/F4/80+/CD206+)) in tumour tissues were 
detected by flow cytometry. (g) Flow cytometry gating and histograms analysis of 
CD11b+/Gr-1+ MDSC cells in mouse tumours. Double positive cells contain two populations, 
including Gr-1highCD11b+granulocytic (G-MDSC) and Gr-1intCD11b+ monocytic (M-MDSC) 
MDSC subsets. The bars represent means±s.e.m. (*P<0.05, **P<0.01, N=3). 
4.4.4 In Vivo Antitumor Activity of PTX-loaded Micelles 
In vivo antitumour activity of PTX-loaded micelles. Figure 21a and Supplementary Fig. 10a 
show the in vivo antitumour activity of PEG2k-Fmoc-NLG(L), Taxol, 
PTX/PEG2k-Fmoc-NLG(S) and PTX/PEG2k-Fmoc-NLG(L) at a PTX dosage of 10 mg kg ︎  1. 
Taxol showed a modest effect in inhibiting the growth of 4T1.2 tumour, which was 
comparable to that of PEG2k-Fmoc-NLG(L) alone. However, both PTX/PEG2k-Fmoc-NLG(S) 
and PTX/PEG2k-Fmoc-NLG(L) were more effective than Taxol or PEG2k-Fmoc-NLG(L) in 
inhibiting the tumour growth. It is also apparent that PTX/PEG2k-Fmoc-NLG(L) was more 
effective than PTX/PEG2k-Fmoc-NLG(S), suggesting a role of released NLG919 in the 
overall antitumour activity of PTX/PEG2k-Fmoc-NLG(L). The antitumour activity of the 
three PTX formulations follows the order of PTX/PEG2k-Fmoc-NLG(L)>PTX/PEG2k- 
Fmoc-NLG(S)>Taxol>PEG2k-Fmoc-NLG(L). 
The effective inhibition of tumour growth by PTX/PEG2k-Fmoc-NLG(L) was associated 
with a significant survival benefit. The median survival time of mice in 
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PTX/PEG2k-Fmoc-NLG(L) group is significantly longer compared with the mice treated with 
Taxol (P<0.01) or PEG2k-Fmoc-NLG(L) (P<0.01). 
Figure 21b show the antitumour activity of PTX/PEG2k-Fmoc-NLG(L) at various doses 
of PTX. Tumour growth was well controlled at all dose groups at early time points. After the 
last treatment at day 13, the tumour growth was almost stalled until day 22 for the groups of 
10 and 20 mg PTX per kg. After that, there was a rebound in tumour growth, particularly in 
the low-dose group. 
Figure 21c and Supplementary Fig. 10c show that PTX/PEG2k-Fmoc-NLG(L) was also 
more effective than a combination therapy that involves oral delivery of NLG together with 
i.v. administration of Abraxane. In addition, PTX/PEG2k-Fmoc-NLG(L) was more active than 
a combination of i.v. Abraxane with i.v. PEG2k-Fmoc-NLG(L). Furthermore, 
PTX/PEG2k-Fmoc-NLG(L) was more active than an i.v. formulation of PEG5k-(Fmoc-Boc)2 
that was co-loaded with PTX and NLG. Improved antitumour activity of 
PTX/PEG2k-Fmoc-NLG(L) was also demonstrated in an aggressive B16 murine melanoma 
model (Fig. 21d). 
All of the treatments were well tolerated by the mice and there were no abnormal 
physical signs in all treated mice. In addition, there were no obvious differences among all of 
the groups in body weights in all of the different therapy studies. 
To delineate a role of immune response in PTX/PEG2k-Fmoc-NLG(L)-mediated 
antitumour activity, the immune cell populations in the tumour tissues with various 
treatments were analysed by flow cytometry one day following five times of treatments. 
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Figure 22a shows infiltration of more CD4+ T cells in the tumours treated with 
PTX/PEG2k-Fmoc-NLG(L) compared with control or Taxol groups (P<0.05). There were 
also more CD8+ T cells in the tumours treated with PTX/PEG2k-Fmoc-NLG(L) compared 
with control group. It was also noted that the numbers of both CD4+ and CD8+ T cells in 
Taxol-treated tumours were lower than those in the tumours treated with carrier alone (Fig. 
22a). Delivery of PTX via PEG2k-Fmoc-NLG(L) was associated with a similar reduction in 
the numbers of CD4+ and CD8+ T cells (Fig. 22a). 
Figure 22b,c shows that the numbers of IFN-g-positive CD4+ or CD8+ T cells were 
significantly increased in the tumours treated with Taxol, PEG2k-Fmoc-NLG(L) or 
PTX/PEG2k-Fmoc-NLG(L). The magnitude of increase was similar among all of the 
treatment groups. 
The numbers of granzyme B-positive CD8+ T cells were also significantly increased in 
all of the treatment groups (Fig. 22d). However, there were significantly more granzyme 
B-positive CD8+ T cells in the tumours treated with PEG2k-Fmoc-NLG(L) or 
PTX/PEG2k-Fmoc-NLG(L) compared with Taxol-treated tumours (Fig. 22d). There were no 
differences between PEG2k-Fmoc-NLG(L) and PTX/PEG2k-Fmoc-NLG(L) groups in the 
numbers of granzyme B-positive CD8+ T cells (Fig. 22d). 
Treg cells were significantly decreased in all treatment groups compared with control 
group (P<0.01) and there were no significant differences among these treatment groups 
(P<0.05) (Fig. 22e). 
Figure 22f shows that the numbers of M2 (CD11b+F4/80+CD206+) tumour-associated 
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macrophages were significantly reduced in the tumours treated with PEG2k-Fmoc-NLG(L). 
Meanwhile, the numbers of M1 (CD11b+F4/80+CD206-) tumour-associated macrophages 
were slightly increased. There were no significant changes in the numbers of either M1 or M2 
macrophages in the tumours treated with Taxol or PTX/PEG2k-Fmoc-NLG(L).  
Figure 22g shows that the numbers of granulocytic myeloid-derived suppressor cells 
(G-MDSC) were significantly decreased in the tumours treated with PEG2k-Fmoc-NLG(L) 
alone. This is consistent with the previous reports that inhibition of IDO leads to decreased 
MDSC in the tumours. Surprisingly, G-MDSC were significantly increased in the tumours 
treated with either PTX/PEG2k-Fmoc-NLG(L) or Taxol. There were no significant 
differences among all of the groups in the numbers of monocytic MDSC (M-MDSC) in the 
tumours (Fig. 22g). 
Overall, the above data suggest that the microenvironment in the tumours treated with 
PTX/PEG2k-Fmoc-NLG(L) was more immune-active than that in Taxol-treated tumours. This 
is consistent with the data that the in vivo IDO activity was more effectively inhibited in mice 
treated with PTX/PEG2k-Fmoc-NLG(L) compared with Taxol-treated mice. 
 
4.5 DISCUSSION 	  
PEG-NLG919-mediated co-delivery of PTX. Different from most drug carriers that are 
‘inert’, PEG-Fmoc-NLG is a prodrug that exhibits immunostimulatory activity. Despite its 
reduced EC50 compared with free NLG with respect to the potency in inhibiting IDO in 
cultured cells, PEG-Fmoc-NLG was significantly more effective than NLG that was 
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formulated in a similar ‘inert’ nanocarrier without a NLG motif (PEG5k-(Fmoc-Boc)2) (Fig. 
18j). In addition, i.v. PEG- Fmoc-NLG was more active than NLG delivered orally (Fig. 18j). 
This is likely due to the effective delivery of PEG-Fmoc-NLG to the tumours (Fig. 20b,c). 
The slow release of NLG from PEG-Fmoc-NLG in tumour tissues (Fig. 20b) may also play a 
role. 
A major advantage of our approach is simultaneous delivery to the tumours of two agents 
of different mechanisms of action. In addition, this system could provide a programmable 
release of various drug components via both chemical conjugation and physical encapsulation. 
PTX and NLG showed different temporal release kinetics upon co-delivery to tumours. PTX 
has a much faster rate of release compared with that of NLG (Fig. 19c). PEG-Fmoc-NLG 
also has a longer retention time in the tumours (Fig. 20b), likely due to its macromolecule 
nature. Delivery of PTX via PEG-Fmoc-NLG was more effective in inhibiting the tumour 
growth than co-delivery of PTX and NLG via a similar ‘inert’ nanocarrier without a NLG 
motif (Fig. 21c). In addition, PTX/PEG2k-Fmoc-NLG(L) was more effective than oral 
delivery of NLG together with i.v. administration of Abraxane (Fig. 21c). We hypothesize 
that the relatively rapid release of PTX will lead to the first round of antitumour response that 
will be further potentiated by the immune response that follows. The immune response could 
result from enhanced antigen presentation following PTX-mediated killing of tumour cells 
and/or direct effect of PTX on immune cells. Meanwhile, the slow release of active NLG919 
from the prodrug helps sustaining or enhancing the magnitude of immune responses by 
reversing IDO-mediated immune suppression. As a result, the combined therapy has 
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produced a substantial inhibition of tumour growth. In fact, PTX/PEG2k-Fmoc-NLG(L) 
outperformed most reported PTX formulations including PTX formulated in our 
non-immunostimulatory dual-functional carriers. It is possible that the carrier-mediated 
antitumour activity can be further improved via incorporation of a tumour 
microenvironment-responsive linkage to facilitate the NLG release. Another advantage of our 
strategy lies in the simplicity with respect to both the synthesis of dual-function carrier and 
the combination therapy protocol, which is expected to facilitate a rapid translation into clinic. 
In addition, our nanocarrier is versatile in formulating various anticancer agents of diverse 
structures (Table 4). Immunological analysis indicates that, compared with those tumours 
from the no-treatment group, tumour tissues isolated from mice treated with 
PEG2k-Fmoc-NLG(L) are more immunoactive with more functional CD4+ and CD8+ T cells, 
decreased Treg and MDSC, and increased M1/M2 ratios. In addition, we showed a more 
immunoactive microenvironment within tumours treated with either Taxol or 
PTX/PEG2K-Fmoc-NLG(L) compared with the no-treatment group in most of the parameters 
examined, indicating immunogenic function of these compounds. However, tumour tissues 
from Taxol or PTX/PEG2k-Fmoc-NLG(L) groups had lower percentages of T cells including 
Treg, CD4+ and CD8+ T cells, but higher percentage of MDSC than the group treated with 
PEG2k-Fmoc-NLG(L) alone. The reduction in the percentage of total intratumoural T cells in 
the PTX/PEG2k-Fmoc-NLG(L) group relative to the PEG2k-Fmoc-NLG(L) group could be 
due to the cytotoxic effect of PTX treatment on these immune cells. Alternatively, it can also 
be attributed to the direct effect of PTX on tumour cells, leading to reduced production of 
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inflammatory factors. Nonetheless, when compared with PEG2k-Fmoc-NLG(L) treatment, 
PTX/PEG2k-Fmoc-NLG(L) does not significantly affect the percentage of T cells that 
produce IFN-g or Granzyme B, suggesting the antitumour effector function of intratumoural 
T cells is not affected by PTX. In addition, the cytotoxic effect of PTX might lead to reduced 
tumour burden, which can help enhance the overall efficacy of immunochemotherapy. 
Moreover, tumours treated with PTX/PEG2k-Fmoc-NLG(L) had more granzyme B-producing 
CD8+ T cells than the tumours treated with Taxol, suggesting IDO inhibition can still enhance 
antitumour T-cell immune responses in spite of repeated chemotherapy. Overall, our in vivo 
results show that the tumoricidal activity of PTX and the immune-enhancing function of 
NLG synergistically produced much more profound antitumour efficacy. 
It should be noted that our strategy does not preclude the development of an oral 
NLG-based treatment. The purpose of our comparative study (Figs 18j and 21c) is to show 
the advantages of our strategy over other approaches at similar doses with respect to both the 
simplicity and potency as far as a combination therapy with a chemotherapeutic agent is 
concerned. Eventually, a therapeutic regimen that involves systemic immunochemotherapy 
followed by oral NLG-based sustained treatment can be developed to maximize the treatment 
outcome. 
In summary, we have developed a simple and rational co-delivery approach that is 
effective in improving cancer immunochemotherapy. Although most of the works in this 
study are focused on PTX, it can be readily extended to immunochemotherapy with other 
anticancer agents such as DOX. Finally, such strategy can be employed in novel cancer 
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therapy combining chemotherapy drugs and other immune modulating agents such as small 
molecule inhibitors of PD-1. 
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5.0 PROGRAMMABLE CO-DELIVERY OF THE IMMUNE CHECKPOINT 
INHIBITOR NLG919 AND CHEMOTHERAPEUTIC DOXORUBICIN VIA A 
REDOX-RESPONSIVE IMMUNOSTIMULATORY POLYMERIC PRODRUG 
CARRIER 
5.1 ABSTRACT 
 
In order to achieve synergistic therapeutic efficacy and prevent cancer relapse, combination 
of chemotherapy and immunotherapy has been developed as a new modality for tumor 
treatment. In this work, we designed a redox-responsive immunostimulatory polymeric 
prodrug carrier PSSN10 for programmable co-delivery of immune checkpoint inhibitor 
NLG919 (NLG) and chemotherapeutics doxorubicin (DOX). NLG-containing PSSN10 
prodrug polymers were self-assembled into nano-sized micelles which served as a carrier to 
load DOX. The particle size, morphology as well as drug loading capacity and in vitro release 
kinetics were evaluated. The pharmacokinetics and tissue biodistribution of DOX-loaded 
micelles were examined in murine breast cancer models. The synergistic antitumor activity of 
DOX formulated in the immunostimulatory nanocarrier and the underlying mechanism were 
investigated. DOX could be formulated into PSSN10 carrier to form DOX/PSSN10 micelles 
with size of ~170 nm. DOX/PSSN10 showed more accumulation of DOX and NLG in the 
tumor tissues compared with those in other organs. PSSN10 was effective in enhancing T-cell 
immune responses and inhibiting tumor growth in vivo. More importantly, DOX/PSSN10 
exhibited significantly higher anti-tumor activity compared to that of DOX and PSSN10. 
Systemic delivery of DOX via PSSN10 nanocarrier results in synergistic anti-tumor activity. 
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5.2 INTRODUCTION 	  
Chemotherapy is one of the most widely used treatments for cancers. Although 
chemotherapeutic agents kill tumor cells mainly through cytostatic and/or cytotoxic effects, a 
large body of evidence suggests that chemotherapy-elicited immune responses also contribute 
to the overall antitumor activity 159. Nevertheless, various negative regulatory mechanisms 
such as inhibitory immune checkpoints are deployed by tumors to evade immune surveillance 
and suppress immune responses, which limits the overall effect of chemotherapy 160, 161. For 
example, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an immune checkpoint 
receptor expressed by activated T cells and transmits an inhibitory signal to T cells 162. 
Tumors exploit the CTLA-4 signaling to inhibit initiation of an immune response, resulting in 
decreased T-cell activation and proliferation 163; Like CTLA-4, programmed cell death 
protein 1 (PD-1) receptor is also expressed on the surface of activated T cells. Its ligand 
PD-L1, overexpressed by tumor cells, can interact with PD-1, leading to inhibition of the 
cytotoxic T cells. Tumor cells utilize the PD-L1/PD-1 pathway to evade detection and inhibit 
the immune response 164, 165, 166. To enhance anti-tumor immunity and prevent cancer relapse, 
combination of checkpoint blockade immunotherapy and chemotherapy has been developed 
as an attracting modality for cancer treatment 167, 168, 169. 
Indoleamine 2, 3-dioxygenase-1 (IDO1) is another immunosuppressive protein that helps 
tumors evade the immune system and facilitates tumor growth and metastasis 170, 171, 172. 
IDO1 is overexpressed by most tumors, which mediates the degradation of essential amino 
acid tryptophan (Trp) into kynurenine (Kyn) and other metabolites, resulting in suppression 
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of effector T cells, and promotion of the regulatory T cells proliferation 173. Thus, blocking 
the function of IDO1 becomes a promising strategy to reactivate the immune response against 
cancer 174. 
NLG919 is a nontoxic IDO1-selective inhibitor, which blocks IDO-mediated immune 
suppressive pathways and leads to tumor regression in preclinical models 175. It has been 
shown that inhibition of IDO pathway can act synergistically with chemotherapy 176, 177. 
However, the success of an immunochemotherapy that combines NLG919 with a 
chemotherapeutic drug is limited by the lack of a strategy to effectively co-deliver the two 
therapeutics to the tumors. Co-loading of the two agents into a nanocarrier may meet with 
limited success due to their differences in physiochemical properties. In addition, 
tempo-spatial control of the release of the different drugs is difficult as all of the loaded drugs 
are often released at the same time. 
To solve these problems, our group previously developed PEG-NLG conjugate 
(PEG2k-Fmoc-NLG) as a prodrug carrier for co-delivery of NLG919 and chemotherapeutic 
drug paclitaxel (PTX) 178. It was found that the immune-enhancing function of NLG and the 
tumor killing effect of PTX synergistically contributed to the increased anti-tumor efficacy. 
In this work, we further improved the NLG-based prodrug system by increasing the units of 
NLG per prodrug molecule via reversible addition-fragmentation chain transfer (RAFT) 
polymerization technology. The new PSSN10 system consists of a POEG hydrophilic block 
and a PNLG hydrophobic block with a number of NLG919 motifs attached via 
redox-sensitive linkage (Fig. 1). PNLG hydrophobic block in the polymeric carrier not only 
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provides immunostimulatory property, but also facilitates the encapsulation of doxorubicin 
(DOX), a potent chemotherapeutic agent that induces immunogenic tumor cell death 179. 
NLG919 and DOX are incorporated into this system through chemical conjugation and 
physical “loading”, respectively, which allows the programmed release of DOX and NLG919 
in the tumors. Besides, disulfide linkage was introduced between NLG919 and polymer 
backbone to facilitate the cleavage of NLG919 from the polymeric carrier at tumor sites. The 
effect of the PSSN10 polymer on IDO activity and T cell proliferation was tested. The 
efficiency of the nanocarrier in selective delivery of DOX to tumors was examined. The 
synergistic antitumor activity of DOX formulated in the immunostimulatory nanocarrier and 
the underlying mechanism were also investigated. 
 
5.3 EXPERIMENTAL PROCEDURES 
 
5.3.1 Materials 
DOX·HCl were purchased from LC Laboratories. 4-nitrophenyl chloroformate was 
purchased from Acros. Dulbecco’s Modified Eagle’s Medium (DMEM), trypsin-EDTA 
solution, 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), Triton 
X-100 and Hoechst 33342 were purchased from Sigma-Aldrich. Penicillin-streptomycin 
solution and fetal bovine serum (FBS) were purchased from Invitrogen. 
2-Azobis(isobutyronitrile) (AIBN, Sigma-Aldrich) was purified by recrystallization in 
anhydrous ethanol 180. N-methacryloyl-N′-(t-butyoxycarbonyl)cystamine (MBC) 181 and 
POEG macroCTA 182 were prepared according to the literatures. All other reagents were of  
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N, N-Diisopropylethylamine (DIPEA) were dissolved in 8 mL anhydrous dichloromethane 
(DCM), and stirred overnight at room temperature. The product (NLG-NO2) was obtained by 
column chromatography purification.  
5.3.2 Synthesis of POEG-b-PMBC Polymers 
MBC monomer (144 mg，0.45 mmol), POEG macroCTA (175 mg，0.0194 mmol), AIBN (1 
mg, 0.0062 mmol) and 1 mL 1, 4-dioxane were added into a Schlenk tube, and deoxygenated 
by free-pump-thawing for three times. Then the Schlenk tube was immersed into an oil bath 
at 90°C. After 24 h, the mixture was precipitated in diethyl ether for 3 times to yield the 
POEG-b-PMBC polymers.  
5.3.3 Synthesis of PSSN10 Polymers 
POEG-b-PMBC polymers were deprotected in a mixture of TFA/DCM (1/1, v/v) at room 
temperature for 2 h, and then precipitated in cold diethyl ether for 3 times and dried in 
vacuum to give the Boc-deprotected polymer products. Then, the as-synthesized 
Boc-deprotected polymers (118 mg, 0.01 mmol) and NLG-NO2 (179 mg, 0.4 mmol) were 
dissolved in 2 mL DMF with 200 µL DIPEA. After stirring at room temperature for 24 h, the 
reaction mixture was precipitated in diethyl ether for 3 times. The final products PSSN10 
were obtained after vacuum drying.  
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5.3.4 Preparation of Blank and DOX-loaded Micelles 
The blank and DOX-loaded PSSN10 micelles were prepared through a dialysis method. 
DOX·HCl was first dissolved in methanol at a concentration of 5 mg/mL containing 
triethylamine (3 equiv.) to remove HCl. PSSN10 polymer was dissolved in THF at a 
concentration of 50 mg/mL. Then, the DOX solution was mixed with the PSSN10 polymer 
solution at a DOX/polymer mass ratio of 1: 20, followed by the dropwise addition of 0.5 mL 
of PBS. After removing solvent under reduced pressure, the solution was dialyzed against 
PBS overnight (MWCO 3.5 KDa). Blank micelles were similarly prepared except that no 
DOX was added. For determination of DOX concentration, DOX-loaded micelles were 
dissolved in DMSO and detected by fluorescence spectroscopy with excitation at 490 nm. 
Drug loading capacity (DLC) and drug loading efficiency (DLE) were calculated according 
to the following formula: 
DLC (wt%) = (weight of loaded drug/weight of input polymer +drug) × 100% 
DLE (%) = (weight of loaded drug/weight of drug in feed) × 100% 
5.3.5 Critical Micelle Concentration (CMC) Measurement 
The CMC value of PSSN10 micelles was measured using nile red as a fluorescence probe 183. 
Briefly, 10 µL of a 0.05 mg/mL stock solution of nile red in DCM was added to each tube. 
After the solvent was completely evaporated, PSSN10 solution in PBS ranging from 1.0×10-4 
to 5×10-1 mg/mL was added. The mixtures were kept overnight and then evaluated by 
fluorescence spectrometry. 
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5.3.6 Polymers and Micelles Characterization  
1H NMR spectrum was performed on a Varian-400 FT-NMR spectrometer (400.0 MHz) with 
CDCl3 and DMSO-d6 as the solvent. Molecular weight (Mn and Mw) and distribution (Mw/Mn) 
of the synthesized polymers were measured by gel permeation chromatography (GPC) with a 
Waters 2414 refractive index detector. A series of polystyrene standards with narrow 
molecular weight distribution were applied to calibrate the GPC elution traces. 
Tetrahydrofuran (THF) was used as the eluent at a flow rate of 1.0 mL/min at 35°C and a 
series of commercial polystyrene standards were used for the calibration. The size 
distribution and morphology of blank and drug-loaded micelles were examined by dynamic 
light scattering (DLS, Malvern Zeta Nanosizer) and transmission electron microscopy (TEM, 
negative staining method), respectively. 
5.3.7 In Vitro DOX Release  
The in vitro DOX release profiles of DOX-loaded PSSN10 micelles were examined under 
different GSH concentrations (0, 10 µM, 10 mM). DOX-loaded micelles with a DOX 
concentration of 0.25 mg/mL were transferred into a dialysis bag (MWCO = 3.5kDa, 
Spectrum Laboratories), and immersed into a tank with 50 mL DPBS (PH =7.4) with 
different GSH concentrations (0, 10 µM, 10 mM) with gentle shaking at 37 °C. At specific 
time intervals, 4 mL PBS solution outside of the dialysis bag was withdrawn and displaced 
with 4 mL fresh solution. The amount of DOX released was determined by fluorescence 
spectrometry as described above.  
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5.3.8 Cell Culture  
Mouse metastatic breast cancer cells (4T1.2), human prostatic carcinoma cells (PC3) and 
human cervical cancer cells (HeLa) were cultured in DMEM culture medium, containing 10% 
(v/v) fetal bovine serum and 100 IU/mL penicillin and 100 µg/mL streptomycin at 37 °C in a 
humidified 5% CO2 atmosphere. 
5.3.9 In Vitro IDO Inhibition 
The IDO inhibitory activity of PSSN10 was tested by an IDO assay 184. Briefly, HeLa cells 
were plated in a 96-well plate (5 × 103 cells/well) and allowed to grow overnight. 
Recombinant human IFN-γ (50 ng/mL) was then added to each well. At the same time, 
various concentrations of PSSN10 or free NLG919 (NLG919 concentrations: 50 nM ~ 20 µM) 
were added to the cells. After incubation for 48 h, 150 µL of the supernatants was transferred 
to a new 96-well plate. Then 75 µL of 30% trichloroacetic acid was added and the mixture 
was incubated at 50 °C for 30 min to hydrolyze N-formylkynurenine to kynurenine. For 
colorimetric assay, supernatants were transferred to a new 96-well plate and incubated with 
equal volume of Ehrlich reagent (2% p-dimethylamino-benzaldehyde in glacial acetic acid, 
w/v) for 10 min at room temperature. Reaction product was measured at 490 nm by a plate 
reader. For HPLC-MS detection (Wastes Alliance 2695 Separation Module combined with 
Waters Micromass Quattro Micro TM API MS detector), the plate was centrifuged for 10 
min at 2,500 r.p.m. and 100 µL of the supernatant per well was collected for tryptophan and 
kynurenine assay. 
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5.3.10 T-cell Proliferation Study  
A lymphocyte-Panc02 cell co-culture experiment was performed to determine whether 
PSSN10 can reverse IDO1-mediated inhibition of T-cell proliferation 185. Murine Panc02 
cells were stimulated by IFN-γ (50 ng/mL) to induce IDO expression and then irradiated 
(6,000 rad) before coculture. Splenocyte suspensions were generated from BALB/c mice by 
passing through the nylon wool columns after lysis of red blood cells. IFN-γ stimulated 
Panc02 cells (1×105 cells/well) were mixed with splenocytes (5×105 cells/well, pre-stained 
with 5-(and 6)-carboxyfluorescein diacetate (CFSE)) in a 96-well plate. Various 
concentrations of PSSN10 and NLG919 were added to the cells. Then 100 ng/mL anti-CD3 
(clone 2C11) and 10 ng/mL mouse recombinant IL-2 were added to the cocultures. The 
proliferation of CD8+ and CD4+T cells was measured by flow cytometric analysis after 3 
days of coculture. 
5.3.11 In Vitro Cytotoxicity Assay 
4T1.2 and PC3 cancer cell lines were used for in vitro cytotoxicity study. Cells were seeded 
in 96-well plates at a density of 1.5 × 103 (4T1.2) and 3 × 103 (PC3) cells/well. After 
incubation for 24 h, cells were treated with free DOX, PSSN10 and DOX/PSSN10 micelles 
in a gradient concentration. After incubation for 72 h, the cell viability was measured via 
MTT assay as reported before 186. Untreated cells were included as a control. 
5.3.12 Cell Uptake and Intracellular Trafficking 
4T1.2 cells were cultured in glass bottom dishes (1 × 105 cells/dish) for 24 h and then treated 
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with DOX/PSSN10 micelles and free DOX (DOX concentration: 20 µg/mL) in FBS-free 
culture medium. After 4 h, the cells were stained with Hoechst 33342 for 20 min and washed 
with PBS for 3 times. The fluorescence images were obtained using a confocal laser scanning 
microscope (CLSM, FluoView 1000, Olympus, Japan). 
5.3.13 Animals  
Female BALB/c mice (6~8 weeks) and C57BL/6 mice (4~6 weeks) were purchased from 
Charles River (Davis, CA). All animals were housed under pathogen-free conditions 
according to AAALAC guidelines. All animal-related experiments were performed in full 
compliance with institutional guidelines and approved by the Animal Use and Care 
Administrative Advisory Committee at the University of Pittsburgh. 
5.3.14 Quantification of Trp/Kyn Ratio in Plasma and Tumor Tissues 
The kynurenine to tryptophan ratios in plasma or tumors in 4T1.2 tumor-bearing mice were 
examined by HPLC-MS/MS as an indication of IDO enzyme activity 187. BALB/c mice 
bearing 4T1.2 tumors of ~50mm3 were treated with DPBS, DOX, DOXIL, PSSN10, 
DOX/PSSN10 at a DOX dosage of 5 mg/kg via tail vein once every 3 days for 3 times. One 
day after the last treatment, the plasma and tumor samples were harvested. Plasma samples 
were mixed with methanol (plasma: methanol, 1:2.5, v/v) and centrifuged at 14,500 r.p.m. for 
15 min. Supernatants were collected for HPLC-MS quantification of kynurenine and 
tryptophan.  
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Tumor samples were homogenized in water and the homogenates were mixed with 
acetonitrile (1:1, v/v), centrifuged and supernatants were transferred to clean tubes. Equal 
volumes of methanol were added to precipitate proteins and supernatants were collected for 
HPLC-MS measurement. 
5.3.15 Plasma Pharmacokinetics and Tissue Distribution 
Female BALB/c mice (5 mice/group) were i.v. administered with DOX·HCl and 
DOX-loaded PSSN10 micelles at a DOX dose of 5 mg/kg. Blood samples were collected at 
different time points (3 min, 10 min, 30 min, 1 h, 2 h, 4 h, 8 h and 12 h) and centrifuged at 
2,500 r.p.m. for 15 min. 350 µL acetonitrile was added to the plasma and centrifuged at 
12,000 r.p.m. for 5 min. Then, the supernatants were collected and dried under airflow. DOX 
concentrations in the samples were analyzed by HPLC. The pharmacokinetic parameters 
were calculated based on a noncompartment model by Phoenix WinNonlin. 
For tissue distribution study, DOX·HCl and DOX/PSSN10 micelles were i.v. injected 
into female BALB/c mice bearing 4T1.2 tumors at a DOX dose of 5 mg/kg. At 24 h post 
injection, mice were sacrificed and the major organs were excised. The tissues were weighted 
and homogenized with 2 mL solvent (acetonitrile: H2O = 1:1, v/v). The samples were 
centrifuged at 3,500 r.p.m. for 10 min, and the supernatants were collected and dried under 
airflow. The residues were then dissolved in 200 mL solvent (methanol: H2O = 1:1, v/v) and 
centrifuged at 14,500 r.p.m. for 10 min. DOX concentrations in the clear supernatants were 
detected by HPLC. 
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5.3.16 In Vivo Therapeutic Efficacy  
Female BALB/c mice bearing 4T1.2 tumors were i.v. administered with saline, free DOX, 
blank PSSN10 micelles and DOX/PSSN10 mixed micelles (5 mg DOX/kg) once every two 
days for 3 times respectively. Tumor volumes were calculated according to the formula: (L × 
W2)/2, in which L is the longest and W is the shortest tumor diameter (mm), and presented as 
relative tumor volume (the tumor volume at a given time point divided by the tumor volume 
prior to first treatment). Besides, changes in body weights of all mice were monitored. At the 
completion of the experiment, tumor tissues were excised and fixed with 10% formaldehyde 
and embedded in paraffin. The sliced tissues at 5 µm were stained by hematoxylin and eosin 
(H&E) and observed by a Zeiss Axiostar plus Microscope (PA, USA). The Kaplan-Meier 
survival of the tumor-bearing mice (n = 8) was followed within 45 days. Mice were 
considered to be dead either when the mice died during treatment or when the tumor volume 
reached ~1000 mm3. 
5.3.17 Quantification of Tumor-infiltrating Lymphocytes  
The immune cell populations in the tumors following various treatments were measured by 
flow cytometry188. One day after the last treatment, cell suspensions from the spleens or 
tumors were filtered and red blood cells were lysed. For extracellular staining, cells were 
co-incubated with combinations of antibodies (CD8, CD4, CD11b, Gr-1, CD45, F4/80 and 
CD206). For intracellular staining, cells were fixed immediately after cell surface staining 
following the manufacturer’s description (eBioscience). Then the combinations of antibodies 
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(IFN-γ, FoxP3 and granzyme B) were added into cells in permeabilization buffer. For IFN-γ 
staining, cells were stimulated with PMA (5 ng/mL) and ionomycin (500 ng/mL) in presence 
of 10 mg/mL BFA for 4 h followed by extracellular and intracellular staining. The data were 
analyzed using the FlowJo software (Tree Star Inc.). 
	  
Figure 23. Synthesis scheme of PSSN10 polymers via RAFT polymerization and 
post-modification 
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5.4 RESULTS 	  
5.4.1 Synthesis and Characterization of the PSSN10 Polymer 
Figure 23 shows the synthesis scheme of PSSN10 polymer. (i) the hydroxyl group of 
NLG919 was activated with 4-nitrophenyl chloroformate to give NLG-NO2. (ii) The MBC 
monomer was synthesized according to the literature181. (iii) POEG (Mn = 9 KDa) was 
synthesized by RAFT polymerization as reported previously182 and further served as 
Macro-RAFT agent to initiate the polymerization of the MBC monomer. POEG-b-PMBC 
polymer was obtained after precipitation, followed by the deprotection of the Boc-groups in 
TFA/DCM solution to yield POEG-b-PSS polymer. The POEG-b-PSSNLG polymer was 
finally synthesized by the chemical coupling of NLG-NO2 to the Boc-deprotected 
POEG-b-PSS polymers. The 1H NMR spectrum of POEG-b-PSSNLG polymer was shown in 
Figure 24. The typical peaks at 7.72-7.17, 5.59, 2.04-0.75 ppm appeared in the 1H NMR 
spectrum of POEG-b-PSSNLG, which corresponded to the protons of NLG group. By 
comparing the intensities of Ic (at 5.59 ppm) and Ia (at 3.39 ppm), the NLG units conjugated 
on each copolymer were determined to be 10, which was translated into a DLC of NLG as 
high as 28% (wt.). The POEG-b-PSSNLG prodrug polymer was denoted as PSSN10 in the 
following study. 
5.4.2 Preparation and Characterization of Blank and DOX-loaded Micelles 
PSSN10 prodrug micelles were prepared using a dialysis method. Figure 25 shows that the 
critical micelle concentration (CMC) of PSSN10 was 15.5 mg/L. The relatively low CMC 
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shall provide a good stability of PSSN10 micelles upon dilution in the blood. DLS 
measurements showed that PSSN10 prodrug micelles had a unimodal size distribution with 
an average diameter of 134.7 nm (Fig. 26b). After loading of DOX, the particle size was 
increased to 175.1 nm (Fig. 26c). TEM images confirmed the spherical morphology for both 
PSSN10 micelles and DOX/PSSN10 mixed micelles. DOX was effectively loaded into 
PSSN10 micelles at a DLC of 4.0% with a loading efficiency of 84.0%. 
	  
Figure 24. 1 H NMR spectrum of PSSN10 polymer in CDCl3. 
	  
Figure 25. Plots of fluorescence intensity ratio at 650 nm versus concentrations of 
PSSN10 micelles 
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Figure 26.	   Schematic illustration of redox-responsive immunostimulatory PSSN10 
polymeric prodrug carrier for co-delivery of NLG919 and DOX.  
(a) Schematic illustration and (b) The particle size distribution of PSSN10 micelle measured 
by DLS (Inset: TEM image of PSSN10 micelle using negative staining. Scale bar is 100 nm.) 
(c) The particle size distribution of DOX/PSSN10 mixed micelle measured by DLS (Inset: 
TEM image of DOX/PSSN10 mixed micelle using negative staining. Scale bar is 100 nm.) (d) 
The in vitro release profiles of DOX from the DOX/PSSN10 mixed micelle in PBS with 
different GSH concentrations (0, 10 µM, 10 mM) at 37 °C. 
The in vitro DOX release studies were carried out in PBS solution with different GSH 
concentrations (0, 10 µM, 10 mM). As shown in Fig. 26d, DOX cumulative release from 
DOX/PSSN10 mixed micelles was about 36 % after 24 h in the absence of GSH. No 
acceleration in DOX release was observed in the presence of 10 µM GSH, which mimics the 
slightly redox environment of extracellular compartment. However, in the presence of 10 mM 
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GSH, about 70% of DOX was released within 24 h, indicating that rapid release of drug 
could be achieved in the highly redox environment after intracellular uptake by tumor cells.  
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Figure 27. In vitro biological activities of PSSN10.  
(a) In vitro inhibitory effect of IDO activity. HeLa cells were treated with IFN-γ together with 
PCCN10, PSSN10 and free NLG919. Kynurenine in supernatants was measured 2 days later. 
(b) The effect of PSSN10 on reversing T-cell suppression mediated by IDO-expressing 
mouse pancreatic cancer cells (Panc02). Panc02 cells and splenocytes were mixed and treated 
with IL-2, anti-CD3 antibody, IFN-γ together with PSSN10 and free NLG919 for 3 days. 
T-cell proliferation was measured by FACS analysis. *P < 0.05 (vs control). 
5.4.3 In Vitro Biological Activities of PSSN10 
In order to evaluate the IDO inhibitory effect of PSSN10 prodrug carrier in vitro, HeLa cells 
were pretreated with IFN-γ to induce IDO expression, and the amount of kynurenine (Kyn) 
was measured following treatment with PSSN10 and NLG919. As shown in Fig. 27a, free 
NLG919 and PSSN10 could block the IDO function in a NLG concentration dependent 
manner, although PSSN10 showed less IDO inhibitory effect than free NLG919. We also 
synthesized PCCN10 polymers without a disulfide linkage as a control. Compared with 
PCCN10, PSSN10 was more active in inhibiting the IDO activity, which might be due to the 
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efficient cleavage of disulfide linkage from PSSN10 in response to the intracellular GSH, 
suggesting the importance of introducing disulfide linkage into the NLG-based prodrug 
polymer. Thus, subsequent studies were focused on the PSSN10 polymers.  
In vitro lymphocyte-Panc02 (a murine pancreatic cancer cell line) co-culture experiment 
was then conducted to examine if the T-cell proliferation could be enhanced via the IDO 
inhibitory effect of PSSN10. Fig. 27b shows that co-culture of splenocytes isolated from 
BALB/c mice with IDO+ tumor cells led to significant inhibition of the proliferation of both 
CD4+ T cell and CD8+ T cells. This inhibition was almost completely reversed by free 
NLG919 at 20 mM. Fig. 27b also showed that PSSN10 blocked the inhibition by the tumor 
cells in a concentration-dependent manner. At the same NLG concentration of 20 mM, 
PSSN10 showed an effect that was comparable to free NLG919.    
5.4.4 Cytotoxicity and Intracellular Trafficking of DOX/PSSN10 Mixed Micelles 
MTT assay was carried out in 4T1.2 and PC3 cells to evaluate the cytotoxicity of 
DOX/PSSN10 mixed micelles. As shown in Fig. 28a, PSSN10 alone was not effective in 
inhibiting the tumor cell growth. Free DOX showed a cytotoxic effect on the tumor cells in a 
concentration-dependent manner. DOX-loaded micelles were comparable to free DOX in the 
levels of cytotoxicity against tumor 4T1.2 tumor cells. Similar results were also found in the 
PC3 cell line (Fig. 28b).  
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Figure 28. MTT assay of cytotoxicity of PSSN10, DOX and DOX/PSSN10 mixed 
micelles  
Micelle cytotoxicity in (a) 4T1.2 mouse breast cancer cell line and (b) PC-3 human prostate 
cancer cell line. Cells were treated for 72 h and results are reported as the means ± SD for 
triplicate samples. (c) Confocal laser scanning microscopic images of 4T1.2 cells at 4 h 
following treatment with free DOX or DOX/PSSN10 mixed micelles. The nuclei were 
stained with Hoechst 33342. 
 
Intracellular trafficking of DOX-loaded PSSN10 micelles was evaluated in 4T1.2 cells 
by confocal laser scanning microscopy with free DOX as a control (Fig. 28c). At 4 h after 
treatment with free DOX or DOX-loaded PSSN10 micelles, large amounts of fluorescence 
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signals were observed in perinuclear region of cells. Some of the DOX fluorescence signals 
were observed in nuclei for cells treated with DOX/PSSN10 mixed micelles, indicating the 
efficient intracellular delivery of DOX/PSSN10. 
	  
Figure 29. Pharmacokinetics and biodistribution of DOX-loaded PSSN10 micelles.  
(a) Blood kinetics of DOX in BALB/c mice following i.v. administration of DOX-loaded 
PSSN10 micelles at a dose of 5 mg DOX/kg with free DOX as a control. (b) Tissue 
distribution of NLG in 4T1.2 tumour-bearing BALB/c mice 24 h following i.v. administration 
of DOX-loaded PSSN10 micelles. (c) Tissue distribution of DOX in 4T1.2 tumour-bearing 
BALB/c mice 24 h following i.v. administration of DOX-loaded PSSN10 or free DOX (5 mg 
DOX/kg). n=5, *P < 0.05, **P < 0.01 (DOX/PSSN10 vs DOX). 
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5.4.5 Plasma Pharmacokinetics and Tissue Distribution 
Free DOX·HCl and DOX/PSSN10 mixed micelles (5 mg DOX/kg) were injected to BALB/c 
and the DOX concentrations in plasma were measured at different time points. As shown in 
Fig. 29a, DOX/PSSN10 remained in the blood circulation for a significantly longer time 
compared with free DOX. The pharmacokinetic parameters were calculated based on a 
noncompartment model and are outlined in Table 1. DOX/PSSN10 formulation showed 
significantly higher T1/2, area under curve (AUC0-inf) and Cmax than those of free DOX. In 
contrast, the volume distribution (Vd) and clearance (CL) for DOX/PSSN10 were 
significantly lower than those of free DOX, which suggests a prolonged circulation time of 
DOX/PSSN10 formulation in the blood. 
The tissue distributions of both NLG and DOX for DOX/PSSN10 mixed micelles were 
also investigated in BALB/c mice bearing 4T1.2 tumor. Fig. 29b shows the biodistribution of 
NLG at 24 h following i.v. administration of DOX/PSSN10 micelles. Significantly higher 
concentrations of NLG were detected in the tumors than those in other organs/tissues 
including heart, liver, spleen, lung and kidney. Besides, very little NLG was found in the 
blood, suggesting the good stability of the                                                                                                                                                             
PSSN10 in the blood circulation. Fig. 29b shows the biodistribution of DOX at 24 hfollowing 
i.v. administration of DOX/PSSN10 micelles with free DOX as a control. Significantly 
greater amounts of DOX were detected in tumors for DOX/PSSN10 mixed micelles 
compared with free DOX. It is also noted that DOX/PSSN10 mixed micelles showed higher 
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accumulation in tumors than in other organs/tissues. These data suggest that DOX and NLG 
can be selectively delivered to the tumor sites via PSSN10 prodrug carrier.  
	  
 
Figure 30.	   In vivo antitumor activity of PSSN10 and various DOX formulations in a 
syngeneic murine breast cancer model (4T1.2).  
(a) Three injections were made on days 0, 3 and 6. **P < 0.01. (b) Kaplan-Meier survival of 
4T1.2 tumor-bearing mice after various treatments. (c) Histological analyses of H&E stained 
sections of tumor tissues collected on day 19. 
5.4.6 In Vivo Therapeutic Study 
Fig. 30a shows the in vivo therapeutic effect of PSSN10 and DOX/PSSN10 with free DOX 
and DOXIL (a clinical formulation of liposomal DOX) as controls (5 mg DOX/kg). PSSN10 
carrier alone showed a modest effect in inhibiting the tumor growth, which was comparable 
to those of DOX and DOXIL. In comparison, PSSN10 showed little cytotoxicity in vitro 
MTT study (Fig. 28a, b), which indicated that the IDO inhibitory effect instead of the 
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cytotoxic effect contributed to the activity of PSSN10 in inhibiting tumor growth. DOX 
formulated in PSSN10 micelles showed enhanced antitumor activity, which was significantly 
higher than that of DOXIL.  
	  
 
 
Figure 31. IDO inhibition in tumor and blood 
Kynurenine concentrations in (a) tumor and (b) blood of BALB/c mice bearing s.c. 4T1.2 
tumors following various treatments. *P < 0.05 (vs control). 	  
Figure 30b shows the Kaplan-Meier survival curves of 4T1.2 tumor-bearing mice 
following different treatments. All formulations improved the survival rate compared to the 
saline control group. Among them, DOX/PSSN10 formulation resulted in the longest overall 
survival with a median survival of 40 days.  
Fig. 30c shows the histology of tumors following different treatments. Tumors from the 
mice treated with DOX/PSSN10 had more necrotic/apoptotic cells compared to the tumors 
from other treatment groups.  
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5.4.7 Effect of DOX/PSSN10 Treatment on Tumor Immune Microenvironment 
The Kyn concentrations, an indicator of IDO enzyme activity, in tumor tissue and blood 
following various treatments were measured by HPLC-MS. As shown in Fig. 31, the Kyn 
concentrations in both blood and tumor were significantly decreased following the treatment 
of PSSN10 and DOX/PSSN10, respectively. Interestingly, the levels of Kyn in the blood 
were also significantly decreased in the mice treated with DOXIL. 
 
 
	  	   124	  
Figure 32. Flow cytometry analysis of immune cell subsets in tumor tissues.  
Tumor bearing mice received various treatments at a DOX dosage of 5 mg/kg for three times 
at an interval of 3 days and tumoral T-cell infiltration, including (A) CD4+ and CD8+， (B) 
granzyme B-positive CD8+ T cells, were measured by flow cytometry. (C) FoxP3+ T 
regulatory cells, (D) MDSC subsets (Gr-1highCD11b+ granulocytic (G-MDSC) and 
Gr-1intCD11b+ monocytic (M-MDSC)) and (E) tumor-associated macrophage (TAM) 
populations (M1-type (CD11b+/F4/80+/CD206-) and M2-type (CD11b+/F4/80+/CD206+)) 
were also detected by flow cytometry. The bars represent means ± s.e.m. *P < 0.05 (vs 
control); &P < 0.05 (vs DOX); #P < 0.05 (vs DOXIL). 	  
We then further examined changes in the immune cell subpopulation in the tumor tissues 
that received different treatments. As shown in Fig. 32a, PSSN10 treatment led to a 
significant increase in relative numbers of CD4+ T cells and CD8+ T cells in the tumors 
compared with control, DOX or DOXIL groups. There was no significant difference in the 
relative numbers of CD4+ T cells between PSSN10 and DOX/PSSN10 (Fig. 32a).  
Fig. 32b shows that the relative number of granzyme B-positive CD8+ T cells in tumors 
was increased in all treatment groups compared with control group. The relative number of 
granzyme B-positive CD8+ T cells in tumor tissues treated with PSSN10 or DOX/PSSN10 
was higher than that of DOX-treated group. No significant difference was found in the 
relative number of granzyme B-positive CD8+ T cells between PSSN10 and DOX/PSSN10 
groups.  
Fig. 32c shows that the relative cell number of regulatory T cells (Treg) was reduced in 
all treatment groups compared with control group. Similarly, the relative cell number of 
granulocytic myeloid-derived suppressor cells (G-MDSC) in the tumors was reduced in all 
treatment groups (Figure 7D). No significant difference was found in the relative cell number 
of Treg (Figure 7C) or G-MDSC cells (Fig. 32d) between PSSN10 and DOX/PSSN10 groups. 
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There was also a slight decrease in the relative cell number of monocytic MDSC (M-MDSC) 
in the tumors after various treatments (Fig. 32d).  
Figure. 32e shows that the relative cell number of M1 (CD11b+F4/80+CD206-) 
tumor-associated macrophages in the tumors was slightly increased in all treatment groups. In 
contrast, the relative cell number of M2 (CD11b+F4/80+CD206-) tumor-associated 
macrophages was significantly reduced following treatment with DOXIL, PSSN10 or 
DOX/PSSN10. 
Overall, these data suggest a more immunoactive tumor microenvironment in mice 
treated with PSSN10 or DOX/PSSN10 in comparison with control or other treatment groups. 
This is consistent with the better in vivo IDO inhibitory effect of DOX/PSSN10 compared 
with that of DOXIL or other groups (Fig. 30). 
 
5.5 DISCUSSION 
 
Checkpoint blockade immunotherapy has been developed as a promising modality of 
treatment for various malignancies189, 190. Currently, immune checkpoint blockade is achieved 
with monoclonal antibodies specific for different immune checkpoint proteins 191. Recently, 
there has been growing interest in developing small molecule immune checkpoint 
inhibitors192, 193. Compared to antibodies-based immunotherapeutics, small molecule 
checkpoint inhibitors have the advantages of excellent safety, ease of production and more 
efficient delivery into tumor site193.  
IDO1 is an important immune checkpoint protein, which suppresses T cell proliferation 
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through Trp catabolism and Kyn production. 1-Methyl-d-tryptophan (1-MT) and NLG919 are 
two important small molecule inhibitors with distinct mechanism for blocking 
IDO1-mediated tumor immune escape194. Compared to 1-MT, NLG919 is a more potent 
IDO1-selective inhibitor with an EC50 of 75 nM195. Some studies have shown that IDO 
inhibitors can improve the therapeutic efficacy of chemotherapy or work synergistically with 
chemotherapy176, 177. However, there is limited information about the combination therapy of 
NLG919 with a chemotherapeutic drug196.  
Our group previously developed PEG-NLG conjugate (PEG2k-Fmoc-NLG) as a prodrug 
nanocarrier for co-delivery of NLG919 and paclitaxel (PTX), a commonly used 
chemotherapeutic drug178. It was found that the immune-enhancing function of NLG and the 
tumor killing effect of PTX synergistically contributed to the increased anti-tumor efficacy. 
In this work, we further improved the NLG-based prodrug carrier system by increasing the 
number of NLG units per carrier molecule via RAFT polymerization. Compared to previous 
system, the NLG loading content in the new PSSN10 system is increased from 9.4 % to 
19.7%, which could help to decrease the amounts of carrier materials for in vivo application. 
In addition, a disulfide linkage is introduced in the PSSN10 system, which shall promote the 
release of NLG from the prodrug carrier (data not shown).  
PSSN10 readily formed small-sized micelles that are capable of loading various types of 
anticancer agents including DOX, PTX, docetaxel and curcumin (data not shown). We 
focused on DOX in this work as DOX can elicit caspase-dependent immunogenicity and 
enhance the proliferation of tumor antigen-specific CD8+ T cells in tumor-draining lymph 
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nodes197, 198, 199, 200. Recent study has shown that the effectiveness of immune checkpoint 
blockade is dependent on a preexisting antitumor immunity161. In addition, it has been 
reported that post-chemotherapy delivery of immunotherapy was a more effective treatment 
mode in inhibiting tumor progression 201. Therefore, combining PSSN10 with DOX that is 
capable of inducing immunogenic tumor cell death represents a rational approach of cancer 
immunochemotherapy.  
One unique feature of our approach is the programmable release of NLG and DOX to 
maximize the efficacy of the combination therapy. DOX was physically loaded into PSSN10 
micelles and shall be rapidly released from the micelles upon reaching the tumor site. 
DOX-mediated killing of tumor cells and/or the direct effect of DOX on immune cells could 
lead to enhanced tumor antigen presentation and improved antitumor immunity. On the other 
hand, NLG was covalently linked to the polymer and will be released at a relatively slower 
pace, which shall help to maintain or enhance the anti-tumor immune response over a 
prolonged period of time thorough reversing IDO-mediated immune suppression. Indeed, 
DOX/PSSN10 mixed micelles were significantly more effective than DOXIL or free DOX in 
inhibiting the tumor growth and prolonging the survival of treated mice. The superior 
antitumor activity of DOX/PSSN10 mixed micelles is likely due to the effective delivery of 
both NLG and DOX to the tumor tissue as demonstrated in the biodistribution study (Fig. 29). 
The synergistic action between DOX and released NLG may also play an important role.  
Immunological analysis indicates that tumor tissues from mice treated with PSSN10 are 
more immunoactive with higher percentage of functional T cells (CD4+ and CD8+) and lower 
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percentage of Treg and MDSC compared with the tumors with no treatment or treated with 
DOX or DOXIL (Fig. 32). Incorporation of DOX into the PSSN10 system does not affect the 
function of PSSN10 in enhancing T cell proliferation and suppressing Treg and G-MDSC 
cells. This is somewhat different from our previous study with PTX-loaded 
PEG2k-Fmoc-NLG system in which incorporation of PTX led to the reduction in the 
percentage of total intratumoral T cells and increase in the percentage of MDSC cells 
compared to the PEG2k-Fmoc-NLG alone 201. It is not clear at present whether this is due to 
the different drug or the dosage of the drug used in the two different studies. More studies are 
needed in the future to better understand the underlying mechanisms.  
In conclusion, we have developed a new redox-sensitive system PSSN10 for 
programmable co-delivery of DOX and NLG. Our data suggest that DOX/PSSN10 had the 
potential to be used as an effective combination regime for cancer immunochemotherapy. 
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6.0 TARGETING OF MDSC TO IMPROVE NANO-IMMUNOCHEMOTHERAPY 
 
6.1 ABSTRACT 
 
Development of an effective treatment against advanced tumors remains a major challenge 
for cancer immunotherapy. We have previously developed a PEG-NLG-based 
chemoimmunotherapy system for targeted delivery of paclitaxel (PTX), but its efficacy is 
restricted by various factors, including the accumulation of myeloid-derived suppressor cells 
(MDSCs). In this study, we determine whether codelivery of a multi-target receptor tyrosine 
kinase inhibitor, sunitinib (SUN) that reduce MDSC levels can further enhance the antitumor 
efficacy of PTX/PEG-Fmoc-NLG micelles. To efficiently encapsulate both PTX and SUN, 
an improved polymeric micelle nano-delivery system (PEG5k-Fmoc-NLG2) is developed 
which has both a lower CMC and longer micellar stability. SUN+PTX/PEG5k-Fmoc-NLG2 
micelles not only increase cytotoxic T-cell infiltration and decrease the number and 
percentage of MDSCs and Tregs in the TME, but also showed enhanced in vivo antitumor 
activity in an advanced murine breast cancer mouse model. Our findings indicated codelivery 
of PTX and SUN via an improved dual-functional nanocarrier (PEG5k-Fmoc-NLG2) led to 
reversal of the immunosuppressive phenotypes associated with PTX/PEG2k-Fmoc-NLG and 
can be used as a novel strategy to enhance the therapeutic efficacy of existing immune-based 
therapies for advanced breast cancer. 
 
6.2 BACKGROUND  
 
Interactions between the immune system and cancerous cells play an important role in 
carcinogenesis and failure of the host immune system to recognize and eradicate malignant 
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cells may lead to tumor development. Various mechanisms are developed by tumor cells to 
escape from immune surveillance. Many of these mechanisms are now known on a cellular 
and molecular level, such as immune checkpoints, which refer to inhibitory receptors 
expressed on immune effector cells or immune inhibitory ligands on tumor cells. Immune 
checkpoint blockade for CTLA-4 and PD-1 using monoclonal antibodies (mAbs) have 
achieved great clinical success, which has the potential to enhance and sustain endogenous 
immunity, establishing durable tumor control. Despites these successes, the clinical efficacy 
of checkpoint blockade is still limited due to the fact that multiple suppressive mechanisms 
have been implicated in the resistance to checkpoint blockade, including increased expression 
of PD-L1 and indoleamine 2,3-dioxygenase (IDO). Another reason which results in a 
limitation of clinical efficacy of checkpoint blockade is the fact that the efficacy of the 
immune checkpoint blocked is closely associated with pre-existing antitumor immune 
responses. Chemotherapy drug can cause immunogenic cell death, which leads to initiation of 
antitumor immune responses. Checkpoint blockade can then further enhance and sustain such 
antitumor immunity. Therefore, combination of immunogenic chemotherapy with checkpoint 
blockade has a great potential of improving cancer therapy. Therefore, it is ideal to develop a 
strategy to induce immunogenic tumor cell death while simultaneously blocking multiple 
tumor immunosuppressive pathways.  
Immunochemotherapy that combines a chemotherapeutic agent with an 
immune-modulating agent represents an attractive approach to improve cancer therapy. 
However, the success of immunochemotherapy is hampered by the lack of a strategy to 
effectively codeliver the two therapeutics to the tumors. Accordingly, we have developed a 
dual-functional, immunostimulatory nanomicellar carrier that is based on a prodrug conjugate 
(PEG2k-Fmoc-NLG) of PEG with NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor 
currently used for reversing tumor immune suppression. IDO is overexpressed in some 
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cancer cells and functions as an enzyme that catalyzes the degradation of essential amino acid 
tryptophan (Trp) and accumulation of its metabolites, resulting in cell cycle arrest and death 
of effector T cells, but increases in the number of regulatory T cells. We show that 
PEG2k-Fmoc-NLG alone is effective in enhancing T cell immune responses and exhibits 
significant antitumor activity in vivo. More importantly, systemic delivery of paclitaxel (PTX) 
using the PEG2k-Fmoc-NLG nanocarrier leads to a significantly enhanced antitumor response 
in in vivo tumor mouse models. However, treatment with PTX/PEG2k-Fmoc-NLG was also 
associated with untoward effects including upregulation of PD-1, PD-L1 and IDO-1 in tumor 
tissues at transcriptional level, and increased infiltration of myeloid-derived suppressor cells 
(MDSCs) compared to carrier alone group. This is likely due to the activation of several 
feedback mechanisms as well as the inflammatory response following the PTX-mediated 
killing of tumor cells and/or induced antitumor immunity. At the same time, the tumor cells 
recruit regulatory cells to attenuate antitumor immunity generated via immune checkpoints 
inhibition, through the liberation of immunosuppressive cytokines and alterations in the 
nutrient content of the microenvironment. The release of colony-stimulating factors, IL-1β, 
VEGF, or PGE2 by tumor cells results in the accumulation of MDSCs. MDSCs are present in 
TME as well as in circulation in cancer patients.  
MDSC plays a major role in creating a tumor immunosuppressive microenvironment and 
is found to accumulate in major organs and tumor tissues in advanced tumor-bearing mice 
and patients. Currently, two main MDSC populations have been characterized: monocytic 
MDSCs and granulocytic MDSCs. Despite their similarities in morphology to monocytes and 
neutrophils, MDSCs are quite different by being highly immune suppressive through a 
number of mechanisms. MDSCs can induce immunosuppression by production of arginase I 
(Arg1) and inducible nitric oxide synthase (iNOS), leading to T-cell inhibition. In addition, 
MDSCs can also promote tumor cell proliferation, promote drug resistance, and facilitate 
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tumor metastasis and angiogenesis. Therefore, high numbers of tumor-infiltrating MDSCs are 
often related to high tumor burden and metastasis, leading to poor treatment outcome. 
Therapeutic targeting of MDSCs might overcome immunosuppression to enhance responses 
to immunotherapy.  
Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. It 
is currently approved for the treatment of gastrointestinal stromal tumors (GIST) and 
metastatic renal cell carcinoma. Sunitinib has shown blocking effects on a variety of receptor 
tyrosine kinases, including ckit, vascular endothelial growth factor receptor 2 (VEGFR2), 
platelet-derived growth factor receptor (PDGFR), and Flt. In addition to its direct effects on 
tumor cells and tumor angiogenesis, sunitinib was reported to decreases the numbers and 
function of MDSCs and Treg cells both systemically and in the tumor microenvironment. 
Sunitinib has been shown to augment tumor-infiltrating T cell IFNg production and 
downregulate the expression of CTLA4, PD1 and PDL1. This reduction in immune 
suppression provides a rationale for combining sunitinib with immunochemotherapy for the 
treatment of certain tumor types.  
We hypothesized that incorporation of sunitinib into PTX/PEG-NLG mixed micelles 
shall lead to a more effective immunochemotherapy for cancer treatment by decreasing 
MDSC recruitment (Fig. 33). Indeed, codelivery of PTX and sunitinib via an improved 
dual-functional nanocarrier (PEG5k-Fmoc-NLG2) led to reversal of the immunosuppressive 
phenotypes associated with previous reported PTX/PEG2k-Fmoc-NLG and further enhanced 
antitumor activity. 
6.3 EXPERIMENTAL PROCEDURES 
6.3.1 Materials 
Paclitaxel (PTX, 499%) was purchased from TSZ Chem (MA, USA). DOX·HCl and 
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Sunitinib (SUN) were purchased from LC Laboratories. α-Fmoc-ε-Boc-lysine, α, 
ɛ-Di-Boc-lysine, N, N’-dicyclohexylcarbodiimide (DCC), triethylamine (TEA) and 
trifluoroacetic acid (TFA) were purchased from Acros Organic (NJ, USA). Monomethoxy 
PEG5000, 4-dimethylaminopyridine (DMAP), Triton X-100 and other unspecified reagents 
were purchased from Sigma Aldrich (MO, USA). Dulbecco’s Modified Eagle’s Medium 
(DMEM) and fetal bovine serum (FBS) were purchased from Invitrogen (NY, USA).  
6.3.2 Synthesis of PEG5K-Fmoc-NLG2 Conjugate 
Monomethoxy PEG5000 (1 equiv.), α-Fmoc-ɛ-Boc-lysine (3 equiv.), DCC (6 equiv.) and 
DMAP (1 equiv.) were mixed in dichloromethane (DCM) and stirred at room temperature 
(RT) for 2 days. Then the mixture was filtered and precipitated in cold ether/ethanol twice to 
yield PEG5K-Lys(Fmoc)-Boc. The Boc group was removed in the mixture of DCM/TFA (1:1, 
v/v) for 2  h at RT, followed by precipitation in cold ether/ethanol to give 
PEG5K-Lysine(Fmoc)-NH2. PEG5K-Lys(Fmoc)-Lys(Boc2) was then synthesized by mixing 
PEG5K-lysine(Fmoc)-NH2 (1 equiv.), α, ɛ-Di-Boc-lysine (5 equiv.), DCC (5 equiv.) and 
DMAP (1 equiv.) in DCM at RT for 2 days. After deprotection of Boc group in DCM/TFA 
(1:1, v/v), PEG5K-Lys(Fmoc)-Lys(NH2)2 was obtained and then mixed with NLG919 (5 
equiv.), DCC (5 equiv.) and DMAP (1 equiv.) in DCM. After stirring at RT for 2 days, the 
mixture was precipitated in cold ether/ethanol for three times, yielding the final product 
PEG5K-Fmoc-NLG2.  
6.3.3 Preparation of PTX+SUN/PEG5K-Fmoc-NLG2 Micelles 
PTX&SUN co-loaded PEG5K-Fmoc-NLG2 micelles were prepared through a thin-film 
hydration method. Briefly, PTX (5 mg/mL in DCM), SUN (5 mg/mL in ethanol), and 
PEG5K-Fmoc-NLG2 (50 mg/mL in DCM) were mixed at designated molar ratios in a glass 
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tube. After removing the organic solvent, thin-film of carrier/drug mixture was formed. Then 
DPBS was added to hydrate the film and a clear solution of PTX+SUN/PEG5K-Fmoc-NLG2 
micelles was obtained. PTX/PEG5K-Fmoc-NLG2, SUN/PEG5K-Fmoc-NLG2, and drug-free 
PEG5K-Fmoc-NLG2 micelles were similarly prepared.  
6.3.4 Characterization  
1H NMR spectra of synthesized materials were performed on a Varian-400 FT-NMR 
spectrometer (400.0 MHz) with CDCl3 and DMSO-d6 as the solvent. The critical micelle 
concentration (CMC) value of PEG5K-Fmoc-NLG2 micelles was measured as previously 
reported by using nile red as a fluorescence probe 202. The size distribution and morphology 
of blank and drug-loaded micelles were detected by dynamic light scattering (DLS, Malvern 
Zeta Nanosizer) and transmission electron microscopy (TEM, negative staining method), 
respectively.  
6.3.5 Cell Culture  
4T1.2 mouse metastatic breast cancer cells, PANC02 murine pancreatic cell line and HeLa 
human cervical cancer cells were cultured in DMEM culture medium, containing 10% (v/v) 
fetal bovine serum and 100 IU/mL penicillin and 100 µg/mL streptomysin at 37 °C in a 
humidified 5% CO2 atmosphere. 
6.3.6 In Vitro IDO Inhibition Assay 
The in vitro IDO inhibitory effect of PEG5K-Fmoc-NLG2 was evaluated by IDO assay. 
Briefly, HeLa cells were seeded at a density of 5 × 103 cells/well in a 96-well plate. After 
incubation for 24 h, recombinant human IFN-γ was added to each well at a concentration of 
50 ng/mL. Then cells were treated with PEG5K-Fmoc-NLG2 or free NLG919 at various 
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concentrations of NLG919 ranging from 50 nM ~ 20 µM. After incubation for 48 h, 150 µL 
of the supernatants was transferred to a new 96-well plate and incubated with 75 µL of 30% 
trichloroacetic acid at 50 °C for 30 min to hydrolyze N-formylkynurenine to kynurenine. For 
colorimetric assay, supernatants were transferred to a new 96-well plate and equal volume of 
Ehrlich reagent (2% p-dimethylamino-benzaldehyde w/v in glacial acetic acid) was added 
into each well. After incubation for 10 min at RT, the mixture was measured at 490 nm by a 
plate reader. For HPLC-MS detection (Wastes Alliance 2695 Separation Module combined 
with Waters Micromass Quattro Micro TM API MS detector), the plate was centrifuged at 
12,500 rpm. for 10 min and 100 µL of the supernatants was taken from each well for 
tryptophan and kynurenine quatification. 
6.3.7 T-cell Proliferation Study  
A lymphocyte-Panc02 cell co-culture experiment was performed to study the T-cell 
proliferation mediated by various treatments 185. Murine Panc02 cells were stimulated by 
IFN-γ (50 ng/mL) to induce IDO expression and then irradiated (6,000 rad). Splenocyte 
suspensions were harvested from BALB/c mice and passed through the nylon wool columns. 
After lysing of red blood cells, splenocytes were pre-stained with 5-(and 
6)-carboxyfluorescein diacetate (CFSE)). Then splenocytes (5×105 cells/well) and IFN-γ 
stimulated Panc02 cells (1×105 cells/well) were mixed together in a 96-well plate. Various 
concentrations of PEG5K-Fmoc-NLG2 and NLG919 were added to the cells. Then 100 ng/mL 
anti-CD3 and 10 ng/mL mouse recombinant IL-2 were added to the cocultures. After 
incubation for 72 h, the number of CD8+ and CD4+ T cells was measured by 
fluorescence-activated cell sorting (FACS) analysis. 
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6.3.8 In Vitro Cytotoxicity Assay 
4T1.2 murine breast cancer cell lines were seeded in 96-well plates at a density of 1.5 × 103 
(4T1.2) and 3 × 103 (PC3) cells/well, respectively. After incubation for 24 h, cells were 
treated with PTX, Carrier alone, PTX/PEG5k-Fmoc-NLG2, SUN/PEG5k-Fmoc-NLG2 or 
PTX+SUN/PEG5k-Fmoc-NLG2 in a gradient concentration. After treatment for 72 h, the cell 
viabilities were measured by MTT assay as previously reported. Untreated cells were 
included as a control. 
6.3.9 Animals  
Female BALB/c mice (6~8 weeks) were purchased from Charles River (Davis, CA). All 
animals were housed under pathogen-free conditions according to AAALAC guidelines. All 
animal-related experiments were performed in full compliance with institutional guidelines 
and approved by the Animal Use and Care Administrative Advisory Committee at the 
University of Pittsburgh. 
6.3.10 Quantification of Trp/Kyn Ratio in Plasma and Tumor Tissues 
The kynurenine to tryptophan concentations in plasma or tumor tissues from 4T1.2 
tumor-bearing mice were examined by HPLC-MS/MS. BALB/c mice bearing 4T1.2 tumors 
of ~50mm3 were treated with DPBS, PEG5K-Fmoc-NLG2, PTX/PEG5K-Fmoc-NLG2, 
SUN/PEG5K-Fmoc-NLG2,PTX+SUN/PEG5K-Fmoc-NLG2 (PTX dosage: 10 mg/kg; SUN 
dosage: 10 mg/kg) via tail vein once every 3 days for 5 times. The plasma and tumor samples 
were harvested at 24 h after the last treatment. Methanol was added into plasma samples at 
ratio of plasma/methanol 1/2.5 (v/v) and the mixture was centrifuged at 12,500 rpm. for 15 
min. Supernatants were collected and analyzed by HPLC-MS for kynurenine and tryptophan 
quantification. Tumor samples were homogenized in water and the homogenates were mixed 
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with acetonitrile (1:1, v/v), centrifuged and supernatants were transferred into new tubes. 
Equal volumes of methanol were added to precipitate proteins and supernatants were 
collected for HPLC-MS detection. 
6.3.11 Quantification of Tumor-infiltrating Lymphocytes  
BALB/c mice bearing 4T1.2 tumors of ~50 mm3 received various treatments via tail vein 
injection once every 3 days for 5 times. Tumors and spleen were harvested at 24 h following 
the last treatment, single cell suspensions were then prepared and stained with CD4, CD8, 
IFN-γ, Granzyme B, FoxP3, myloid-derived suppressor cell (CD11b and Gr-1) and 
macrophage (F4/80 and CD206) for FACS analysis. 
6.3.12 Plasma Pharmacokinetics and Tissue Distribution 
Female BALB/c mice (5 mice/group) were injected i.v. with Taxol, Sunitinib malate 
PTX/PEG5K-Fmoc-NLG2, SUN/PEG5K-Fmoc-NLG2 or PTX+SUN/PEG5K-Fmoc-NLG2 (PTX 
dosage: 10 mg/kg; SUN dosage: 10 mg/kg). Blood samples were collected at different time 
points (3 min, 10 min, 30 min, 1 h, 2 h, 4 h, 8 h and 12 h) and centrifuged at 12,500 rpm. for 
15 min. The plasma was mixed with 350 µL acetonitrile and centrifuged at 12,000 rpm. for 5 
min. The concentrations of PTX and SUN in the supernatants were determined by HPLC. 
The pharmacokinetic parameters were calculated based on a noncompartment model by 
Phoenix WinNonlin. 
For tissue distribution study, Taxol, Sunitinib malate, PTX/PEG5K-Fmoc-NLG2, 
SUN/PEG5K-Fmoc-NLG2, PTX+SUN/PEG5K-Fmoc-NLG2 micelles (PTX dosage: 10 mg/kg; 
SUN dosage: 10 mg/kg) were i.v. injected into female BALB/c mice bearing 4T1.2 tumors. 
At 24 h post injection, mice were sacrificed and the major organs/tissues were collected, 
weighted and homogenized with 2 mL mixed solvent (acetonitrile: H2O=1:1, v/v). The 
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mixture was centrifuged at 12,500 rpm. for 10 min, and the supernatants were collected and 
dried under airflow. The residues were then dissolved in 200 ml solvent (methanol to 
H2O=1:1, v/v) and centrifuged at 14,500 rpm. for 10 min. The collected supernatants were 
analyzed by HPLC for detection of PTX and SUN concentration. 
6.3.13 In Vivo Anti-tumor Activity  
For combination therapy of PTX loaded micelle and Gr-1 antibody, groups of four female 
Balb/C mice were administered Saline, control IgG, PTX-loaded PEG5k−Fmoc−NLG2 
micelles, PTX-loaded PEG5k-Fmoc-NLG2 micelles +control IgG or PTX-loaded 
PEG5k−Fmoc−NLG2 micelles+Gr-1 antibody for 5 times (10 mg PTX/kg, 100ug Gr-1 
antibody 100µg/mouse i.p.). The tumor volumes and body weights of all mice were 
monitored. Tumor volumes were calculated according to the formula: (L × W2)/2, in which L 
is the longest and W is the shortest tumor diameter (mm), and presented as relative tumor 
volume (the tumor volume at a given time point divided by the tumor volume prior to first 
treatment). 
For in vivo antitumor activity of SUN and PTX combination, female BALB/c mice 
bearing 4T1.2 tumors were treated with saline, PEG5K-Fmoc-NLG2, 
PTX/PEG5K-Fmoc-NLG2, SUN/PEG5K-Fmoc-NLG2, PTX/SUN/PEG5K-Fmoc-NLG2 (PTX 
dosage: 10 mg/kg; SUN dosage: 10 mg/kg) through intravenous injection every three days for 
5 times. Tumor volumes were followed as described above. At the completion of the 
experiment, tumor tissues were excised, fixed with 10% paraformaldehyde solution and then 
embedded in paraffin. The sliced tissues with a thickness of 5 µm were stained by 
hematoxylin and eosin (H&E) and observed by the microscope (Zeiss Axiostar Plus, USA).  
The Kaplane-Meier survival of the tumor-bearing mice (n = 8) was examined within 45 days. 
Mice were considered to be dead either when the mice died during treatment or when the 
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tumor volume reached ~1000 mm3. 
The immune cell populations in the tumors following various treatments were measured 
by flow cytometry188. Cell suspensions from the spleens or tumors were filtered and red 
blood cells were lysed. For extracellular staining, cells were co-incubated with combinations 
of antibodies (CD8, CD4, CD11b, Gr-1, CD45, F4/80 and CD206). For intracellular staining, 
cells were fixed immediately after cell surface staining following the manufacturer’s 
description (eBioscience), then the combinations of antibodies (IFN-γ, FoxP3 and granzyme 
B) were added into cells in permeabilization buffer. For IFN-γ staining, cells were stimulated 
with PMA (5 ng/mL) and ionomycin (500 ng/mL) in presence of 10 mg/mL BFA for 4 h 
followed by extracellular and intracellular staining. The data were analyzed using the FlowJo 
software (Tree Star Inc.). 
 
6.4 RESULTS 	  
6.4.1 Combination of PTX and Gr-1 Antibody Enhances Tumor Therapy 
To examine the effects of PTX/PEG-Fmoc-NLG micelle in combination with Gr-1 antibody, 
we inoculated 4T1.2 cells into the mammary fat pad of syngeneic mice following treatment 
with control IgG, anti-Gr-1 antibody, PTX/PEG-Fmoc-NLG micelles, the combination of 
PTX/PEG-Fmoc-NLG micelles and anti-Gr-1 antibody, the combination of 
PTX/PEG-Fmoc-NLG micelles and control IgG, or saline for 5 times. Combined treatment of 
PTX formulated micelles with anti-Gr-1 antibody resulted in the best tumor inhibition effect 
among the 6 groups (Fig. 34a). There was no significant change in the mouse body weight 
(Fig. 34b). 
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Figure 33. Schematic illustration of PTX+SUN co-loaded micelles. 	  
6.4.2 Immune Activation With Combinational Therapy 
Consistent with our previous in vivo experiment, PTX/PEG-Fmoc-NLG treatment 
significantly increased GMDSC cell percentage but the MMDSC was not significantly 
affected (Fig. 35a-c). With treatment of anti-Gr-1 antibody, the GMDSC cell percentage 
decreased significantly (Fig. 35a-b). Moreover, combined therapy of PTX micelles and 
anti-Gr-1 antibody enhanced the immune activation not only by increasing the number of 
CD8+ and CD4+ TILs, but also decreasing the IFN-γ+ TILs percentage compared to 
PTX/PEG-Fmoc-NLG or Gr-1 antibody treatment(Fig. 35d-j). There was also a slightly 
increase in granzyme B+ CD8+ T cells in the tumor of the combination therapy than single 
therapy. This suggests that combined therapy with anti-Gr-1 antibody and PTX micelle 
formulation might induce tumor regression by attenuating the immunosuppressive MDSCs 
cells to achieve maximal anticancer efficacy. 
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Figure 34. In vivo antitumor activity of PTX/PEG-Fmoc-NLG micelles in combination 
of Gr-1 antibody in a 4T1.2 breast cancer mouse model.  
Black arrows indicate the i.v. treatment. A: relative tumor volume. N=5, *P<0.05, compared 
to control(saline), §P<0.01, compared to PTX/PEG-Fmoc-NLG. B: body weights of different 
treatment groups. 	  
6.4.3 PTX Induces Chemokine Overexpression In Vitro and In Vivo 
We next examined whether chemokine expression related to MDSC cell recruitment was 
altered following PTX treatment. As shown in Fig. 36 and Fig. 37, PTX treatment 
significantly increased the gene expression of a series of chemokines in 4T1.2 cells and SUN 
treatment decreased the gene expression. To further understand the mechanisms, we 
investigated the chemokine expression profiles in the TME in the tumor bearing mice after 3 
treatments by RT-PCR. Figure 37 showed the PTX treatment significantly increased the 
chemokine expression in tumor tissues. However, all of the chemokines gene expression 
decreased with treatment of SUN and a combination of PTX and SUN. These data 
demonstrate that the upregulation of MDSCs with paclitaxel treatment might due to induction 
of chemokines related to MDSC recruitment and maturation and SUN treatment could 
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reverse this immunosuppressive status. 
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Figure 35. Flow cytometry analysis of immune cell subsets in tumor tissues with various 
treatments.  
(a-c) Flow cytometry analysis of Gr-1highCD11b+ granulocytic (G-MDSC) and Gr-1intCD11b+ 
monocytic (M-MDSC) MDSC subsets. (d-l) Abundance of tumor infiltrating CD4+ T cells(e), 
CD8+ T cells(f), IFN+CD4+ T cells(i), IFN-γ+ CD8+ T cells(j) and granzyme B+ CD8+ T 
cells(l) in 4T1.2 tumor bearing mice. The bars represent means±s.e.m. (*p<0.05). 
6.4.4 Characterization of PEG5K-Fmoc-NLG2  
The self-assembly of PEG5k-Fmoc-NLG2 and the loading of hydrophobic drugs into the 
PEG5k-Fmoc-NLG2 micelles are illustrated in Fig. 33. The synthesis scheme of 
PEG5k-Fmoc-NLG2 was presented in Fig. 38. The chemical structures of PEG5k-Fmoc-NLG2 
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were confirmed by NMR. 
 
	  
Figure 36. Expression of genes with a role in recruitment of MDSCs in 4T1.2 cells after 
treatment with PTX.  
For each gene, expression values are normalized and plotted as log-transformed values 
(row-scaled and colored on a white-red scale to show the difference between samples). 
 
 
	  
 
Figure 37. Expression of genes with a role in recruitment of MDSCs in 4T1.2 cells and 
tumor tissues after treatment with PTX, Sunitinib or combination. 
6.4.5 IDO Enzyme Inhibition Effect 
The IDO enzyme inhibitory activity of PEG5k-Fmoc-NLG2 was evaluated on Hela cells by 
examining the Trp to kynurenine (Kyn) concentration change in cell culture medium. HeLa 
cells were placed in a 96 well plate and stimulated with IFN-γto induce IDO expression. Cells 
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were treated with various concentration of carrier or free NLG drug. The amounts of Trp and 
Kyn in culture medium were examined by a colorimetric assay. Fig. 39 showed the free 
NLG919 could effectively inhibit the IDO enzyme activity by decreasing Trp/kyn conversion. 
The free drug had a low EC50 of 0.3 µM, the PEG5k-Fmoc-NLG2 could also maintain the 
IDO inhibition activity with a EC50 of 1.4 µM.  
	  
Figure 38. Synthesis scheme of PEG5k-Fmoc-NLG2. 	  
6.4.6 Enhanced T Cell Proliferation Effect 
As we showed before, T cell proliferation was greatly inhibited when lymphocytes were 
co-cultured with IDO expressing tumor cells. We examined whether PEG5k-Fmoc-NLG2 can 
lead to enhanced T-cell proliferation via inhibition of IDO expression on tumor cells in an in 
vitro lymphocyte-tumor cell co-culture study. In Fig. 40, co-culture of IDO+ panc02 cells 
with splenocytes isolated from spleen of BALB/c mice led to significant inhibition of T-cell 
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growth. When co-cultured tumor cells were treated with NLG919 or PEG5k-Fmoc-NLG2, the 
T cell proliferation could be significantly restored, however, the PEG5k-Fmoc-NLG2 was 
slightly less effective than NLG919 free drug.   
	  
Figure 39. In vitro IDO inhibition assay of PEG5K-Fmoc-NLG2.  
HeLa cells were stimulated with 50ng/ml of IFN-γ and treated with free NLG919 or 
PEG5K-Fmoc-NLG2 conjugate. Kynurenine concentration in supernatants was measure‘d 48h 
after incubation by Ehrlich's reagent. Data represent means ± s.e.m. 
 
6.4.7 Preparation and Characteristics of Drug Loaded PEG5k-Fmoc-NLG2 Micelles 
This PTX+SUN formulated PEG5k-Fmoc-NLG2 nano-drug delivery system was prepared 
through a film hydration method. Meanwhile, PTX or SUN loaded micelles and drug free 
micelles were prepared as control in a similar way. The sizes and morphologies of blank and 
drug-formulated micelles were examined by DLS and TEM, respectively (Fig. 41). The DLS 
measurements showed that the mean diameter of blank micelle was 122 nm and the average 
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particle size of PTX/PEG5k-Fmoc-NLG2 and PTX+SUN/PEG5k-Fmoc-NLG2 were 
determined to be 125 nm and 126 nm, respectively (Table. 7). The co-formulation of PTX 
and SUN did not affect the particle size. TEM showed both blank and drug loaded micelles 
exhibited a spherical morphology with smooth surfaces. The observed micellar size was 
approximately 40 nm, which was slightly smaller than the hydrodynamic diameter obtained 
from the DLS experiment. 
	  
Figure 40. PEG5K-Fmoc-NLG2 reversed T cell growth inhibition mediated by 
IDO-expressing Panc02 cancer cells.  
Panc02 cells were stimulated with 50ng/ml of IFN-γ, irradiated and co-cultured with mouse 
splenocytes. IL-2, anti-CD3 were used to stimulate T cell growth. Free NLG919 or 
PEG-NLG conjugate were added to co-cultured cells and proliferation of (A) CD4+ and (B) 
CD8+ T cells were examined by flow cytometer. 	  
Most polymer micelles have poor physical stability after drug loading. In general, the 
stability of polymer micellar systems decreases as drug loading increases. 
PEG5k-Fmoc-NLG2 micelles were found to possess a lower CMC of 0.161µM (Fig. 42) and a 
higher drug loading capacity for PTX and SUN compared to previous PEG2k-Fmoc-NLG 
system. Tab. 7 shows the PTX+SUN co-loaded PEG5k-Fmoc-NLG2 micelles could be stored 
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at room temperature for one week without a significant change in particle size and drug 
content, which was significantly higher than 48h of previous PEG2k-Fmoc-NLG system, 
indicating excellent stability in vitro.  
 
Figure 41. Size distribution and morphology of blank and PTX-loaded 
PEG5K-Fmoc-NLG2 micelles  
Size distribution and morphology of micelles were examined by a zeta sizer and TEM at a 
carrier to drug ratio of 2.5:1. PTX concentration was kept at 1 mg/ml and blank micelle 
concentration was 20 mg/ml.  
6.4.8 Release Kinetics of PTX & SUN From PEG5k-Fmoc-NLG2 Micelles  
The in vitro release behaviors of PTX and SUN from PEG5k-Fmoc-NLG2 in PBS buffer 
solutions (pH 7.4) were studied through a dialysis method and are shown in Fig. 43. PTX or 
Sun loaded micelles, Taxol and sunitinib malate were used as controls. As shown in Fig. 43, 
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Taxol and SUN showed a burst release with more than 70% and 60% of drugs released, 
respectively, in the first 6 h. However, the PTX and SUN formulated in the micelles were 
exhibited significantly sustained release over free drugs. In particular, about 40% of PTX was 
released from micelles over 48 h, while over 80% of PTX was released from Taxol 
formulation. And for the SUN/micelles, only approximately 40% of cumulative release was 
monitored after 10 h, whereas, a burst release of SUN was recorded for the sunitinib malate 
with more than 80% of drug released from the dialysis bag. In addition, PTX release from 
PTX+SUN/PEG5k-Fmoc-NLG2 micelles was similar to that from PTX/PEG5k-Fmoc-NLG2, 
while SUN release from PTX+SUN/PEG5k-Fmoc-NLG2 was slightly faster compared to the 
single agent formulation. Overall, the PTX and SUN showed comparable release kinetics 
from co-formulated micelles. Importantly, this release profile of PTX and SUN from micelle 
formulation may benefit to the combinational treatment of chemotherapy drug, targeted 
therapy drug and immune therapy. 	  
 
Table 7. Characterizations and Comparison of Two PEG-NLG Nanocarriers 
	  
 
Drug concentrations in micelle were 1 mg/mL and blank micelle concentration was 
20mg/mL.  Size were measured by dynamic light scattering sizer.  
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Figure 42. Measurement of CMC of PEG5K-Fmoc-NLG2 micelles. 
 
 
Figure 43. The in vitro release behaviors of PTX and SUN from PEG5k-Fmoc-NLG2 in 
PBS buffer. 
(a) PTX release kinetics from Taxol, PTX/PEG5K-Fmoc-NLG2 or 
PTX+SUN/PEG5K-Fmoc-NLG2 micelles at the PTX concentration of 1mg/ml. (b) SUN 
release kinetics from free sunitinib, SUN/PEG5K-Fmoc-NLG2 or 
PTX+SUN/PEG5K-Fmoc-NLG2 micelles at the SUN concentration of 1mg/ml.  
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Figure 44. Cytotoxicity of micelles in 4T1.2 cells.  
Cytotoxicity of PEG5K-Fmoc-NLG2 alone, free PTX, PTX/PEG5K-Fmoc-NLG2 mixed 
micelles, Sun/PEG5K-Fmoc-NLG2 mixed micelles and PTX+Sun/PEG5K-Fmoc-NLG2 mixed 
micelles were examined in a 4T1.2 mouse breast cancer cell line. Cells were incubated with 
various treatments for 3 days and cytotoxicity was determined by MTT assay. 
	  
Figure 45. Biodistribution of different PTX and Sun formulations in 4T1.2 
tumor-bearing mice.  
Tissue and organs were harvested 24 h after i.v. administration of (a) Taxol, PTX/PEG5K 
-Fmoc-NLG2 mixed micelles or PTX+Sun/PEG5K-Fmoc-NLG2 mixed micelles at a PTX dose 
of 10 mg kg-1 or (b) Sun, Sun/PEG5K-Fmoc-NLG2 mixed micelles or PTX+Sun/PEG5K 
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-Fmoc-NLG2 at a Sun dose of 10 mg/kg. PTX and Sun concentrations were measured by 
HPLC-MS. *P<0.05 (N=3). 
	  
Figure 46. In vivo antitumor activity of PTX+Sun/PEG5k-Fmoc-NLG2 mixed micelles. 
(a) Enhanced in vivo antitumor activity of PTX+Sun/PEG5k-Fmoc-NLG2 mixed micelles 
compared to Sun formulated PEG5k-Fmoc-NLG2 (#P < 0.05, N = 5), PTX formulated in 
PEG5k-Fmoc-NLG2 micelles (&P < 0.05, N = 5) or PEG5k-Fmoc-NLG2 blank micelles. *P < 
0.05 (vs control, N = 5). Data represent means ± s.e.m. (b) Survival rate of various treatment 
groups. (c) Tumors and lungs were harvested by the end of five treatments. Lung metastases 
were indicated by the black arrows. 
6.4.9 In Vitro Cytotoxicity 
The cytotoxicity of blank and drug loaded PEG5k-Fmoc-NLG2 micelles against 4T1.2 were 
determined using an MTT assay and compared with free PTX or SUN (Fig. 44). The 
PEG5k-Fmoc-NLG2 carrier alone exhibited negligible cytotoxicity at various polymer 
concentrations ranged from 0.07 to 17.5 µg/mL for 72 h, which indicated good 
biocompatibility of nanocarriers. The IC50 of SUN/PEG5k-Fmoc-NLG2 and sunitinib malate 
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was 5.14 and 7.78 µM, respectively. The slightly enhanced cytotoxicity of SUN loaded 
micelle could be attributed to the enhanced delivery of drug to the 4T1.2 cells by micelle 
delivery system. As expected, the PTX/PEG5k-Fmoc-NLG2 (IC50=103 ng/mL) also showed 
enhanced cytotoxicity compared to free PTX (IC50=112 ng/ml). Moreover, the 
PTX+Sun/PEG5k-Fmoc-NLG2 showed the best in vitro antitumor activity with a low IC50 of 
95ng/ml, this could due to the combined cell killing effect of PTX and SUN towards tumor 
cells. 
	  
Figure 47. Histological analyses (H&E) of lung and tumor tissues  
Tissues were collected at day 19 in the in vivo therapeutic study. 
6.4.10 In Vivo Biodistribution and Blood Kinetics of PTX+SUN Formulated Micelles 
The distribution, accumulation and elimination of administrated drugs in main organs and 
tumors could directly affect their therapeutic efficacy. To test whether PEG5k-Fmoc-NLG2 
could specifically deliver SUN and PTX into tumors, in vivo biodistribution studies were 
performed in 4T1.2 tumor-bearing mice. Groups of 3 mice were treated intravenously with 
SUN+PTX/PEG5k-Fmoc-NLG2, PTX/PEG5k-Fmoc-NLG2, SUN/PEG5k-Fmoc-NLG2, Taxol 
or sunitinib malate at the same dosage of SUN and PTX (10mg/kg), major organs and tumor 
tissues were collected after 24h and PTX or SUN concentrations were measured by HPLC. 
As shown in Fig. 45, SUN+PTX/PEG5k-Fmoc-NLG2 showed higher drug accumulation in 
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tumors while lower distribution in other organs including lung, liver and kidney compared to 
Taxol or sunitinib malate. The single drug formulation did not show significant difference 
compared to co-loaded micelles. It can be concluded that PEG5k-Fmoc-NLG2 can selectively 
deliver both SUN and PTX to tumors, which favored the reduction of systemic toxicity.  
6.4.11 In Vivo Antitumor Efficacy  
The antitumor activity of PTX+SUN/PEG5k-Fmoc-NLG2 was evaluated in a 4T1.2 murine 
tumor metastasis model. Various formulations were given intravenously and tumor growth 
was followed during the therapeutic period (Fig. 46). As shown in Fig. 46a, all treatment 
groups including carrier alone group exhibited antitumor effect at day 19 compared to control 
group (saline treatment). PTX+SUN/PEG5k-Fmoc-NLG2 exhibited the best antitumor activity 
compared to PTX/PEG5k-Fmoc-NLG2 and Sun/PEG5k-Fmoc-NLG2, the antitumor effect still 
remained after stopping treatment on day 14. The tumor inhibition indexes of, carrier alone, 
PTX/PEG5k-Fmoc-NLG2, SUN/PEG5k-Fmoc-NLG2 and PTX+SUN/PEG5k-Fmoc-NLG2 
group were 53.4%, 67.4%, 43.8% and 80.9% compared with saline group, respectively, 
which could be attributed to direct tumor killing effect of PTX/SUN and the subsequent 
immune stimulation effect by SUN and NLG. Fig. 46b displayed the body weights of mice, 
no significant fluctuation of the body weights was shown in all treatment groups, suggesting 
that no obvious systematic toxicity of the micelle formulations. The pathological H&E 
staining examinations of tumor tissue and lung tissue were carried out at day 19 (Fig. 47). 
Consistent with the lung tissue harvested by the end of therapeutic study, there are obvious 
lung metastasis nodules in the control group (Fig. 46c, Fig. 47). Administration of carrier 
alone, PTX/PEG5k-Fmoc-NLG2, SUN/PEG5k-Fmoc-NLG2 all caused some tumor cell death 
and nuclei breakdown in the tumor tissues and the PTX+SUN/PEG5k-Fmoc-NLG2 group 
showed a higher percentage of tumor cell death. This demonstrated that the 
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PTX+SUN/PEG5k-Fmoc-NLG2 treatment resulted in the most effective apoptosis of tumor 
cells (Fig. 47). Nevertheless, the detailed mechanisms of cell apoptosis are still unclear and 
need further investigation. 
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Figure 48. Flow cytometry analysis of immune cell subsets in tumor tissues. 
4T1.2 tumor bearing mice were received various treatments of Taxol, PEG5K-Fmoc-NLG2, 
PTX/PEG5K-Fmoc-NLG2 mixed micelles, Sun/PEG5K-Fmoc-NLG2 mixed micelles or 
PTX+Sun/PEG5K-Fmoc-NLG2 mixed micelles at a PTX dosage of 10 mg/kg and sunitinib 
dosage of 10 mg/kg for three times at an interval of 3 days and tumoral T-cell infiltration, 
including (a-c) CD4+ and CD8+，(d-e) FoxP3+ T regulatory cells, (f-g)IFN-γ+CD4+ T cells, 
(h-i)IFN-γ+CD8+ T cells and (j-k) granzyme B-positive CD8+ T cells, were measured by flow 
cytometry. (l-m) MDSC subsets (Gr-1highCD11b+ granulocytic (G-MDSC) and 
Gr-1intCD11b+ monocytic (M-MDSC)) were also detected by flow cytometry. The bars 
represent means ± s.e.m. *P < 0.05.	  
6.4.12 The Change of Immune Cell Populations in the TME  
Tumor tissues from mice received various treatments were harvested and analyzed for their 
tumor infiltrating immune cell populations using flow cytometry. Antitumor cytotoxic CD8+ 
T cells and CD4+ T helper cells are of paramount importance in immune defense against 
tumors. Figure. 48a-c showed infiltration of more CD4+ and CD8+ T cells in the tumors 
treated with PEG5k-Fmoc-NLG2 compared to control group and the combination treatment of 
PTX+SUN/PEG5k-Fmoc-NLG2 yielded the highest percentages of CD8+ T cells in the TME 
among all of the groups (p<0.001 vs. PBS; p<0.05 vs. Taxol and PTX/PEG5k-Fmoc-NLG2). 
All treatment groups showed a decrease of Foxp3+CD4+ cells (Fig. 48d-e). It is interesting to 
note that the PTX+SUN/PEG5k-Fmoc-NLG2 exhibited a dramatically increased IFN-γ+CD8+ 
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T cell infiltration but not IFN-γ+CD4+ T compared to carrier alone, Taxol or the 
PTX/PEG5k-Fmoc-NLG2 micelles (Fig. 48f-i). The percentage of granzymeB+CD8+ cells also 
greatly elevated in the combinational treatment group compared to Taxol or 
PTX/PEG5k-Fmoc-NLG2 (Fig. 48j-k). For the immune suppressive cell populations, the 
myeloid-derived suppressor cells (MDSCs) play important roles in tumor immune escape and 
similarly as we observed before, an increase in MDSCs cells in the tumor was observed in 
Taxol or PTX/PEG5k-Fmoc-NLG2 treatment group (Fig. 48l-m). To combat this unfavorable 
upregulation, we treated the mice with SUN/PEG5K-Fmoc-NLG2, both the intratumoral 
GMDSCs and MMDSCs were significantly decreased and when combined with PTX 
treatment, the percentage of MDSCs remained as low as those of SUN monotherapy, 
indicating the strong ability of SUN to reverse the tumor's immune suppression. 
 	  
6.5 DISCUSSION 	  	  
Previous we developed a PEG2k-Fmoc-NLG based dual-functional carrier for efficient 
delivery of PTX. This carrier was synthesized by conjugating one molecule of NLG to a 
hydrophilic motif PEG (MW = 2000), it could significantly inhibit the murine 4T1.2 breast 
cancer and effectively induce the antitumor immune response in tumor site, however, the 
percentage of immunosuppressive MDSC cells was significantly increased in the 
PTX/PEG2k-Fmoc-NLG groups and there was also a slight decrease in tumor infiltrating 
CD4+ and CD8+ T cells compared to carrier alone. Meanwhile, the tumoral expression of 
other immune checkpoint proteins such as PD-L1 and PD1 were significantly upregulated in 
tumor with PTX treatment. We subsequently showed that selective depletion of MDSCs with 
anti-Gr-1 antibody in combination with chemoimmunotherapy significantly improved 
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antitumor efficacy in a murine mouse model, providing evidence that MDSCs upregulation 
contribute to tumor immune evasion and relapse (Fig. 34). Induction of MDSCs is a 
fundamental immune escape mechanism employed by the tumor-bearing host in response to 
chemotherapy treatment such as doxorubicin and cyclophosphamide203, 204. The increased 
MDSCs in tumor might due to a series of inflammatory cytokines, chemokines and growth 
factors induced by PTX, which promoted the immature myeloid cells proliferation and 
expansion. As shown in Figs. 36 and 37, CCL2, CXCL1, CXCL2 and CXCL12 were among 
chemokine mediators induced by PTX/PEG-Fmoc-NLG treatment, candidate effector 
molecules that may promote the proliferation and recruitment of MDSCs. We tried to 
knockdown one of the critical chemokine gene in the tumor cells, however, it could not 
reverse the immune-inhibitory MDSC increase exerted by PTX/PEG-Fmoc-NLG. This 
inspired us to find a combinational therapy that can affect all these chemokines and decrease 
MDSCs accumulation in tumor area.  
It has been reported that the tyrosine kinase inhibitor SUN decreased tumor growth and 
improved survival in B16F10 melanoma and treatment of tumor-bearing mice with SUN lead 
to reduced vessel density and decreased accumulation of CD11b+Gr1+ myeloid derived 
suppressor cells in tumors. The ability of SUN reversing immune suppressive tumor 
microenvironment might due to inhibition of differentiation of dendritic cells (DCs) by 
inhibiting tyrosine kinases (VEGFR, PDGFR-α and –β, Fms-like TK-3 and kit) or prevent the 
accumulation of MDSCs by inhibition of STAT3 and c-Kit or directly induce the apoptosis of 
MDSCs. In this study, either SUN alone or co-treated with PTX significantly decreased the 
chemokine expression both in vitro and in vivo (Fig. 37). In order to co-delivery SUN with 
PTX, we developed a more advanced drug delivery system PEG5k-Fmoc-NLG2 with 
increased amount of NLG, which not only contributed to the carrier/drug interaction but the 
anticancer effect of carrier. The PEG5k-Fmoc-NLG2 had a lower CMC value compared to 
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PEG2K-conjugates (Fig. 42). Our data indicated that the PEG5k-Fmoc-NLG2 conjugates were 
significantly more effective than the PEG2k-Fmoc-NLG system in micelle stability and drug 
loading capability (Tab. 7). The PTX loaded PEG5k-Fmoc-NLG2 showed 3 times longer 
stable time than the previous system with no significant change of the micelle size. This 
might due the increase in the hydrophobic core, which contributes to the loading of 
hydrophobic drug through hydrophobic interaction and π−π interaction. Another modification 
in the carrier was increasing the PEG chain to 5000kd, which significantly increased the in 
vivo circulation time of micelles as we reported before31. It has been demonstrated that the 
new delivery system can well accommodate both PTX and SUN in one formulation and 
achieve enhanced in vitro cytotoxity and in vivo antitumor activity.  
In addition to the simplicity in codelivery, our system could provide a programmable 
release of various drug components via both physical encapsulation (for PTX and SUN) and 
chemical conjugation (for NLG). PTX/SUN and NLG shall have different temporal release 
kinetics upon codelivery to tumors. PTX/SUN has a much faster rate of release compared to 
that of NLG. The relatively rapid release of PTX and SUN will lead to the first round of 
antitumor response that will be further potentiated by the immune response that follows. The 
immune response could result from enhanced antigen presentation following PTX- and 
SUN-mediated killing of tumor cells and/or direct effect of SUN and PTX on immune cells. 
More importantly, addition of SUN effectively reverses some of the untoward effects that are 
associated with delivery of PTX via PEG-NLG-based nanocarrier. Meanwhile, the slow 
release of active NLG919 from the prodrug will help to sustain or enhance the magnitude of 
immune response by reversing IDO-mediated immune suppression. As a result, our approach 
has led to significantly improved antitumor activity as shown in Fig. 46a. It is also 
demonstrated that the SUN+PTX/PEG-Fmoc-NLG significantly increased tumoral 
infiltrating CD8+ T cells, while reducing intra-tumor MDSCs and Tregs, creating a more 
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immunogenic microenvironment for antitumor therapy.  
Our results showed that combining the targeted therapy SUN treatment, chemotherapy 
treatment of PTX and immunocheckpoint inhibition of NLG919 exerted potent 
complementary antitumor effects mediated by direct tumor cell killing effect, dendritic cell 
activation, a reduction in MDSC and reversing immunosuppressive environment, resulting in 
enhanced recruitment of cytotoxic T-cells and significant antitumor activity. 
 
6.6 CONCLUSION 	  	  
In this report, we found that tumor-targeted codelivery of PTX and SUN in 
PEG5k-Fmoc-NLG2 micelles changed the chemokine profile of the tumor which led to 
decreased percentage of MDSCs and increased cytotoxic T cell infiltration in the TME, 
thereby abrogating tumor-associated immune suppression. Our studies provide evidence in an 
in vivo animal model that targeted co-delivery of tyrosine kinase inhibitors and small 
molecule chemotherapy drug to tumors can be used as a novel strategy to enhance the 
therapeutic efficacy for advanced tumors. 
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7.0 TARGETED CODELIVERY OF DOXORUBICIN AND IL-36γ EXPRESSION 
PLASMID FOR AN OPTIMAL CHEMO-GENE COMBINAITON THERAPY 
AGAINST CANCER LUNG METASTASIS 
 
7.1 ABSTRACT 	  	  
Cancer metastasis is the main cause for the high mortality in breast cancer patients. 
Co-delivery of chemodrugs and gene therapeutics in a single system is a promising strategy 
for effective anti-metastatic therapy. In this work we developed two novel copolymers 
(POEG-st-Pmor and POEG-st-Ppipe) for targeted co-delivery of IL-36γ expression plasmid 
and doxorubicin (Dox) to lung metastasis of breast cancer. Both polymers readily formed 
micelles that were effective in loading Dox and simultaneously forming complexes with 
IL-36γ plasmid. Interestingly, particles co-loaded with Dox and plasmid or siRNA were 
significantly smaller and more stable than the particles loaded with Dox only. Intravenous 
delivery of the co-loaded nanoparticles led to effective delivery of both Dox and 
siRNA/plasmid to lungs as well as distant s.c. solid tumors. Gene transfection in both lungs 
and s.c. tumors was significantly higher with our two polymers compared to PEI. In the 
tumor therapy study, the Dox+IL-36γ plasmid/POEG-st-Pmor polymer could not only bring 
improved anti-metastatic effect but synergistically enhance the type I immune response by 
increasing the IFN-γ positive CD4+ and CD8+ T cells and simultaneously decreasing the 
immunosuppressive myeloid-derived suppressor cell (MDSCs) in the lung. POEG-st-Pmor 
and POEG-st-Ppipe may represent a simple and effective delivery system for an optimal 
chemo-gene combination therapy. 
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7.2 INTRODUCTION 
  
Cancer metastasis, which refers to the spread of cancer cells from the primary tumor site to 
distant tissues or organs, is the main cause of breast cancer-related deaths205, 206. Lung, liver, 
bone and brain are major organs for breast cancer metastases and more than 60% of breast 
cancer patients show metastasis in lungs at late stages207, 208. Although surgery may be 
effective in treating the primary tumor, chemotherapy is necessary for advanced lung 
metastases209, 210. Despite recent advancements in chemotherapy, the five-year survival rate of 
metastatic breast cancer remains low (~20%) with serious side effects, mainly due to 
off-target toxicity211. Therefore, the development of therapies to achieve efficient targeting of 
metastasis is highly demanded, which will likely achieve enhanced therapeutic efficacy and 
reduced systemic toxicities. 
Current lung metastasis targeted delivery largely relies on the size-driven systems such 
as nanoparticles, micelles and liposomes212, 213, 214. Although these nanoscale carriers show 
promising results, drawbacks such as poor stability, complex formulation strategy and 
potential toxicity remain unresolved. Most current nanocarriers can improve therapeutic 
effect through enhancement of permeation and retention (EPR) effect in primary tumors with 
vasculature pore sizes above 100 mm3,126. However, small metastatic tumors are usually less 
vascularized, which limits the access of nanoparticles to these lesions215. Thus, drug delivery 
systems with well-defined carrier structures, sufficient in vivo stability and high targeting 
efficiency are urgently needed to overcome the current problems. It has been reported that 
small ligands such as linear tertiary amines on the carriers may benefit lung targeted drug 
delivery since the lung is proven to be a site for accumulation of numerous basic amines216, 
217. These studies have inspired us to explore the potential of tertiary amine-derived carriers 
as targeting systems for treatment of lung metastasis. 
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We herein developed two multifunctional delivery systems that are based on an 
amphiphilic polymer with morpholine or piperazine attached to the pendant side chains 
(POEG-st-Pmor and POEG-st-Ppipe) for codelivery of small molecule chemotherapy drugs 
and nucleic acids (siRNA and plasmid). The hydrophobic anticancer drugs are expected to be 
incorporated into the hydrophobic core through hydrophobic-hydrophobic interaction and π-π 
stacking. Morpholine or piperazine is incorporated into the polymer to introduce positives 
charges to form complexes with nucleic acids. The positively charged morpholine and 
piperazine groups in the polymers can also facilitate the accumulation of the carrier in the 
lung due to the presystemic extraction and the interaction of positively charged tertiary amine 
with negatively charged cell membrane in the lung. Doxorubicin (Dox) and IL-36γ plasmid 
were selected as the model drug and DNA for the combination therapy. Dox is a first-line 
chemotherapeutic drug in the treatment of a broad range of cancers including breast, ovary, 
bladder, and lung cancers, and breast cancer metastasis218, 219. Interleukin cytokine is reported 
to have a synergistic effect in combination with conventional antitumor treatments such as 
chemotherapy220, 221. Interleukin 36 (α, β, γ) belongs to IL-1 family of cytokines and the three 
isoforms share the same receptor complex222. IL-36γ is reported to promote the 
differentiation of type 1 effector lymphocytes, including CD8+, NK, and γδT cells in vitro222. 
The tumoral expression of IL-36γ exerts strong antitumor immune responses in vivo and 
transforms the tumor microenvironment in favor of tumor eradication222. We hypothesized 
that codelivery of Dox and IL-36γ plasmid via our multifunctional carriers represents a 
simple and effective approach for the treatment of lung metastasis. We first examined the 
biophysical properties of the nanocarrier co-loaded with Dox and IL-36γ plasmid. The 
efficiency of delivery and transfection was then examined both in vitro and in vivo. Finally, 
the antitumor effect of Dox+ IL-36γ/polymer as well as the underlying mechanism was 
investigated. 
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7.3 EXPERIMENTAL PROCEDURES 	  
7.3.1 Materials and Reagents  
Doxorubicin (>99%) was purchased from LC Laboratories (MA, USA). 
Dicyclohexylcarbodiimide (DCC) was purchased from Alfa Aesar (MA, USA). 
4-(Dimethylamino) pridine (DMAP) was purchased from Calbiochem−Novabiochem 
Corporation (CA, USA). Vinylbenzyl chloride, 4-Cyano-4-[(dodecylsulfanylthio 
carbonyl)sulfanyl]pentanoic acid, oligo(ethylene glycol) methacry-late OEGMA (average Mn 
= 500), 2,2-Azobis(isobutyronitrile) (AIBN), trypsin-EDTA solution, 
3-(4,5-dimethylthiazol-2-yl)-2,5-di phenyl tetrazolium bromide (MTT) and Dulbecco’s 
Modified Eagle’s Medium (DMEM) were all purchased from Sigma-Aldrich (MO, U.S.A.). 
Opti-MEM medium was purchased from Invitrogen (Carlsbad, USA). AIBN was purified by 
recrystallization in anhydrous ethanol. Fetal bovine serum (FBS) and penicillin-streptomycin 
solution were purchased from Invitrogen (NY, U.S.A.).  
7.3.2 Synthesis of VBMor and VBPipe-Boc Monomer 
Vinylbenzyl chloride (167.2 mg, 1.1 mM), morpholine (95.8 mg, 1.1 mM) or piperazine-Boc 
(94.7 mg, 1.1mM), and K2CO3 (0.69 g, 5 mM) were dissolved in 6 mL DMF and stirred at 
50°C for 6 h. After cooling down to room temperature, 20 mL water was added to the 
mixture, followed by three times extraction with 50 mL CH2Cl2. After evaporation of CH2Cl2, 
the crude product was purified by column chromatography with petroleum ether/ethyl acetate 
(v/v, 4/1~2/1) as the elution liquid. VBMor or VBPipe-Boc monomer was obtained with a 71% 
or 75% yield, respectively. 
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7.3.3 Synthesis of POEG-st-Pmor, POEG-st-P(pipe-Boc) and POEG-st-Ppipe Polymer 
VBMor monomer (228.8 mg, 1.13 mmol) or VBpipe-Boc monomer (341.2 mg, 1.13 mmol), 
OEG500 (100 mg, 0.20 mmol), AIBN (1 mg, 0.0062 mmol), 
4-Cyano-4-[(dodecylsulfanylthiocarbonyl) sulfanyl] pentanoic acid (6 mg, 0.015 mmol), and 
1 mL of dried tetrahydrofuran were added into a Schlenk tube, and deoxygenated by 
free-pump-thawing for three times. Then the mixture was filled with N2 and immersed into an 
oil bath thermostated at 80 °C to start the polymerization. After 24 h, the reaction was 
quenched by immersing the tube into liquid nitrogen and the mixture was precipitated in 
hexane for 3 times. The product POEG-st-Pmor or POEG-st-P(pipe-Boc) was obtained after 
vacuum drying. POEG-st-Ppipe polymer was further synthesized by Boc deprotection of 
POEG-st-P(pipe-Boc) precursor in a mixture of CH2Cl2/TFA (1: 1, v/v). 
7.3.4 Preparation and Characterization of IL-36γ Plasmid/Dox-co-formulated Micelles  
Dox-loaded POEG-st-Pmor and POEG-st-Ppipe micelles were prepared by the dialysis 
method. Briefly, 10 mg of polymer was dissolved in 5 mL of DMSO and mixed with 100 µL 
of Dox DMSO solution (10 mg/ml). To remove free Dox from the Dox-incorporated micelles, 
the solution was dialyzed against PBS using dialysis membrane with a MW cutoff of 3500. 
The solution was lyophilized and resolubilized in 1mL PBS. Drug-free micelles were 
prepared similarly. For plasmid DNA complexation, polymeric micelles were diluted to 
different concentrations in water and mixed with plasmid DNA solution to obtain the desired 
N/P ratios. This mixture was allowed to incubate at RT for 20 min prior to further 
characterization.  
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7.3.5 In Vitro Characterization of Polymers 
The particle size and zeta potential of POEG-st-Pmor and POEG-st-Ppipe polymers were 
determined by dynamic light scattering (Nano-ZS 90, Malvern Instruments, Malvern, UK). 
The morphology of POEG-st-Pmor and POEG-st-Ppipe polymers was observed under a 
transmission electron microscope (TEM). The micelles were placed on a copper grid covered 
with nitrocellulose. The samples were negatively stained with phosphotungstic acid and dried 
at room temperature before measurement.  
Drug loading capacity (DLC) and Drug loading efficiency (DLE) were determined as 
described before. The amount of Dox loaded in the micelles was determined by high 
performance liquid chromatography (HPLC, Shimadzu LC-20AD, Japan). The DLC of 
Dox/micelles were calculated using the equation： DLC=Drug incorporated/(input 
polymer+Drug)×100% 
7.3.6 Critical Micelle Concentration 
The critical micellar concentration (CMC) was determined using Nile Red as a fluorescence 
probe 223. Micelles of various concentrations (0.0001 to 1 mg/mL) were first prepared. Two 
µl of a Nile Red solution in acetone (0.97 mg/mL) were then added to each sample and 
acetone was evaporated prior to fluorescence measurements using a microplate reader. 
Fluorescence from emission wavelength ranging from 560 to 750nm was recorded with an 
excitation wavelength of 550 nm.  
7.3.7 In Vitro Drug Release Study 
The in vitro Dox release kinetics for the POEG-st-Pmor and POEG-st-Ppipe micelles was 
determined by a dialysis method. Briefly, 0.5ml of Dox-loaded micelles and micelles 
co-loaded with Dox and IL-36γ plasmid at a Dox concentration of 0.5 mg/mL were placed 
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into a dialysis bag (MW cutoff 3500), respectively. The dialysis bag was incubated in 100 
mL PBS with gentle shaking at 37 °C. Two ml of PBS solution outside of the dialysis bag 
was collected at different time points and equal amount of fresh PBS was added back. The 
concentrations of released Dox were determined by HPLC 224.  
7.3.8 Gel Retardation Assay  
Plasmid/polymer complexes were prepared at different N/P ratios, ranging from 0.1 to 20 
(plasmid DNA concentration was fixed at 5 mg/ml). The resulting complexes were then 
electrophoresed on a 1% agarose gel in TAE buffer at 120 mV for 30 min, and visualized 
using a UV illuminator with ethidium bromide staining. Free plasmid DNA was used as a 
control.  
7.3.9 Cell Culture  
The murine breast cancer cell line 4T1.2 was cultured in DMEM medium supplemented with 
10% FBS and 1% penicillin/streptomycin at 37 °C in 5% CO2 atmosphere.  
7.3.10 In Vitro Cytotoxicity  
The cytotoxicity of Dox-formulated POEG-st-Pmor and POEG-st-Ppipe micelles, IL-36γ 
plasmid-complexed micelles and Dox+IL-36γ plasmid-co-loaded micelles were assessed in 
4T1.2 breast cancer cells and compared to free Dox. Briefly, 4T1.2 cells (2000 cells/well) 
were seeded in 96-well plates for overnight and were treated with various concentrations of 
Dox formulations for 72h. MTT solution was added to each well and MTT formazan was 
solubilized by DMSO after 2h of incubation. The absorbance in each well was measured by a 
microplate reader at a wavelength of 570 nm. Cell viability was calculated as [(ODtreat − 
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ODblank)/(ODcontrol − ODblank) × 100%]. The cytotoxicity of POEG-st-Pmor and 
POEG-st-Ppipe micelles alone was similarly tested in 4T1.2 cells as described above. 
7.3.11 Stability of the Micelles in BSA 
BSA was used to simulate the physiological environment to investigate the stability of 
POEG-st-Pmor and POEG-st-Ppipe micelle complexes under the mimicked physiological 
conditions. Plasmid DNA/micelle complexes and plasmid DNA+Dox/micelle complex were 
prepared as described above and incubated with BSA (30 mg/ml). pDNA/PEI complexes 
were used as a control. Sizes of complexes were followed at different time point as an 
indication of stability. 
7.3.12 Intracellular Localization of Micelle Complexes 
4T1.2 cells (1×104 cells/well) were seeded in 6 well plates and incubated for 24 h. 
FAM-siRNA/POEG-st-Pmor micelle complexes, Dox+FAM-siRNA/POEG-st-Pmor micelles, 
FAM-siRNA/POEG-st-Ppipe micelles, and Dox+FAM-siRNA/POEG-st-Ppipe micelles 
(siRNA concentration: 10 pmol/well) were then added and incubated with the cells for 2h. 
After removing the cell culture medium, cells were washed with cold PBS for three times. To 
label the cell nucleus, cells were treated with Hoechst (0.1 µg/mL) for 15 min. Cell were then 
washed with cold PBS for three times before observation under a confocal scanning 
microscope.  
7.3.13 In Vitro Plasmid Transfection  
4T1.2 cells were seeded in a 96-well plate and incubated for 24 h until cells were 80% 
confluent. Cells were then transfected with EGFP plasmid/POEG-st-Pmor micelle complexes 
(N/P=20), EGFP plasmid/POEG-st-Ppipe micelle complexes (N/P=20) or EGFP plasmid/PEI 
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(N/P=20) complexes in serum-free opti-DMEM medium. After 4 h incubation, transfection 
medium was removed and 100 µL of fresh complete medium were added to each well. PBS 
group was used as a control. After 48h, the transfected cells were observed under a 
fluorescence microscope (OLYMPUS America, Melville, NY).  
7.3.14 In Vivo Fluorescence Imaging 
Female Balb/C mice bearing 4T1.2 tumor (~400 mm3) in the mammary fat pad were used to 
investigate the biodistribution and in vivo transfection efficiency of our micellar carriers. 
AF647 siRNA was used to examine the biodistribution of nucleic acids-loaded 
POEG-st-Pmor and POEG-st-Ppipe in vivo. At 24 h after injection of the AF647 
siRNA-loaded nanomicelles through tail vain, major organs and tissues (lung, liver and 
tumors) were collected, embedded in OCT, and frozen in liquid nitrogen. The specimens 
were cryosectioned into 20 µm sections. The signals of AF647-labeled siRNA in tissues were 
examined under a confocal microscope.  
The in vivo transfection efficiency of POEG-st-Pmor and POEG-st-Ppipe micellar 
carriers was evaluated with EGFP plasmid as a reporter gene. Linear PEI was used to as 
control. Various formulations were injected i.v. into tumor-bearing mice at a dose of 50 µg 
plasmid per mouse, and one day later, the mice were injected with 1 µg of Hoechst one hour 
before sacrifice. The fluorescence signal of GFP in the cryosections was examined under a 
confocal microscope. 
7.3.15 Breast Cancer Lung Metastasis Mouse Model  
Female Balb/c mice at 4-6 weeks of age were injected with 2×105 4T1.2 cells through the tail 
vein. Five days after tumor cell injection, mice were randomly divided into 6 groups. 
POEG-st-Pmor was chosen as a representative carrier system for codelivery of IL-36γ 
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plasmid and Dox. Animals were treated intravenously with free POEG-st-Pmor micelles, 
IL-36γ plasmid/POEG-st-Pmor micelles, Dox+control plasmid/POEG-st-Pmor micelles and 
Dox+IL-36γ plasmid/POEG-st-Pmor micelles every three days for three times. The PBS 
treatment group was used as control. Dox dosage was 5 mg/kg and plasmid dosage was 50µg 
per mouse. Lung tissues were harvested and weighted 11 days after the first injection. 
Pulmonary metastases were enumerated by intra-tracheal injection of India ink solution. India 
ink-injected lungs were washed in Feket’s solution (300 ml 70% EtOH, 30 ml 37% 
formaldehyde and 5 ml glacial acetic acid) and white tumor nodules against a dark blue lung 
background were counted. 
7.3.16 Histopathological Analysis 
The lung tissues were harvested and fixed in 10% formalin after the above treatments. The 
fixed samples were then embedded in paraffin and the tissue sections were stained with 
hematoxylin/eosin and analyzed for the presence of metastases under microscope. The total 
number of metastases per lung section was counted in different treatment groups. 
7.3.17 Analysis of Tumor-infiltrating Lymphocytes and Myeloid-derived Suppressor 
Cells 
Lung tissues were collected in serum free RPMI medium and cut mechanically with scissors. 
Liberase TL (0.3mg/ml) and DNase I (0.3 mg/ml) were used to digest the lung tissue and 
tumor nodules. Tissues were further grinded and filtered through a 40-mm cell strainer. TILs 
and MDSC cells were further purified and stained with fluorescence-labeled antibody for 
flow cytometry analysis using a FACS flow cytometer.  
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7.4 RESULT 	  
7.4.1 Synthesis of POEG-st-Pmor and POEG-st-Ppipe Polymers 
The synthesis scheme and proton NMR spectrums for POEG-st-Pmor and POEG-st-Ppipe 
polymers were shown in Fig. 49 and Fig. 50. First, VBMor and VBPipe-Boc monomers were 
synthesized by reacting vinylbenzyl chloride with morpholine and piperazine-Boc, 
respectively. Then, statistical copolymers POEG-st-Pmor and POEG-st-P(pipe-Boc) were 
prepared via reversible addition-fragmentation chain-transfer (RAFT) polymerization of 
OEG500 monomer and VBMor or VBPipe-Boc monomer, espectively. The structures and 
molecular weights of POEG-st-Pmor and POEG-st-P(pipe-Boc) polymers were characterized 
by 1H NMR and gel permeation chromatography (GPC). The average degree of 
polymerization (DP) of the OEG500 monomer was calculated to be 9 according to the 
conversion of OEG500 monomer at the end of the polymerization. The DP of the VBMor and 
VBPipe-Boc monomer was determined to be 50 and 45 respectively, by comparing the 
intensities of Ia and Ic (Fig. 51 and 52 of the Supporting Information). The average molecular 
weight Mn determined by GPC is 9,260 for POEG-st-Pmor and 14,200 for 
POEG-st-P(pipe-Boc), and the polydispersity is 1.13 and 1.25, respectively, which indicated 
the successful synthesis of POEG-st-Pmor and POEG-st-P(pipe-Boc) copolymers with 
well-defined structures. POEG-st-Ppipe polymer was obtained by TFA-mediated Boc 
deprotection of POEG-st-P(pipe-Boc) precursor in CH2Cl2. The molecular structure of 
POEG-st-Ppipe polymer was further confirmed by 1H NMR (Fig. 53). The strong peaks at 
1.42 ppm (Boc groups) disappeared, indicating the successful removal of Boc groups. 
	  	   175	  
	  
Figure 49. Synthesis scheme of (a) POEG-st-Pmor and (b) POEG-st-Ppipe polymers. 
	  
Figure 50.	  1H NMR of POEG-st-Pmor polymer 
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Figure 51.1H NMR of POEG-st-P(pipe-Boc) polymer 
 
	  
Figure 52.	  1H NMR of POEG-st-Ppipe polymer	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7.4.2 Characterization of Micellar Nanoparticles 
POEG-st-Pmor and POEG-st-Ppipe micelles were prepared via a dialysis method. As shown 
in Fig. 53, both micelles had sizes around 200 nm (Fig. 53, Tab. 9) as tested with a zetasizer 
and TEM. The critical micelle concentrations (CMC) of both polymers were determined 
using nile red as a fluorescence probe. Both POEG-st-Pmor and POEG-st-Ppipe polymers 
have a low CMC around 0.04 mg/ml (Fig. 54).  
The Dox-loaded POEG-st-Pmor and POEG-st-Ppipe micelles were similarly prepared as 
blank micelles and both carriers could load Dox at a carrier/drug mass ratio starting from 
10:1 with sizes ranging from 160 to 190 nm (Fig. 53, Tab. 8) and could remain stable for two 
weeks and one week at room temperature, respectively. Then we tested whether the 
POEG-st-Pmor and POEG-st-Ppipe could from stable complexes with plasmid DNA. A gel 
retardation assay was performed to assess the pDNA binding ability of the pMor- and 
pPipe-based polymers. Plasmid DNA/carrier complexes were fabricated at various N/P ratios 
from 0.1:1 to 30:1. As shown in Fig. 55a, b, complete complexation of plasmid DNA by 
POEG-st-Pmor or POEG-st-Ppipe polymer was achieved at an N/P ratio of 5/1 or greater. 
The surface zeta potentials of the POEG-st-Pmor and POEG-st-Ppipe blank micelles were 
26.4 mV and 36.8 mV, respectively before the addition of IL-36γ plasmid (Fig. 56 and Tab. 
8). At the N/P ratios of below 1, the complexes were negatively charged and the particle sizes 
were similar to the sizes of the micelles alone. There was a significant increase in the sizes of 
the complexes at an N/P ratio of 3. At this ratio, the particle charges were close to neutral. 
Interestingly, further increases in the N/P ratios led to a significant decrease in the particle 
sizes and the particles became more positively charged with continuous increases in the N/P 
ratios. Specifically, when the micelles were mixed with IL-36γ plasmid at an N/P ratio of 
20:1, the average size of the complexes decreased to 70-80 nm (Tab. 8, Fig. 56). Nonetheless, 
DNA/micelle complexes were less positively charged compared to free micelles with a 
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surface zeta potential of 10.3 and 17.8 mV for plasmid/POEG-st-Pmor and 
plasmid/POEG-st-Ppipe complexes, respectively (Tab. 8). 
	  
Figure 53. Particle size distribution and TEM images of micelles	  
(a-b)Particle size distribution and (c-d) TEM images of Blank micelles, Dox-loaded micelles, 
IL-36γ plasmid complexed micelles and micelles co-loaded with IL-36γ plasmid and DOX. 
Scale bars: 100 nm. 
 
 
We then went on to further explore the possibility of co-delivery of pDNA and Dox by 
POEG-st-Pmor and POEG-st-Ppipe micelles. As shown in Fig. 53 and Tab. 8, the size 
distribution and zeta-potential were not significantly affected when Dox was added to the 
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pDNA/polymer complexes at a drug concentration of 1 mg/mL and a carrier/drug ratio of 
20/1 (m/m).  
7.4.3 Stability of the Complexes in BSA 
The colloidal stability of DNA/micelle complexes was tested in BSA solution (30mg/mL). 
PEI/DNA complexes were used as a control (N/P=20, zeta potential=18.3 mV). As shown in 
Fig. 57, exposure of PEI/DNA complexes to BSA led to a rapid increase in the particle sizes. 
At 5 h post-incubation, the sizes of PEI/DNA complexes increased from 149 to 261 nm. It is 
also apparent that both POEG-st-Pmor/DNA and POEG-st-Ppipe/DNA complexes were 
resistant to BSA-induced aggregation and showed minimal changes in sizes throughout the 
entire 18 h of observation. 
7.4.4 In Vitro Dox Release  
The profile of Dox release from the Dox-loaded micelles was examined by a dialysis method 
with Dox.HCl solution as a control (Fig. 58). Free Dox exhibited a burst release with more 
than 80% of drug released at the first 4 hours. However, Dox formulated in POEG-st-Pmor 
and POEG-st-Ppipe micelles showed a significantly slower kinetics of release with less than 
25% of Dox being released outside of dialysis bag at the first 4 hours, and only 35% and 31% 
of Dox released at 24h for POEG-st-Pmor and POEG-st-Ppipe micelles, respectively. The 
micelles co-loaded with Dox and plasmid exhibited an even slower Dox release profile 
compared to micelles loaded with Dox alone at later time points.  
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Figure 54. The CMC values of POEG-st-Pmor and POEG-st-Ppipe polymers. 
CMC of (a) POEG-st-Pmor and (b) POEG-st-Ppipe polymers determined from the plot of 
nile red fluorescence intensity.  
7.4.5 Cytotoxicity of Bank Micelles and Dox+IL36γ Plasmid/micelle Complexes 
The in vitro cytotoxicity of Dox+IL36γ plasmid/micelle complexes was evaluated with 4T1.2 
breast cancer cells via MTT assay. Cells were treated with various treatments for 72 h and the 
final concentrations of Dox ranged from 4 to 1000 ng/mL (Fig. 59a). The free Dox and the 
Dox-loaded micelles showed a dose-dependent cell killing profile. The Dox/POEG-st-Pmor 
and Dox/POEG-st-Ppipe had lower IC50s (60ng/ml and 110ng/ml, respectively) compared to 
free Dox (IC50=130ng/ml) (Fig. 59a). Incorporation of IL36γ plasmid into Dox-loaded 
micelles led to slightly increased cytotoxicity on 4T1.2 cells. POEG-st-Pmor or 
POEG-st-Ppipe alone showed minimal cytotoxicity to 4T1.2 cells at the polymer 
concentration as high as 20µg/mL (Fig. 59b).  
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Table 8. Biophysical Characteristics of Blank Micelles and the Micelles Co-loaded With 
IL-36γ Plasmid and DOX	  
 
Drug concentrations in micelle were 1 mg/mL and blank micelle concentration was 20 
mg/mL. Size and zeta potential were measured by dynamic light scattering sizer.  
7.4.6 Cellular Internalization of Nanomicelles  
The cellular uptake of siRNA/micelle complexes was investigated by confocal laser scanning 
microscopy. The siRNA/micelle complexes were prepared at an N/P ratio of 20:1 to ensure 
complete siRNA binding to the micelles. 4T1.2 mouse breast cancer cells were incubated for 
4 h with micelle complexes carrying Dox and/or FAM-labeled siRNA and then observed 
under a confocal microscope. As shown in Fig. 60, Dox-loaded POEG-st-Pmor and 
POEG-st-Ppipe micelles showed more Dox cellular uptake compared to free Dox at the same 
Dox concentration. The signals for free Dox were largely found in nucleus while the signals 
for the micellar Dox were mainly located outside the nucleus. This might be due to the 
different cellular uptake routes of free Dox and Dox micelles.  
Fig. 61 showed even more uptake of micellar Dox following complexation with 
FAM-siRNA. Moreover, both Dox+FAM-siRNA/POEG-st-Pmor and 
Dox+FAM-siRNA/POEG-st-Ppipe showed substantial yellow fluorescence signals in a 
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merged channel likely due to the overlap of Dox (red) and FAM-siRNA (green), suggesting 
co-localization of Dox and FAM-siRNA.  
	  
 
Figure 55. Gel retardation assay of IL-36γ plasmid/polymer complexes at different N/P 
ratios.  
Samples were incubated for 20 min at room temperature before being loaded onto a 1% (w/v) 
agarose gel (100 V, 30 min). Representative gel images of plasmid/POEG-st-Pmor polymer 
(a) and plasmid/POEG-st-Ppipe polymer (b) are shown from three independent experiments. 
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7.4.7 In Vitro Transfection with EGFP Plasmid 
The above results indicate that POEG-st-Pmor and POEG-st-Ppipe micelles were effective in 
delivering nucleic acids into cancer cells. To further assess the capability of the micelle 
complexes to enter cells, release plasmids, leading to expression of biologically active protein, 
we performed in vitro transfection with EGFP plasmid. Fig. 62 shows that 4T1.2 tumor cells 
were effectively transfected with EGFP plasmid complexed with POEG-st-Pmor or 
POEG-st-Ppipe micelles. 4T1.2 cells were also effectively transfected with branched PEI, a 
control carrier.  
	  
Figure 56. Particle sizes and zeta potentials of IL-36γ plasmid/POEG-st-Pmor and 
IL-36γ plasmid/POEG-st-Ppipe complexes. 
Particle sizes (a) and zeta potentials (b) of IL-36γ plasmid/POEG-st-Pmor and IL-36γ 
plasmid/POEG-st-Ppipe complexes formed at different N/P ratios. Data are expressed as 
means ± s.e.m. (n=3). 
7.4.8 In Vivo Distribution of AF647-siRNA-loaded Nanomicelles  
To gain insight into the distribution of siRNA/micelle complexes, confocal examination of 
the tissue sections was performed at 24 h following i.v. administration of 
AF647-siRNA/micelle complexes. As shown in Fig. 63, substantial amounts of fluorescence 
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(AF647) signals were detected in s.c. tumor tissues for both POEG-st-Pmor and 
POEG-st-Ppipe formulations. We also observed significant amounts of AF647 signals in 
lungs but much fewer signals in liver. In contrast, AF647-siRNA/PEI complexes were largely 
found in lungs with little accumulation in the tumors.   
	  
Figure 57. The BSA stability of DOX+ IL-36γ plasmid coloaded micelles.  
The stability of (a) DOX+ IL-36γ plasmid/POEG-st-Pmor and (b) DOX+IL-36γ 
plasmid/POEG-st-Ppipe was examined by incubating complexes (1 mg DOX/mL in PBS, pH 
7.4) with bovine serum albumin (BSA, 30mg/mL) at 37°C. Changes in sizes of the 
complexes were followed by DLS. Data are means ± s.e.m. (n=3). 
7.4.9 In Vivo Transfection Efficiency  
EGFP was used as a reporter gene with linear PEI as a control carrier. Gene expression in 
tissue sections was examined with a confocal microscope. As shown in Fig. 64a, there were 
significantly more EGFP signals in tumors with POEG-st-Pmor or POEG-st-Ppipe 
formulation compared to linear PEI. In agreement with previous reports, lungs could be 
effectively transfected by linear PEI (Fig. 64b). However, more and stronger signals of EGFP 
were observed in lungs transfected with POEG-st-Pmor or POEG-st-Ppipe formulation (Fig. 
64b). Liver was hardly transfected with either of our formulations or control linear PEI. 
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These results suggest that POEG-st-Pmor and POEG-st-Ppipe polymers are suitable for in 
vivo gene delivery to both lungs and distant solid tumors (Fig. 64c).  
	  
Figure 58. In vitro drug release profiles.  
In vitro drug release of DOX from (A) DOX+IL-36γ plasmid/POEG-st-Pmor and (B) 
DOX+IL-36γ plasmid/POEG-st-Ppipe in PBS at 37°C. Data are mean ± s.e.m. (n=3). 
7.4.10 Anti-tumor Activity of Micelles Co-loaded With Dox and IL-36γ Plasmid   
Next we investigated the anti-tumor activity of Dox+IL-36γ plasmid/POEG-st-Pmor 
complexes in vivo. A mouse model of breast cancer lung metastasis (4T1.2) was generated in 
female Balb/c mice and various treatments were given to each group of mice via tail vein 
injection (Fig. 65a). As shown in Fig. 65b, the carrier alone did not show therapeutic activity 
compare to control group. Free Dox showed a modest inhibition of lung metastasis and 
micelles co-loaded with Dox and IL-36γ plasmid showed the best anti-metastasis effect 
	  	   186	  
compared to free Dox, Dox+control plasmid/micelles and IL-36γ plasmid/micelles. The H&E 
staining of lung tissues showed clear tumor cell infiltration from all of the groups except for  
the co-delivery group (Fig. 65c). The group with more tumor nodules had more lung weights 
(Fig. 65d&e). Body weights were also monitored during the treatment period. No significant 
decrease of body weight was observed, indicating the safety of the formulation (Figure. 65f). 
	  
Figure 59.	  In vitro cytotoxicity study.  
(a) In vitro cytotoxicity of DOX+IL-36γ plasmid/POEG-st-Pmor and DOX+IL-36γ 
plasmid/POEG-st-Ppipe in 4T1.2 cells. (b) In vitro cytotoxicity of drug-free micelles. Cells 
were treated for 72 h, and cytotoxicity was determined by MTT assay. Values were reported 
as means ± s.e.m. from triplicate samples. 
7.4.11 Immune Cell Infiltration Profile in Tumor-bearing Lungs 
Following demonstration of the significant antitumor activity of Dox+IL-36γ 
plasmid/POEG-st-Pmor, we examined the immune cell infiltration in the tumor-bearing lungs 
to elucidate a role of immune response in the overall antitumor activity. As shown in 
Fig.66a&c, there was a significant increase of cytotoxic CD8+ T cells in the lung tissues 
treated with free Dox, IL-36γ plasmid/POEG-st-Pmor or the combination of both compared 
to untreated control group. Although there was no significant difference in the total number 
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of T cells between Dox+IL-36γ plasmid/POEG-st-Pmor and Dox+control 
plasmid/POEG-st-Pmor, the numbers of IFN-γ+ CD4+ and IFN-γ+ CD8+ T cells were 
significantly increased in the combination treatment group compared to either of the other 
treatment groups. We also examined the immunosuppressive myeloid-derived suppressor 
cells (MDSCs) in lung tissues. The granulocytic MDSCs (GMDSCs) express high levels of 
Gr-1 and monocytic MDSCs (MMDSCs) express intermediate level of Gr-1 and both of them 
are positive for CD11b. The numbers of GMDSC were significantly decreased in all 
treatment groups except the carrier alone group (Fig. 66h-j). Surprisingly, there was a 
significant increase in the number of Foxp3+ CD4+ T cells (regulatory T cells (Treg)) in the 
mice treated with IL-36γ plasmid, alone or in combination with Dox (Fig. 66k-l). 
 
	  	  
Figure 60. Cellular uptake of free DOX, DOX-loaded POEG-st-Pmor micelles and 
DOX-loaded POEG-st-Ppipe micelles in 4T1.2 cancer cells.  
Photos were taken at 2h of incubation. Cell nuclei were stained with Hoechst 33342. 
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Figure 61. Internalization and colocalization of (a) DOX+siRNAFAM/POEG-st-Pmor and 
(b) DOX+siRNAFAM/POEG-st-Ppipe in 4T1.2 cancer cells.  
From left to right: fluorescein-labeled siRNA (green); DOX (red); nuclear staining with 
Hoechst 33342 (blue); an overlay of siRNA, DOX and Hoechst. 	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Figure 62. EGFP transfection in vitro 
Expression of EGFP 48 h following transfection of 4T1.2 cells with pEGFP-C1 complexed 
with PEI, POEG-st-Pmor, and POEG-st-Ppipe, respectively. 
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Figure 63. In vivo siRNA distribution in tumors, lung, and liver. 
In vivo siRNA distribution in tumors, lung, and liver 24 h following i.v. injection of (a) 
siRNA/PEI, (b) siRNA/POEG-st-Pmor, and (c) siRNA/POEG-st-Ppipe. Cell nucleus was 
stained by hoechst. 
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Figure 64. In vivo GFP expression in liver, lung and tumor tissues.  
Balb/c mice bearing 4T1.2 tumor were i.v. injected with EGFP plasmid/PEI, EGFP 
plasmid/POEG-st-Pmor and EGFP plasmid/POEG-st-Ppipe. GFP expression in (a) tumor, (b) 
lung, and (c) liver was examined 24 h later. 
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Figure 65. Synergistic antitumor activity of IL36γplasmid and DOX codelivered by 
POEG-st-Pmor micelles in a mouse model of breast cancer (4T1.2) lung metastasis.  
(a) experimental scheme for the establishment of lung metastasis and treatment. (b) 
representative gross images of lungs collected from mice receiving various treatments. (c) 
H&E staining of lung tissues. (d) quantification of tumor nodules. (e) mouse lung weights (n 
= 5). (f) changes in mouse body weights during the treatment period. Data are presented as 
the means ± SEM. *p < 0.05 versus control.  
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Figure 66. Flow analysis of infiltration of immune cells in tumor-bearing lungs following 
various treatments.  
Balb/c mice were injected with 2*105 4T1.2 cells via tail vein. 5 days later, mice were treated 
with POEG-st-Pmor carrier, free Dox, IL-36γplasmid/POEG-st-Pmor, Dox+control 
plasmid/POEG-st-Pmor and Dox+IL-36γplasmid/POEG-st-Pmor, respectively for three times. 
(a-c) T lymphocyte subsets isolated from lung tissues with 4T1.2 metastasis were analyzed by 
flow cytometry. The percentage of CD4+ and CD8+ T cells in the lung tissues with various 
treatments was determined by flow cytometry analysis. (d-g) IL-36γplasmid/micelles 
increased the IFNγ+ CD4+ and IFNγ+ CD8+ T cells in tumor-bearing lungs. (h-j) MDSC 
subsets (GMDSC and MMDSC) were stained with CD11b and Gr-1 antibody and determined 
by flow cytometry. The results are shown as the means ± s.e.m of 3 mice in each group. *P< 
0.05. (k-l) flow analysis of Foxp3+ T regulatory cells in mouse lungs. 	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7.5 DISCUSSION 	  
Most delivery systems developed so far are designed for delivery of either small molecule 
drugs or nucleic acid-based therapeutics. In this study, we have developed a simple micellar 
system that is highly effective in codelivery of small molecules and nucleic acids (siRNA and 
plasmids). In addition to providing a platform for any new combination therapy that involves 
both small molecule drugs and nucleic acid therapeutics, our approach also resolves the issue 
of instability that is associated with most micellar carriers. Micelles are formed through the 
self-assembly of amphiphilic monomers, which is a reversible and dynamic process. Micelles 
tend to fall apart when they are diluted in the blood upon systemic administration. This can 
be further aggravated by the lipid exchange as a result of interactions with lipoproteins in the 
blood. A number of strategies have been reported to cross-link the monomers to stabilize the 
micelles. Some of the approaches involve a complicated procedure and/or modification of the 	  
structure of the monomer. In our system, the multivalent charge-charge interactions between 
the cationic polymer and nucleic acids (both siRNA and plasmid DNA) serve as a simple 
approach to cross-link the micelles. As a result, micelles that are co-loaded with small 
molecules and plasmid or siRNA are likely to be more stable than free micelles or the 
micelles that are loaded with small molecule alone. This is supported by the data from Dox 
release study: Dox formulated in the co-loaded nanoparticles exhibited a slower kinetics of 
release compared to the formulation that is loaded with Dox only (Fig. 58). Interestingly, the 
size of the co-loaded micelles (~80 nm) is also significantly smaller that of free micelles 
(~180 nm) or the micelles loaded with Dox alone (~170 nm) (Tab. 8). This might be 
	  	   196	  
attributed to a decreased repulsion among the positively monomers as a result of charge 
neutralization following complexation with siRNA or plasmid DNA. More studies are needed 
to better understand the underlying mechanism. 
The complexes of DNA with either POEG-st-Pmor or POEG-st-Ppipe polymer were 
significantly more stable than PEI/DNA complexes following exposure to BSA (30 mg/mL). 
This is likely due to the dynamic shielding of the complexes by PEG despite the fact that both 
complexes remain positively charged. The improved stability of the two complexes in the 
presence of serum proteins may contribute to the efficient delivery of siRNA to distant s.c. 
tumors (Fig. 63). A more effective accumulation in the lung (Fig. 63) is likely due to the 
interaction of tertiary amine moiety with negatively charged cell membrane in the lung. 
Amine-containing basic compounds have been reported to be predominantly accumulate in 
the lung due to the specific binding to acidic phospholipids on the cell membrane, which is 
abundantly distributed in lung tissue. Therefore our carriers are suitable for codelivery of 
nucleic acid therapeutics and small molecule drugs to both distant solid tumors and lung 
metastatic lesions. 
POEG-st-Pmor and POEG-st-Ppipe were comparable to PEI in transfecting tumor cells 
in vitro (Fig. 62). However, they were more effective than PEI in transfecting either lungs or 
tumor tissues in vivo (Fig. 63&64). The higher efficiency of POEG-st-Pmor and 
POEG-st-Ppipe polymers might be due to the improved stability of POEG-st-Pmor and 
POEG-st-Ppipe complexes in blood circulation due to the PEG shielding. It is also possible 
that POEG-st-Pmor and POEG-st-Ppipe form more stable complexes with DNA compared to 
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PEI due to an additional mechanism of polymer/DNA interaction through the π-π interactions 
between the benzene rings in DNA and our polymers. 
POEG-st-Pmor polymer was chosen to further examine the therapeutic effect of 
codelivery of Dox and IL-36γ as both POEG-st-Pmor and POEG-st-Ppipe polymers showed 
similar biophysical properties (Tab. 8) and comparable efficiency in codelivery (Fig. 62, 
63&64). POEG-st-Pmor alone was not active in the 4T1.2 lung metastasis model. Delivery of 
Dox or IL-36γ alone via POEG-st-Pmor polymer showed a modest activity in inhibiting the 
lung metastasis. Combination of the two led to a significant improvement in antitumor 
activity as shown by both smallest number of tumor nodules in the lung and the lowest 
weights of the tumor-bearing lungs (Fig. 65b,d&e). Flow study showed that codelivery of 
IL-36γ and Dox was most effective in activating T cell response, suggesting that the 
synergistic effect of Dox and IL-36γ combination on the immune system may play a role in 
the improved antitumor activity. Interestingly, the Treg cells were also increased following 
treatment with IL-36γ, alone or in combination with Dox (Figure 66k-l). This may be due to 
high amounts of IFN-γ accumulated locally, which may trigger the induction of Foxp3 
expression in T cells225. Combination of IL-36γ/Dox codelivery with other therapies that can 
block the conversion of CD4+CD25– T cells to CD4+ Tregs may help to further enhance the 
outcome of treatment. 
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7.6 CONCLUSION 
 
 
In this study, we developed and systematically evaluated the potential of POEG-st-Pmor and 
POEG-st-Ppipe nanocarriers for codelivery of Dox and IL36γ plasmid. Stable and nanosized 
micelles co-loaded with plasmid/siRNA and Dox could be readily prepared and were highly 
effective in delivery to lungs as well as distant s.c. tumors. Significantly improved antitumor 
activity was demonstrated with codelivery of Dox and L36γ plasmid in comparison with 
other control groups in a 4T1.2 lung metastasis model. POEG-st-Pmor and POEG-st-Ppipe 
may represent a simple and effective deliver system for an optimal chemo-gene combination 
therapy. 
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8.0 SUMMARY AND PERSPECTIVES 
 
New drug candidates often face the problems of poor bioavailability and undesirable side 
effects in the transition to clinic. Further, therapeutic effect of the newly emerging gene 
therapy using DNA and proteins is completely dependent on the delivery efficiency. 
Nanomedicines have been investigated for the targeted delivery of anticancer reagents to the 
critical site of action with improved therapeutic efficacy. Many different nanomedicines are 
well designed for longer stability, increased solubility, enhanced 
pharmacokinetics/biodistribution, decreased toxicity, and improved efficacy of drugs. 
Basically, the nanomedicines can be divided to liposomes, polymeric conjugates, polymeric 
nanoparticles, polymeric micelles and other types. Polymeric micelles present a promising 
delivery system for hydrophobic drugs, which possess a unique core-shell structure. The 
hydrophobic core incorporates water-soluble drugs via hydrophobic interaction and the 
hydrophilic outer layers play an important role in systemic administration, particular in 
enhancing circulation time and interaction with targeted cells.   
During my graduate study, I worked on several projects to develop multi-functional 
polymeric micelle system for the targeted delivery of anticancer agents. I firstly discovered 
significant synergistic effect between curcumin and FTS in treatment of prostate cancers and 
we demonstrated curcumin could be effectively loaded into PEG-FTS micellar system and 
achieved enhanced antitumor activity both in vitro and in vivo. In a metastatic 4T1.2 breast 
cancer mouse model, tumor growth was significantly inhibited by curcumin/PEG5K-FTS2(L) 
mixed micelles compared to curcumin formulated in Cremophor/EL. In order to further 
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improve the drug loading and formulation stability of the PEG-FTS2, a drug-interactive Fmoc 
motif was incorporated into the carrier system. As a result, curcumin-loaded 
PEG5K-Fmoc-FTS2 micelles were more effective in inhibiting tumor cell colony formation 
and the curcumin/PEG5K-Fmoc-FTS2 demonstrated superior antitumor activity compared to 
curcumin/Cremophr EL and curcumin/PEG5K-FTS2 in 4T1.2 mouse model.  
In order to counteract undesirable upregulation of immunecheckpoint proteins during the 
treatment and further improve the antitumor efficacy by stimulating anticancer immune 
response, efforts were also made to develop a novel micellar nanocarrier based on 
PEG-derivatized NLG919 prodrug. The prodrug not only well retained the IDO enzyme 
inhibition effect in an in vitro kynurenine inhibition assay and T cell proliferation study, but 
could be used as nanocarrier for delivery of chemotherapy drugs. Pharmacokinetics and 
biodistribution studies showed that PTX formulated PEG-Fmoc-NLG mixed micelles were 
able to retain PTX in the bloodstream for a longer time period than Taxol formulation and 
efficiently deliver the drug to tumor sites. More importantly, PTX loaded PEG-Fmoc-NLG 
led to superior antitumor activity in breast cancer and melanoma cancer models. Then we 
further improved the PEG-NLG carrier system by increasing the number of NLG content in 
the carrier (from 9.4% to 19.7%) via RAFT polymerization. The new polymer could not only 
decrease the amounts of carrier materials in in vivo application by increase the drug loading 
capacity and micelle stability but increase NLG release by introducing a disulfide linkage 
into the PSSN10 system. However, there were many untoward immunesuppressive 
mechanisms were activated during the PTX/PEG-NLG treatment including upregulation of 
MDSCs or other immunecheckpoints. A multi-target receptor tyrosine kinase inhibitor, SUN 
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that reduces MDSC levels was introduced to an improved PEG5k-Fmoc-NLG2 micelle system 
that was capable for loading both SUN and PTX. SUN+PTX/PEG5k-Fmoc-NLG2 micelles 
not only decreased the number and percentage of MDSCs and Tregs in the TME, but also 
showed enhanced in vivo antitumor activity in an advanced murine breast cancer mouse 
model. 
Our improved vectors worked well for most of the hydrophobic chemotherapeutics, but 
could not simultaneously deliver genes that could target to most of the disease target.  
Multifunctional nanocarriers PEG-pMor and PEG-pPipe were carefully designed and 
synthesized for targeted co-delivery of IL-36γ plasmid DNA and Dox to lung metastasis of 
breast cancer. The Dox+IL-36γ plasmid/PEG-pMor polymers could not only decrease the 
tumor lung metastases but also synergistically enhance the antitumor immune response by 
increasing the functional lymphocyte infiltration and simultaneously decreasing MDSC cell 
accumulation in lung. 
Although all these micelle systems allowed for passive accumulation inside tumors with 
leaky vasculature, the majority of these nanoparticles were still cleared by the RES system, 
resulting in short half lives and unwanted micelle deposition in the liver and spleen. 
Development of multifunctional micelles, either through conjugation of targeting ligands on 
the micelle surface or a triggered release mechanism, can lessen these problems by increasing 
particle/drug exposure to the tumor.  
Targeting ligands are designed to conjugate to the out layer of the micelles in order to 
induce specific targeting and uptake of the micelle by tumor cells. Small organic molecules 
such as folic acid targeting on receptor over-expressed on cancer cells, peptide ligands such 
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as cRGD peptide targeting the avb3 integrin, or the tumor specific antibodies are now widely 
used as targeting ligand for micelle system to improve the drug accumulation in tumor sites. 
Another strategy for improve current micelle system is to trigger site-specific drug 
release by modifying micelle structures. After reaching the targeted site, efficient drug 
release from micelle carriers becomes critically important to ensure drug bioavailability, and 
hence achieve the desired cytotoxic effect. The incorporation of pH sensitive linkage using 
acid-labile bonds or adding pH-sensitive components for effective protonation in the structure 
of micelle will help with the accumulation of drug in tumor site. 
In addition, more investigations on the structure-activity relationship of polymeric 
micellar are needed to improve the drug-carrier interaction. Investigations of new 
combinational therapy strategies are necessary to offer better antitumor activity in designing 
drug delivery system. These studies shall lead to the development of further improved 
micellar systems to advance the treatment of cancers. 
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